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Interferon regulatory factor 1 (IRF-1) is a tumour suppressor protein and 
transcription factor. It has been shown to modulate target gene expression in 
response to stimuli, which include viral infection and D N A  damage, and to be down- 
regulated in several form s o f  cancer. This thesis details the developm ent o f  an 
intrabody, an intracellular antibody, that binds specifically to endogenous IRF-1. The 
binding o f  the intrabody to ERF-1 enhanced transcription from  ERF-1-responsive 
reporter gene constructs and endogenous promoters, thus it was shown to activate 
IRF-1. Intrabody binding also increased the rate at which IRF-1 was degraded, 
suggesting that the intrabody epitope may be regulating both IRF-1 activity and 
turnover. These results were supported point mutation within the intrabody epitope 
(P325 to A ) as the resultant mutant also displayed both a higher transcriptional 
activity and increased rate o f  degradation.
In an effort to understand the mechanisms which regulate IRF-1 activity a search for 
novel IRF-1-interacting proteins was carried out using phage peptide display. This in  
vitro  technique enables the identification o f  peptides able to bind a specific target 
protein. The sequence o f  these peptides can then be used to search protein databases 
for hom ologous, full-length proteins that could also bind the target protein. This led 
to the identification o f  an IRF-1-binding peptide that held sequence similar to a 
region o f  Z in c Finger 350 (ZN F350), a transcription factor involved in regulating the 
D N A  damage response. Subsequently, endogenous ZN F350 and IRF-1 were co - 
immunoprecipitated from a human cancer cell line. The extreme C-terminus o f  ERF-1 
was shown to be sufficient for an interaction with ZN F350, although a second, m ore 
N-terminal site was also shown to be essential for a stable intracellular interaction.
This data sheds new light on the role o f  the extreme C-terminus o f  IRF-1 in 
modulating the protein’ s activity. This study also provides new and IR F-1-specific 
m olecular tools, in the form  o f  intrabodies and IRF-1-binding peptides, w hich could 
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1 Introduction
The w ork reported in this thesis is aimed at increasing current understanding o f  the 
mechanisms through which IRF-1 (interferon regulatory factor 1) is regulated. This 
introduction is split into two parts; the first describes the disease types associated 
with dysfunctional IRF-1, mechanisms o f  IRF-1 induction, its functions and 
structure. The second part o f  this introduction focuses upon phage display 
technology as this thesis details the use o f  both antibody and peptide phage display in 
the study o f  IRF-1.
1.1 IRFs (Interferon regulatory factors)
There are currently nine known human IRFs (interferon regulatory factors), 
identified through a highly conserved D N A -binding domain. IRF-1 was the first to 
be identified and was initially characterised as a transcription factor able to bind 
enhancer elements in the prom oter o f  the IFN-P gene [1, 2], A  transcription factor is 
a D N A -binding protein that attaches to only specific sequences within the promoter 
regions o f  its target genes [3], This binding is a rate-limiting step regulating 
transcription o f  D N A  to m R N A , with transcription factors able to both repress and 
activate this process by controlling the recruitment o f  R N A  polym erase [4],
IRF-2, an inhibitor o f  I R F -l ’ s transcriptional activity that possessed a similar D N A - 
binding domain structure was described soon after IRF-1 [5], M echanism s through 
which IRF-2 may regulate IRF-1 are detailed in section 1.2.3.2. Both bind and 
com pete for a com m on D N A  m otif, which was found in other promoters regulated 
by  the interferon signalling pathway [6], This IRF-binding m otif was therefore 
named the IFN-stimulated response element (ISRE) [7, 8]. IRF-1 targeted ISRE have 
been found in a large number o f  genes which can be either induced or repressed by 
IRF-1 [9-11], These genes are involved in diverse pathways including the immune- 
response, anti-proliferation, apoptosis and tumour suppression.
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1.2 IRF-1
1.2.1 Association with cancer
Upregulation o f  IR F -1  is associated with growth inhibition in several cancer cell 
lines [12-14] and reversion o f  c-m yc- or fosB -induced transformation [15]. Although 
IR F -1  null m ice do not spontaneously develop tumours, unlike those lacking the 
tumour suppressor p 53, em bryonic fibroblasts (EFs) from IR F -/ -  m ice can be 
transformed by  activated c-Ha-ras expression [16, 17]. It is again possible to reverse 
the transformed phenotype through concom itant expression o f  exogenous IR F-1 . In 
addition IRF-/- cells are protected from  the c-Ha-ras oncogene triggered apoptosis 
that can be observed in w ild  type cells under conditions o f  low  serum concentration, 
high cell density or fo llow ing treatment by  anticancer drugs or ionizing radiation 
[17].
IR F -1  mutations have been observed in a variety o f  human cancers. Chrom osom al 
loci 5 q 3 1 is the smallest, m ost com m only deleted region in leukemia and 
myelodysplasia (M D S), and IR F - 1  has been identified as the most frequently deleted 
gene at this loci in patients with these diseases and 5q31 aberrations [18]. Strikingly, 
IR F - 1  m R N A  is undetectable in approximately 20%  o f  patients with M D S or overt 
leukemia from  M D S [18]. Furthermore, skipping o f  exon 2 o f  the IR F -1  gene, which 
contains the A U G  translation initiation codon  [18], has also been linked to the 
developm ent o f  leukaemia and M D S [6, 19, 20].
IRF-1 has been reported to be reduced in 53%  o f  human hepatocellular carcinomas 
(although this study involved a limited sample size o f  only 13 tissue samples) [21]. 
Additionally, during mutational analysis o f  gastric genes implicated in 
adenocarcinoma, a tum our-specific point mutation was identified in exon 2 (A T G  to 
T T G ) [22], which resulted in a substitution o f  IRF-1 amino acid 8 from  methionine 
to leucine. This mutant was found to bind to D N A  with a similar affinity to the w ild 
type protein, but unlike wild type IRF-1, was unable to activate the IFN-[3 p 125- 
luciferase prom oter or inhibit cell growth when over expressed [22], Other exon 
deletions, which would cause truncated form s o f  the protein to be produced, have 
also been identified in chronic m yeloid leukaemia [23] and cervical cancer patients 
[24],
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Taken together the data described in this section have identified IRF-1 as a tumour 
suppressor protein i.e. one that protects the cell from  cancer.
1.2.2 Induction of IRF-1
Although expressed at low  levels by most types o f  resting cells [2, 25-27], IRF-l can 
be upregulated by  a wide range o f  agents including: viruses, concanavalin A  (con A ), 
lipopolysaccharide (LPS), interleukin-1 (IL -1), IL -12, IFN-p, IFN-y and tumour- 
necrosis factor (TN F) [2, 5, 25, 27, 28]. These factors are part o f  a signalling network 
that indicates the presence o f  an infection and their induction o f  IRF-1 is an 
important part o f  host defence. Furthermore, it has been shown that IRF-1 can be 
induced in response to D N A  damage [29] or in a cell-cycle-dependent manner to 
inhibit proliferation prior to D N A  synthesis [6], IR F -1  has been well characterised as 
a downstream target o f  the interferon-stimulated JAK /STA T-signalling pathway in 
virus-infected cells [28, 30, 31]. This signalling pathway is initially stimulated by 
interferons released by lym phocytes in response to infection. Interferons belong to a 
class o f  glycoproteins known as cytokines, w hich signal locally between cells to 
stimulate an immune response. Interferons (IFNs) play key roles in both innate (IFN- 
a and IFN-P) and adaptive (IFN-y) immunity. The two most studied type I 
interferons are IFN-a and IFN-P, both o f  which can be expressed in all cell types.
The type II interferon, IFN-y, is produced only in activated T lym phocytes (T -cells) 
and natural killer (N K ) cells.
Type 1 interferons bind a heterodimer o f  IFNARs (IFN -a receptor) 1 and 2. The type 
II interferon, IFN-y binds to a tetramer o f  two IFNGR2 (IFN-y receptor 2) chains and 
two IFNGR1 chains. B y binding to their receptors IFNs activate JAK  (Janus Kinase) 
phosphotyrosine kinases, which phosphorylate tyrosine residues on the interferon 
receptors. This allows STATs (Signalling Transducers and Activators o f  
Transcription) to bind the receptors via a phosphotyrosine-binding SH2 domain [32], 
STA T dimers can then m ove into the nucleus and bind to the IFN-activated 
palindrom ic G A S (gamma activated site) sequence within the IR F - 1  promoter [33].
13
IRF-1 p ro m o te r  f r  
DNA dam age ^ ^ A T M
Figure 1.1: Synergistic induction of IRF-1 gene expression by STAT dimers 
and NF-kB. Based upon the following publication [33].
Other pathways have also been shown to induce IRF-1 expression. Overlapping the 
GAS element targeted by the JAK/STAT pathway is a binding site for NF-kB 
(Nuclear Factor kappa B). Binding o f  the p50/p65 heterodimer form o f  NF-kB to this 
region has been shown to stimulate IRF-1 expression and allow it to act in concert 
with NF-kB to stimulate other downstream targets [33, 34]. Whereas the JAK/STAT 
cascade is an essential element o f  an anti-microbial response, IRF-1 is also 
stimulated in DNA damaged cells, this time by the ATM (ataxia telangiectasia, 
mutated) -signalling pathway [29], In cells in which ATM was knocked down IRF-1 
could still be induced as part o f  a viral response, but only when ATM was present 
could IRF-1 be induced by DNA damage [29], indicating that IRF-1 is a downstream 
target o f  distinct pathways. IR F-l’ s ability to respond to a range o f  stimuli helps
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explain its involvem ent in diverse cellular functions, w hich are discussed in section 
1.2.3.
1.2.3 Functions of IRF-1
First recognised for its role in viral response, IRF-1 later becam e characterised as a 
tumour suppressor m olecule. T o  understand how  these two functions are intertwined 
it is important to first understand the “ tumour surveillance”  hypothesis [35], which 
suggests that as tumour cells have an abnormal physiology the immune system 
should be able to recognise them and attempt their eradication. This theory has been 
supported by  experiments showing that m ice lacking factors essential for immune 
development, such as perforin (a cytolytic protein released by natural killer and 
cytotoxic T -cells) or IFN-y, show impaired tumour resistance [36, 37]. It has also 
been shown that cells involved in immuno-surveillance can recognise tumour- 
specific antigens [38, 39]. For example, D N A  damage has been shown to lead to the 
upregulation o f  ligands for the N K G 2-D  receptor [40], which is expressed on the 
surface o f  natural killer cells, cytotoxic T-cells and macrophages and which 
recognises specific “ n o n -se lf ’ antigens. These ligands have been shown to be 
upregulated on the surface o f  numerous tumour cells [38] and their ectopic over 
expression has been shown to target cells for destruction [39],
This section details IR F -l ’ s role in the immune system, cell growth and apoptosis 
(also known as program med cell death), how ever these functions are not really 
separate but together help explain I R F -l ’ s tumour suppressor activities. A s part o f  
the immune system IRF-1 can be activated follow ing the detection o f  tumour or 
D N A  damaged cells [29], and then elicit the appropriate response; either halting 
progression o f  the cell cycle  (section 1.2.3.2) or triggering a signalling cascade 
ending in cell death (section 1.2.3.3).
1.2.3.1 Immune-response
Follow ing microbial infection, interferons are able to swiftly induce IRF-1 
expression through the JA K /S T A T  signalling pathway [2]. IRF-1 is then able to 
regulate the induction o f  IFN-response genes involved in the host’ s defence 
response. For instance, IFN-induced IRF-1 has been shown to form  a com plex with
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IRF-8 and bind ISRE elements in the nitric oxide synthase (iN O S) prom oter [41]. 
This results in the production o f  nitric oxide (N O ), which is used by macrophages to 
destroy intracellular infectious agents [42]. IFN-induced IRF-1 also mediates the 
transcriptional activation o f  the p35 subunit o f  interleukin-12 (IL -12) [43], which is 
essential for phagocytic cell activation and inflammation follow ing infection [44] 
and which stimulates further IRF-1 expression in natural killer and T-cells [27].
IRF-1 also plays an important role in the adaptive immune system, specifically in the 
activation o f  cytotoxic T -lym phocytes (also know n as C D 8+ T -cells) w hich are able 
to induce the death o f  infected or tumour cells [45], These T-cells are activated when 
their cell surface receptor binds to “ n on -se lf ’ antigens [46]. These antigens are 
peptides released follow ing the degradation o f  invading pathogen by the 
im m unoproteosom e in antigen-presenting cells (A PC s). Peptides are then presented 
as part o f  the m ajor histocom patibility com plex (M H C ) on the surface o f  APCs [46]. 
IRF-1 has been shown to regulate expression o f  T A P I (Transporter for Antigen 
Processing 1) [9], This transmembrane pump transports peptides from the cytoplasm 
o f  antigen-presenting cells into the lumen o f  the endoplasm ic reticulum where they 
bind nascent M H C class I m olecules and the immunoproteasome com ponents LMP2 
and M ECL1 in response to IFN-y [9, 47, 48], thereby influencing the presentation o f  
viral and tumour antigens to C D 8+ T-cells. IRF-1 also regulates antigen display 
follow ing induction by the CD 40 receptor on antigen-presenting cells by  the CD40 
ligand (C D 40L) on the surface o f  T-cells. C D 40L can induce IRF-1 via recruitment 
o f  N F-kB to a prom oter element proximal to the IR F -1  gene transcription start site 
[34]. D e  oovo-synthesized IRF-1 then acts in concert with N F-kB to regulate the 
expression o f  genes responsible for antigen processing and transport such as the 
T A P I, TA P2, tapasin, LM P 2 , and L M P 10 genes.
It has also been shown that IRF-1 regulates genes involved in differentiation o f  T- 
helper 1 (T h I) cells [43], which in turn activate cytotoxic T-cells and macrophages. 
In antigen-presenting cells (A PC s), IRF-1 activates the transcription o f  p35 and p40, 
com ponents o f  the ThI-cell-inducing cytokines IL-12 and IL-23 [43], Furthermore, 
IRF-1 binds three different sites in the IL-4 prom oter and represses IL-4 
transcription, thereby inhibiting differentiation into Th2 cells [11], In bone marrow,
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IRF-1-m ediated IL-15 production promotes the maturation o f  natural killer (N K )-cell 
precursors [49], Mature N K  cells then produce IFN-y, which induces APCs and TH1 
cells to synthesize IR F-1. hr a positive-feedback loop, the IRF-1 that is produced by 
T hI cells further increases the activity o f  A PC s and differentiation into T H1 cells (see 
figure 1.2).
Additionally, IRF-1 has been implicated in the initial induction o f  type I interferons a 
and p. Overexpression o f  IRF-1 enhances virus-stimulated IFN-p expression in 
human fibroblasts [50], and IRF-1 has been described as part o f  an autoregulatory 
loop  in which it is both a target and a transcriptional activator o f  IFN-P [51 -53]. It 
has also been demonstrated that transient expression o f  DR.F-1 can upregulate the 
IFN-a promoter, but did not increase endogenous IFN -a expression [54].
M ore recently, studies in IRF-1 null cell lines and m ice have indicated that an IRF-1 - 
independent mechanism for IFN-uJp induction exists [55, 56]. IRF-1 - /-  mouse 
em bryonic fibroblasts showed unimpaired IFN-P induction follow ing infection with 
Newcastle Disease Virus (N D V ), but three to ten-fold  reduction in p o ly (I):poly (C )- 
mediated IFN-P induction [55], P oly(I):poly(C ) is a synthetic analogue o f  double­
stranded R N A  that simulates viral-infection [57]. IFN- ¡1 induction by 
poly (I):poly (C ) could  be restored by pre-treating the cells with IFN-P (a process 
referred to as priming), thus triggering a positive feedback-loop  [55], This result 
indicated that IFN-stimulated factors were responsible for the IRF-1-independent 
induction o f  IRF-fi. A  separate study confirm ed that IFN-p could  be induced in IRF-1 
null mouse em bryonic stem cells (fo llow ing 4 or 8 days o f  differentiation), although 
this induction was 1.3 to 6.6 fold  low er than that observed in the presence o f  IRF-1 
[58], It was subsequently shown in vivo that IFN-P could be induced by both N D V  
and poly (I):poly (C ) in m ice lacking IRF-1 [56]. The authors o f  this paper report no 
significant difference IFN-P induction between the control and IRF-1 null m ice, but 
did point out that considerable variation was seen between the individuals in each 
treatment group.
Taken together the data suggests that although IRF-1 can enhance IFN-p induction, it 
is not essential for expression o f  this gene. Chromatin immunoprecipitation has 
verified that IRF-1 (and IRF-2) bind to the IFN-P promoter in HeLa cells follow ing
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viral infection [59], but the importance o f  IRF-1 in IFN -a /fi gene stimulation is still 
unclear. IRF-3 and IRF-7 have also been shown to bind the I F N - f l  promoter [60] and 
IFN- [3 expression is com pletely disrupted in IR F -3 /7  double knockout mouse 
em bryonic fibroblasts [61]. It has therefore been proposed that, unlike IRF-1, the 
IRF-3:IRF-7 com plex plays an essential role in IR F -  ¡3 expression [61].
IFN-y induces IRF-1 expression in 
T-he lper 1 cells and APCs
Releases cytolytic proteins 





Releases cytolytic proteins 
that cause target pathogen 
cells to apoptose
Figure 1.2: IRF-1 expression in T-helper 1, antigen presenting, macrophage 
and natural killer cells has been linked to the activation of the innate and 
adaptive immune responses. Furthermore, positive feedback loops continue 
to stimulate IRF-1 expression during the immune response. Specifically, IRF- 
1 induces IL-12 expression in macrophages and causes natural killer cells to 
mature, which enables them to produce IFN-y; these cytokines then signal to 
T-helper 1 and antigen presenting cells producing an increase in the 
expression of IRF-1 in these cells.
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1.2.3.2 Inhibition of cell proliferation
IR F -1 regulates interferon-responsive genes involved in negative growth control [ 1, 
62] and is involved in Gi cell cycle  arrest [63]. Its overexpression leads to a 
pronounced reduction in cell growth [64], whereas knockdow n o f  endogeneous IRF- 
1 stimulates cell proliferation [65], M odulation o f  the IRF-2:IRF-1 ratio appears to 
be a critical mechanism in regulation o f  cell growth; for instance it has been shown 
that IR F -1-induced growth inhibition in human breast cancer cell lines can be 
overcom e through the induction o f  IRF-2 [6, 66], IRF-1 expression peaks in cells 
arrested by  serum starvation (Gi arrest), rapidly declines fo llow ing serum 
stimulation, then once m ore gradually increases prior to the onset o f  D N A  synthesis 
[6], In contrast, IRF-2 m R N A  expression remains essentially constant throughout the 
cell cycle  [6],
In further support o f  the importance o f  the IRF-2:IRF-1 ratio, exogenous IRF-1 
expression was able to revert IRF-2-induced cellular transformation and enhanced 
tum origenicity in nude m ice [6], There are currently two m odels to explain the 
mechanism through which ERF-2 suppresses interferon-induced gene expression: that 
it is able to out-com pete IRF-1 for promoter binding ow ing to its longer half life (8 
hours com pared to 30 minutes) [67], or alternatively that it induces changes in 
chromatin structure that silence gene expression through the inhibition o f  core 
histone acetlylation by p300 [68]. In correspondence with the effects seen follow ing 
its knockdow n and overexpression, IRF-1 ’ s target genes are known to include a large 
number o f  those involved in cell cycle  regulation. Som e examples are outlined 
below :
IRF-1 was observed to induce cell cycle  arrest in coronary artery smooth m uscle 
cells in the G0/G1 phase [63], The cyclin  A /C D K 2  kinase com plex is activated in 
late Gi at the G j/S  transition [69] and can be inhibited by cycle  dependent kinase 
inhibitors o f  the cip/kip fam ily such as p21 [70], IRF-1 has been shown to repress 
CD K 2 expression, lowering endogeneous protein levels and repressing transcription 
o f  a CD K 2 promoter luciferase construct [62]. IRF-1 has also been shown to induce 
expression o f  firefly luciferase encoding gene under the control o f  the p21  promoter 
sequence [63] and to upregulate p21 expression in cooperation with the tumour
19
suppressor protein p53 follow ing D N A  damage [71]. It was subsequently shown that 
p21  stimulation by IRF-1 is independent o f  IRF-1 binding D N A  and instead involves 
IRF-1 binding to the p53 coactivator p300, which stimulates p53 acetylation [72], 
thus up-regulating p53-dependent p21  activation (which is extensively described 
elsewhere [73, 74]). Additionally, IRF-1 has been shown to mediate IFN-y-induced 
upregulation o f p 2 7  [75], a cyclin-dependent kinase inhibitor that causes cell cycle 
arrest by binding to CD K 2 and thus suppressing the formation o f  cyclin  E /CDK 2 
com plexes essential for cell cycle  progression [76, 77], Exogenous expression o f  
IRF-1 stimulated p27 expression and IFN-y stimulation o f  p27 was abrogated in IR F -  
1-/- m ouse em bryonic fibroblasts [75],
Thus IRF-1 represses CD K2 on two levels: by  directly binding to its promoter to 
decrease its expression or by prom oting the expression o f  its inhibitor p21 and p27.
C yclin  D1 is a regulatory subunit o f  the CD K 4 holoenzym e that phosphorylates and 
inactivates the tumour suppressor pRb, this is a critical event in the Gi cell cycle  
checkpoint [78], In m yc/ras-transformed m ouse EFs, IRF-1 expression resulted in a 
marked decrease in cyclin  D1 protein and m R N A  levels and was able to decrease 
expression from a luciferase construct under the control o f  the cyclin  D 1  promoter 
[79]. In agreement with this observation, p R b ’ sphosphorylation was also reduced 
fo llow in g IRF-1 activation. Concomitant C yclin  D1 overexpression was able to 
overcom e the growth inhibitory effects o f  IRF-1 [79],
IRF-1 is also involved in the regulation o f  cell cycle  progression genes that do not 
directly b lock  C yclin /C D K  com plex formation. For instance, IRF-1 functionally 
interacts with and activates the histone 4 promoter cell cycle  element (C C E ), 5 '- 
C TT T C G G T T T T -3 ', which controls transcription at the G l/S  phase transition [80], 
A n  increase in histone transcription is coupled to D N A  synthesis during S phase o f  
the cell cycle  [81]. Regulation o f  histone transcription may therefore be linked to the 
gradual increase in IRF-1 expression seen prior to the onset o f  D N A  synthesis [6],
1.2.3.3 Apoptosis
A poptosis is the process o f  programmed cell death, and misregulation o f  apoptosis is 
associated with tumour developm ent and autoimmune disease [82, 83], In IFN-
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gamma-sensitive ovarian cancer cells, IFN-y-induced apoptosis was reduced through 
the knockdow n oiIRF-1 or overexpression o f  IRF-2. Furthermore, apoptosis could 
be strongly induced through IRF-1 transient expression without IFN-y treatment.
This effect was repressed when IRF-1 was co-expressed with its antagonist IRF-2 
[84],
IRF-1 has been shown to bind directly to the promoters o f  several pro-apoptotic 
genes, thus inducing their expression and triggering a signalling cascade ending in 
cell death. Such targets include: caspase 1, PUMA, TRAIL, XAF1 and the 
Angiotensin II type 2 (AT2)  receptor.
Caspases are aspartate-specific cysteine proteases, and their activation leads to the 
proteolysis o f  proteins essential for cell survival, thereby ultimately causing cell 
death [85]. IRF-1-induced apoptosis is also inhibited when cells are treated with 
caspase 1-inhibitors [84], and an IRF-1 binding site has been identified within the 
caspase 1 promoter [86], the mutation o f  which reduced IFN-y-stimulated caspase 1 
expression [87]. Another apoptosis-related target o f  IRF-1 transcriptional activation 
is PUMA (p53 upregulated modulator o f  apoptosis) [88], Characterised as a critical 
mediator o f  p53-dependent and -independent apoptosis, PU M A  functions by 
inducing mitochondrial dysfunction and caspase activation [89].
One target o f  IRF-1 o f  particular interest, given IRF’ s tumour suppressor function, is 
TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) [90]. T R A IL  is a 
potent inducer o f  death o f  cancer but not normal cells [91], which also functions 
through activation o f  the caspase signalling pathway (reviewed in [92]). XAF1 (X - 
linked inhibitor o f  apoptosis protein (XIAP)-associated factor 1) is also an IRF-1 
stimulated gene involved in the caspase signalling pathway. IFN-a induction o f  
XAF1 was shown to be mediated by IRF-1 and abrogated by  mutation o f  the IRF-1 
binding site (ISRE) in th eX 4F 7  prom oter [93, 94], XAF1 promotes apoptosis by 
associating with and antagonising X IA P , an inhibitor o f  caspase catalytic function 
[95].
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Finally, stimulation by IRF-1 has been shown to enhance apoptosis mediated by  the 
angiotensin II type 2 (A T 2) receptor [96], Expression o f  this receptor was shown to 
be regulated by IR F -l/IR F -2  com petition for an ISRE m otif within its promoter [97],
1.2.4 Structure/function mapping of IRF-1
The IRF-1 gene consists o f  10 exons. Mutant forms o f  the protein with impaired 
tumour suppressor activity have been identified in gastric adenocarcinom a [22], 
chronic m yeloid  leukaemia [23] and cervical cancer [24]. In som e cases only specific 
functions o f  IRF-1 are abrogated by  mutation. For example an exon 2 missense 
mutation (A 22T ) in human gastric adenocarcinom a produced an IRF-1 protein with 
unimpaired D N A  binding ability but reduced transcriptional activity [22], Another 
mutant protein, identified in cervical cancer patients, that lacked the C-terminal 
transactivation domains o f  IRF-1 (splicing variants involving exons 7, 8 and 9) was 
shown to com pete with wild type IRF-1 for D N A  binding, have a longer half life 
and, unlike the wild type protein, be expressed in a cell cycle  independent manner 
[24], Understanding the function o f  discrete domains in the w ild type IRF-1 protein 
could increase current understanding o f  the role these mutants play in tumour 
progression.
A  series o f  studies based on deletion mutants have already provided broad mapping 
o f  IRF-1 domains. These studies were carried out on either human (325 amino acids) 
or murine IRF-1 (329 amino acids). Com parison o f  m ouse and human IRF-1 has 
shown the two proteins are highly hom ologous (84%  identity: determined using the 
B L A S T  (Basic Local A lignm ent Search T oo l) sequence com parison program [98]) 
and that both can activate transcription o f  the target genes IF N -fi, iN O S , and C O X -2  
[99], therefore studies describing structural mapping o f  both m ouse and human IRF- 
1 are included here. Studies involving murine IRF-1 are indicated by an “ m after the 
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Figure 1.3: Mapping of human IRF-1 functions and regulation. NLS: nuclear 
localisation signal.
1.2.4.1 The DNA binding domain
The N-terminal D N A  binding domain o f  IRF-1 (defined as amino acids 1-124) 
shares significant h om ology  with other members o f  the IRF fam ily (see figure 1.4) 
and is characterized by five conserved tryptophan repeats, each o f  which are 
separated by  10-18 amino acids. These tryptophan residues mediate the specific 
binding o f  IRF-1 to the IFN-stimulated response element (ISRE) in target promoters 
[5]. The first 113 amino acids o f  IRF-1 have been crystallised bound to a 13 base- 
pair IFN-stimulated response element [100],
1.2.4.2 N-terminal transrepressor
The N-terminal 60 amino acids o f  IRF-1 were shown to act as an internal repressor 
o f  IRF-1 activity [101] m. In this study truncated sections o f  IRF-1 were fused to the 
D N A  binding domain (D B D ) o f  the transcription factor Gal4, and the ability o f  these 
IR F -1 regions to modulate activation o f  a prom oter bound by the Gal4 D B D  was 
assessed. In this w ay the enhancer domain (see section 1.2.4.7) o f  IRF-1 was 
identified; and a “ G A L 4 DBD-IRF-1 transactivation and enhancer dom ain”  fusion 
protein was shown to have a reduced ability to activate transcription when com bined 




IRF-3 MG--- --------TPKPRILPWLVSQLDLGQLEGVAWVNKSRTRFRIPWKHGLRQDAQ-QEDFGIFQAWAEATGA 63
IRF-4 MNLEGGGRGGEFGMSAVSCGNGKLRQWLIDQIDSGKYPGLVWENEEKSIFRIPWKHAGKQDYNREEDAALFKAWALFKGK 80
1 RF-6 MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQEEENTIFKAWAVETGK 66
1RF-7 a MALAPERA— --------APRVLFGEKLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLS-EADARIFKAWAVARGR 69
IRF-8 MCDRNGGR— ------------ RLRQWLIEQIDSSMYPGLIWENEEKSMFRIPWKHAGKQDYNQEVDAS X FKAWAVFKGK 66
IRF-9 - MASGRARC TRKLRNWWEQVESGQFPGVCWDDTAKTMFRIPWKHAGKQDFREDQDAAFFKAWAIFKGK 68
IRF-1 YKAGE-------- KEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRVYRMLPPL----------- TKNQRKERK 124
IRF-2 HQPGV-------- DKPDPKTWKANFRCAMNSLPDIEEVKDKSIKKGNNAFRVYRMLPLS----------- ERPSKKGKK 124
IRF-3 YVPGR-------- DKPDLPTWKRNFRSALNP.KEGLRLAEDRSK-DPHDPHKIYEFVNS---- GVG----DFSQPDTSP 124
IRF-4 FREGI--------- DKPDPPTWKTRLRCALNKSNDFEELVERSQLDISDPYKVYRIVPE-------------- GAKKGAK 137
IRF-6 YQEGV--------- DDPDPAKWKAQLRCALNKSREFNLMYDGTKEVPMNPVKIYQVCDI-------------- PQPQGSI 123
IRF-7a WPPSSRGGGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSG-DPADPHKVYALSRELCWREGPGTDQTEAEAPAAVP 14 8
IRF-8 FKEG---------- DKAEPATWKTRLRCALNKSPDFEEVTDRSQLDISEPYKVYRIVPE--------------EEQKCKL 122
IRF-9 YKEG---------- DTGGPAVWKTRLRCALNKSSEFKEVPERGRMDVAEPYKVYQLLPP-------------- GIVSGQP 124
Figure 1.4: Sequence alignment of IRF family DNA binding domain (DBD). 
The N-terminal 124 amino acids of human IRF-1 were compared to IRF-2 to 
9, (excluding IRF-5) using the BLAST program [98]. IRF-5 was excluded as it 
has low primary sequence homology to the IRF-1 DBD, although it still 
retains the 5 highly conserved tryptophan repeats that characterise the IRF 
DBD (highlighted in blue for the other IRFs) [102] and 36% sequence identity 
to a C-terminal region of IRF-1 (amino acids 291-315) (noted during BLAST 
analysis: data not shown). Only the sequence of isoform-a of IRF-7 was 
used in this analysis, other isoforms of this protein were excluded to simplify 
analysis.
1.2.4.3 Homodimerisation domain
Amino acids 90-115 were shown to be essential for an intracellular interaction 
between two recombinant IRF-1 proteins [103]m. The crystal structure o f IRF-1’ s 
DNA binding domain indicates that a monomeric IRF-1 binds to the core GAAA 
sequence within the ISRE, however, the authors o f  this study speculate that as some 
ISRE contain two GAAA core sequence they could accommodate two IRF-1 
molecules [100],
1.2.4.4 Nuclear localisation signal
The nuclear localisation signal o f  IRF-1 has been mapped to amino acids 117-141 
[104]m. When fused to GFP, this discrete domain was able to re-localise the 
fluorescent protein to the nucleus.
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1.2.4.5 Heterodimerisation domain
A  region o f  IRF-1 overlapping the N LS, spanning amino acids 125-219, was shown 
to be necessary but not sufficient for heterodimerisation with IRF-8 (an IRF-1 c o ­
factor) [1 0 4 ]m. This association is further discussed in section 1.2.5.4.3.
1.2.4.6 Transactivation domain
Fusion to fragments containing IRF-1 amino acids 185-220 or 220-256, enabled the 
D N A  binding domain to induce transcription thus defining the transactivation 
domain (amino acids 185-256) [101, 104] m. This domain was further reduced to 
amino acids 233-257 in human IRF-1 and was able to transactivate the D N A  binding 
domains o f  other transcription factors as part o f  fusion proteins [105]. Deletion o f  
this region interfered with wild type IR F -l ’ s ability to stimulate IFN-J3 expression, 
inhibit growth and induce apoptosis, possibly through formation o f  an inactive 
hom odim er or by  com peting for target promoters [105]. Follow ing identification o f  
the transactivation domain it was demonstrated that this region o f  IRF-1 could 
mediate downstream signalling in a manner independent o f  D N A  binding activity. 
p53 and IRF-1 can act synergistically to prom ote p21 expression [71] and p300- 
dependent acetylation was previously shown to increase p53 transcriptional activity 
[106-108]. It was revealed that specific regions o f  IRF-1 (amino acids 226-245 
known as CT3, and amino acids 271-290 known as C T2) could bind directly to the 
acetyl transferase p300, prom ote p300 binding to p53 and the acetylation o f  D N A - 
bound p53 at the p21 promoter [72].
The transactivation domain also appears to be involved in post-translational 
m odification, as the deletion o f  IRF-1 amino acids 219-231 blocked  in  vitro  
phosphorylation o f  IRF-1. Additionally, mutation o f  four putative phosphoaceptor 
residues in the transactivation domain significantly decreased transactivation 
mediated by IRF-1. Interestingly, in this same study casein kinase II was co-purified 
from  cell lysate with exogenous His-tagged IRF-1 and shown to bind to it directly, 
indicating that it may be involved in the regulation o f  IRF-1 function [1 0 9 ]m.
1.2.4.7 Enhancer domain
Unlike the transactivation domain, a m ore C-terminal region o f  IRF-1 spanning 
amino acids 257-329 could  not independently increase transcriptional activity o f  a
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G A L4 D N A  binding domain [1 0 1 ]m. H owever, the inclusion o f  this region increased 
transcriptional activation com pared to that generated by the Gal4 D B D - 
transactivation domain alone. This extreme C-terminal region was therefore 
identified as an enhancer domain [101] m.
As a link between the C-terminus o f  IRF-1 and its ability to activate transcription had 
been established, it was possible that this trans-acting region could influence IRF-1 
repressor functions. IRF-1 has been shown to repress certain genes including S L P I  
(secretory leukocyte protease inhibitor) and C D K 2  (cyclin-dependent kinase 2) [10, 
62], Deletion o f  the C-terminal 25 amino acids increased IRF-1-dependent induction 
o f  IF N -p , but mitigated C D K 2  repression. Smaller deletion mutants and alanine 
substitutions revealed that amino acids 311-317 act as an internal suppressor o f  IRF- 
1 ’ s transcriptional activator function. Thus, mutation o f  these residues increases IF N -  
p  induction. Furthermore, amino acids 306-310 were shown to be essential for C D K 2  
suppression [64], These C-terminal mutants did not affect IR F -l ’ s D N A  binding 
suggesting that they may modulate IR F -l ’ s association with as yet unidentified c o ­
factors.
The extreme C-terminus was also shown to play a role in the stability o f  IR F-1. IRF- 
1 has an extremely short half life o f  20-40 min [1 1 0 ]m and [111], Truncations o f  
more than 39 C-terminal amino acids generated a degradation resistant form  o f  IRF-1 
[1 1 0 ]m. It has also been shown that the protein is capable o f  being polyubiquitinated 
and degraded by  the 26S proteosom e [1 1 0 ]m. Inhibition o f  the proteosom e leads to 
an increase in polyubiquitinated forms o f  IRF-1 [110] m, indicating that IR F -l ’ s 
ubiquitination is linked to its degradation. During a m ore detailed mapping o f  this 
function it was seen that deletion o f  the last 70 amino acids o f  IRF-1 prevented both 
polyubiquitination and degradation, whereas deletion o f  the last 25 amino acids did 
not prevent ubiquitination, but did inhibit degradation [111]. Furthermore, exogenous 
expression o f  the C-terminal 70 amino acids was shown to reduce ubiquination o f  
endogenous w ild type IRF-1. This suggests that the C-terminus may act as a docking 
region for ubiquitin-promoting co-factors (e.g. E3 ligases) and com pete in trans with 
full-length IRF-1 for binding to these proteins. A n increase in the half life o f  IRF-1 
has previously been linked to its upregulation during ATM -dependent D N A  damage
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response [29], highlighting the physiological importance o f  IR F -l ’ s degradation in 
its regulation.
A n  L X X L L  m otif residing between amino acids 306 and 318 in the C-terminus o f  
IR F -1 has been shown to be o f  particular significance in regulation o f  IR F -1 
turnover, as an Hsp90-dependent increase in half life and protein levels o f  nuclear 
IRF-1 was shown to be reliant on direct binding o f  FIsp70 to this m otif [112].
1.2.5 Post-translational regulation of IRF-1
IRF-1 expression is tightly regulated during the cell cycle  and in response to 
infection. H owever, several lines o f  evidence also indicate that it is regulated post- 
translationally. Its phosphorylation state has been linked to its ability to form  
heterodimers [113], ubiquitination and SUM Oylation seem to affect its degradation 
and activity [110, 114] and the exchange o f  co-factors enables it to respond to a 
range o f  stimuli including DN A-dam age, interferon stimulation and toll-like receptor 
activation (detailed in section 1.2.5.4). The repression or activation o f  diverse sets o f  
genes by  IRF-1 in response to specific stimuli appears to be dependent on the c o ­
factor associated with IR F-1. Thus these post-translational associations may 
determine which o f  a range o f  possible responses will be induced follow ing IRF-1 
expression.
1.2.5.1 Phosphorylation
IRF-1 was shown to bind directly to the alpha catalytic subunit o f  CKII (casein 
kinase II), a tetrameric serine/threonine protein kinase, through its N-terminal 120 
amino acids [109]. Alanine substitution o f  potential CKII phosphoacceptor sites in 
the C-terminus o f  IRF-1 (amino acids 2 19 -2 3 1 ) blocked in vitro  phosphorylation and 
reduced the IRF-1 dependent activation o f  the interferon p promoter [109]. IRF-1 has 
also been shown to be tyrosine phosphorylated follow ing IFN-y stimulation [113], 
supporting the possibility that phosphorylation is a means through which IRF-1 is 
regulated.
1.2.5.2 Ubiquitination
Covalent attachment o f  small (8.5K D a) ubiquitin moieties to lysine residues in a 
target protein has been linked to directing proteins for degradation or altering
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localisation and activity [115]. Figure 1.5 summarises the attachment o f  ubiquitin to 
a target protein. Inhibition o f  the proteasome, a multi-protein com plex responsible 
for protein degradation, causes an increase in polyubiquitinated forms o f  IRF-1 
[110], indicating that ubiquitination o f  IRF-1 mediates its degradation. Deletion o f  
the last 25 amino acids o f  ERF-1 does not prevent its ubiquitination, but does inhibit 
degradation [111], suggesting that follow ing ubiquination the C-tenninus o f  IRF-1 is 
involved in a further regulatory step that enables degradation. An Hsp70 binding site 
has been identified in this region and this interaction was shown to be essential for an 
Hsp90-dependent increase in IRF-1 stability [112], it is therefore possible that 
abrogation o f  Hsp70 binding may mediate IRF-1 degradation. Reduced degradation 
o f  IRF-1 has also been linked to its upregulation during the ATM -dependent D N A  
damage response [29] highlighting the physiological importance o f  this form  o f  
regulation. The E3 ubiquitin ligases that facilitate IRF-1 degradation have not yet 
been identified.
1.2.5.3 SUMOylation
The attachment o f  a SU M O protein (Small Ubiquitin-like M odifier) to lysine 
residues is a post-translational m odification similar to ubiquitination and can also 
affect target protein activity [117]. U bc9, a SU M O  E2-conjugating enzym e and 
SUMO-1 were shown to directly interact with IRF-1 and, when overexpressed, to 
decrease IRF-1-dependent transcription [118]. Furthermore, co-expression o f  
SUM O-1 and IRF-1 was seen to increase the h alf life o f  IRF-1 suggesting 
SUM Oylation may stabilise the protein [114]. This data suggests that SUM Oylation 
may hold IRF-1 in a less active form  with a low er rate o f  degradation. Additionally, 
SUM Oylated IRF-1 has been reported to be elevated in cancer cells lines [114], 
indicating that this m odification has physiological relevance.
One drawback o f  co-expressing SUM O-1 is that it can bind to a w ide range o f  
cellular proteins [117]; thus changes in IRF-1 activity observed may not have been 
caused by  its SUM Oylation, but rather as a product o f  SUM O-1 ’ s off-target effects. 
Another study into this post-translational m odification demonstrated that IRF-1 fused 
C-terminally to a SU M O m oiety, thus m im icking SUM Oylated IRF-1, was able to 
transform mouse em bryonic fibroblast-cells and down-regulate IRF-1-dependent
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transcription [119]. Covalent attachment o f  a SU M O  m oiety has been used in 
functional studies o f  other proteins, together with untagged mutant proteins that 
could not be SUM Oylated as controls [120, 121], however in the SUM O-IRF-1 study 
no such mutants were used, and it is not clear that this fusion accurately m im icked 
the functions o f  a SUM Oylated IRF-1.
Figure 1.5: Flow diagram showing ubiquitination of a target protein substrate 
by the E1 ubiquitin-activating enzyme, E2: ubiquitin-conjugating enzyme and 
E3: ubiquitin ligase. Based on the following reference [116].
The SU M O E3 ligase PIAS3 (Protein inhibitor o f  activated STA T 3) was identified as 
an IRF-1 interacting protein in a yeast-2-hybrid screen [122], It was further shown 
that a point mutation in the ring finger domain o f  PIAS3 (C 334S), which is required 
for its SU M O-ligase activity, prevented SUM Oylation o f  IRF-1 without interfering 
with IRF-1 :Pias3 binding. Co-transfection o f  w ild type PIAS3 also inhibited
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expression from  an IRF-1 reporter gene 30%  m ore than the C334S mutant, 
supporting the idea that IRF-1 is negatively regulated by SUMOylation.
1.2.5.4 IRF-1 co-factors
1.2.5.4.1 NF-kB
E M SA  and co-im m unoprecipitation assays involving cell lysates or nuclear extracts 
have been used in the past to show IRF-1 and NF-kB form  com plexes able to 
enhance or suppress transcription from  target promoters [123-125]. For example, 
IRF-1 was co-im m unoprecipitated in com plex with H D AC-1 (histone deacetylase 1) 
and p65 (an NF-kB subunit) at the P D G F  -D  (platelet-derived growth factor-D ) 
prom oter follow ing stimulation by the proinflammatory cytokine interleukin (IL )-l [3 
[126]. This com plex was abrogated by H DAC-1 knockout; but when intact mediated 
silencing o f  its target promoter. A  direct interaction between purified IRF-1, H D A C - 
1 and/or the p65 subunit o f  NF-kB was not validated, meaning that other proteins 
may also form  integral parts o f  the com plex and mediate its association. Another 
study demonstrated that IRF-1 can bind directly to the p50 NF-kB subunit [127]. In 
the same study IRF-1 was also shown to bind H M G I(Y ) (High m obility group I (Y )), 
a non-histone chromatin protein [128], H M G I(Y ) and p50 were shown to stabilise 
IRF-1 binding to a prom oter targeted by both IRF-1 and NF-kB ( V C A M -1 ), and c o ­
transfection with IRF-1 and NF-kB was seen to enhance transcription to a greater 
extent than was generated by overexpressing either transcription factor alone [127], 
indicating that the two acted synergistically. Subsequently the NF-kB/IRF- 
1/H M G I(Y ) com plex was shown to activate other promoters (IF N -ff)  and was 
described as an enhanceosom e [129], The enhanceosom e form ed on the IFN-/3  
prom oter was also shown to recruit the co-activator protein p300 which bound 
directly to both IRF-1 and the NF-kB subunit p65 [130]. p300 is an intrinsic 
acetyltransferase and ubiquitin ligase involved in transcriptional regulation [131, 
132], The contribution o f  IRF-1 to the enhanceosom e is debated [133], as IRF-1 null 
m ice still show IFN-P expression [56] (discussed in section 1.2.3.1). H owever, these 
studies still suggest a process o f  co-factor exchange m ay exist that determines 
whether the IR F -1 :NF-kB com plex functions as a transcriptional activator as on the 
IF N -P  promoter, or repressor as on the P D G F - D  promoter.
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1.2.5.4.2 STAT1
IRF-1 has also been shown to directly interact with the transcription factor STAT1 
(signal transduction and transcription 1) [134], This interaction was shown to 
mediate transcription from  a gene targeted by both transcription factors: L M P 2  (low  
m olecular mass polypeptide 2). His-tagged STAT1 im m obilised on an 
oligonucleotide based on the L M P 2  promoter could bind to both purified and 
endogenous IRF-1. The minimal region o f  IRF-1 required for STAT1 binding was 
mapped to amino acids 170-200. Additionally, the adenovirus E l A  protein was able 
to b lock  the STAT1:IRF-1 interaction and thereby inhibit expression from the LMP2 
promoter [134], indicating that disruption o f  this association is one o f  the 
mechanisms em ployed by  the virus to overcom e the host’ s im m une response.
1.2.5.4.3 IRF-8
Another transcription factor capable o f  interacting with IRF-1 is IRF-8. IRF-1 and 
IRF-8 have been shown to com pete for interferon response elements (ISRE) in target 
promoters, thus IRF-8 has been described as a repressor o f  IRF-1 [135]. IRF-8 has 
also been shown to repress IRF-1-induced activity by directly binding to IRF-1 and 
disrupting its interaction with other co-factors such as the H IV protein Tat (Trans- 
Activator o f  Transcription) [136], H owever, the IR F-1 : IRF-8 com plex has also been 
described as activating transcription. It was initially demonstrated that IRF-1 binding 
could enhance IR F-8 ’ s affinity for the ISRE [137]; and that the IRF-1 :IRF-8 com plex 
can bind and thereby activate transcription from the I L  (in terleukin )-1 2 p 3 5  [138] 
and R A N T E S  (Regulated on Activation, Normal T -cell Expressed and Secreted)
[139] genes. M ore recently IRF-1 and IRF-8 have been shown to bind overlapping 
regions o f  the IL -2 7 p 2 8  prom oter in vivo  fo llow ing stimulation by  IFN-y [140]. 
siRN A knockdow n o f  IRF-8 was also shown to reduce IRF-1 binding to the IL -2 7  
p 2 8  promoter, in agreement with the observation that expression o f  this gene was 
defective in IRF-8 deficient cells [140], Furthermore, IRF-1 and IRF-8 
synergistically activated IL-27 p28 expression when co-expressed [140],
It has also been demonstrated that the interaction between IRF-1 and IRF-8 can be 
blocked  by tyrosine kinase inhibitors [113]. H owever, as both IRF-1 and IRF-8 are
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tyrosine phosphorylated, the mechanism through which this post-translational 
m odification facilitates this interaction requires further investigation.
1.2.5.4.4 p300
Induction o f  the I L  (in terleukin )-12p40  promoter by the IRF-1 :IRF-8 com plex was 
enhanced by  co-transfection o f  another IR F-l-b inding protein: p300 [141]. In a 
separate study IRF-1 binding to p300 was shown to stimulate p53 acetylation, 
thereby up-regulating p53-dependent p21 activation [72], but the exact role o f  p300 
in the IRF-1 :IRJF-8 com plex still requires elucidation.
1.2.5.4.5 PCAF
Histone acetylases associated with transcription factors have been found to generally 
enhance transcription [142, 143]; a finding consistent with reports that 
transcriptionally active chromatin is com posed o f  highly acetylated histones [144, 
145] and that a histone acetylase is one o f  the com ponents o f  the T A T A  binding 
protein (TBP)-associated factor [146], Histone deacetylases on the other hand have 
been linked to transcriptional repression [147-149]. IRF-1 was shown to recruit the 
histone acetylase PCAF (P300/CBP-associated factor) to an interferon-stimulated 
response element (ISRE) [150]. PCAF was seen to increase IRF-1 induction o f  an 
ISRE-reporter gene in a dose-dependent manner. Taken together with the previously 
discussed finding that the histone deacetylase H D A C  forms a silencing com plex with 
IRF-1 and p65 [126], this data suggests that switching between histone acetylase and 
deacetylase co-factors may be a mechanism through which IRF-1 mediates activation 
or repression o f  a target gene.
This system can also be utilised by pathogens to deactivate IRF-1. For instance, the 
human papillomavirus oncoprotein E7 is implicated in the malignant phenotype o f  
cervical cancer and has been shown to directly interact with the C-terminus o f  IRF-1 
(amino acids 2 17 -3 2 5 ) [151]. This interaction inhibits IRF-1-directed stimulation o f  
an IFN-P reporter gene construct, but does not affect IRF-1 degradation. E7 
repression o f  IRF-1 activity was shown to be alleviated by a H D A C  (histone 
deacetylase) inhibitor or by deletion o f  the carboxyl-terminal zinc finger domain o f  
E7 which was previously shown to associate with H D A C  [151], indicating that IRF-1 
repression is mediated by E7 recruitment o f  H D AC.
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1.2.5.4.6N PM
Other non-transcription factor proteins have also been shown to m odify  IRF-1 
activity. For example, IRF-1 has been shown to bind directly to N PM  
(nucleophosm in) [144], a multifunctional protein that shuttles between the nucleus 
and cytoplasm  and regulates rRN A export from  the ribosom e [152] and the activity 
o f  tumour suppressor proteins A RF and p53 [153, 154], Association with NPM 
negates I R F -l ’ s ability to bind D N A  and thus reduces IRF-1 dependent transcription 
[144]. N PM  has been characterised as an oncogene; it is present at elevated levels in 
several leukaemia cell lines, and its exogenous overexpression can transform mouse 
em bryonic fibroblasts [144], It is therefore possible that suppression o f  IRF-1 is one 
o f  the mechanisms through which the oncogenic effects o f  N PM  are mediated.
1.2.5.4.7 GRIP-1
GRIP-1 (G lucocorticoid  receptor-interacting protein 1) is able to bind IRF-1 directly, 
but unlike N PM , GRIP-1 enhances transcription o f  IR F -l ’ s downstream targets; with 
siR N A  targeting GRIP-1 reducing IRF-1-dependent reporter gene activity by more 
than 57%  [155], The C D 3 8  (cluster o f  differentiation 38) gene which is expressed in 
an IRF-1-dependent manner also showed reduced expression follow ing knockdow n 
o f  G RIP-1, suggesting that this interaction can modulate IRF-1 activity in vivo  [155].
1.2.5.4.8 MyD88
Another IRF-1 co-activator is M yD 88 (M yeloid  differentiation primary response 
gene 88), an adapter protein recruited by TLRs (Toll-like receptors) upon pathogen 
recognition that then interacts with and activates down-stream mediators o f  the TLR  
signalling pathway, such as IRF-5 or IRF-7, to induce an immune response [156,
157], M yD 88 can bind directly to IR F-1. Additionally co-expression with M yD 88 
increases the rate at which IRF-1 was translocated to the nucleus and enhances 
expression from an IRF-1 dependent reporter gene [158], Controlling transcription 
factor sub-cellular localisation has been described as an efficient w ay o f  regulating 
their activity [159],
1.2.5.4.9 KPNA2
IRF-1 is also translocated into the nucleus by KPN A2 (karyopherin a2, also known 
as importin a) [160], a cytosolic receptor that docks nuclear localisation signal
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(NLS)-€<SBtei««ig proteins al the nuclear pore com plex on the nuclear membrane 
[ M l ] ,  L i fe  M F 'l*  &FM A2 is expressed fo llow in g stimulation with IFN-y, which 
suggests KPM A2 m ay b e  induced to facilitate downstream IFN-y signalling by 
prom oting 1RF-J nuclear localisation [160], H owever, the effect o f  KPNA2 
©xpfcssisffl ©0 JRF-1 -dependent promoters was not investigated nor was its binding to 
the prcviottsly identified 1RF-1 NLS [104],
Thei© studies indicate that IRF-1 can function as part o f  a com plex o f  transcription
factors and that facilitation o r  disruption o f  such com plexes could be a means 
through w hich IMF-1 activity is regulated. They also show that viral proteins like Tat 
or  E l A  hijack IRF-1 b y  com peting against its normal co-factors to limit the IR F -1 - 
dependent «untune response.
T he studies described here support the idea that post-translational m odification and 
proteinrprottein interactions play an important role in controlling IRF-1 activity. 
H ow ever these experiem enfs necessarily relied on transfected IRF-1 for most o f  their 
findings, and it w ou ld  be interesting to see i f  these interactions arc rate-limiting for 
the activity © f the endogenous protein. Furthermore, it is clear that important IRF-1 
interactions remain » id e n t if ie d . W hat is/are the E3 ubiquitin ligase(s) that target 
IR F-1? D o  ©tiser kinases beside CK11 phosphorylate IRF-1? Are other proteins 
important com ponents o f  its activating o r  silencing com plexes? The identification o f  
novel IRF-1 interacting proteins w ill hopefully begin to answer som e o f  these 
questions. Phage display has been used in this study to both isolate antibodies that 
b ind t© specific regions o f  IRF-1 and to identify IRF-1 binding peptides. The 
antibodies w ere subsequently developed into intrabodies able to modulate the 
activities o f  endogenous IRF-1 and the phage display peptide sequences have been 
used to select potential IRF-1-interacting proteins for future characterisation. Section
1.3 describes the phage display techniques that arc central to the work described in 
tins thesis.
1.3 Phage display
A  bacteriophage (usually shortened to phage) is any virus capable o f  infecting 
bacteria [162]. Filamentous phage M l 3 [163] and ftl [164] arc the most com m only
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used carriers in phage display, but lytic bacteriophage, such as T4 [165], T7[ 166], 
and X [ 167] phage have also been used.
Phage display technology relies on a physical linkage between phenotype and 
genotype; a polypeptide displayed on the surface o f  a phage virion is also encoded 
within the phage genom e. Extremely diverse libraries (> 1 0 10) o f  D N A -encodcd  
peptides or proteins can be generated and cloned into phage [ 168], These 
polypeptides are then expressed as fusions to phage coat proteins and selected for 
binding to im m obilised ligands [169]. In this way the phage library becom es 
enriched for those that bind specific ligands. Phage that do not bind the target ligand 
are simply washed away before high affinity phage are eluted. The new ly generated 
p oo l o f  high affinity phage can be amplified in host bacteria and used again in 
another selection round [169]. Finally, and most importantly, the amino acid 
sequence o f  any protein or peptide displayed can be easily determined b y  sequencing 
the D N A  inside the phage particles.
Several factors influence the choice o f  phage carrier. The exposed end o f  m ost coat 
proteins differs between the filamentous (N-terminal) and lytic (C-tenninal) phage. 
The presented peptide can therefore be affixed to the carboxy (filamentous) or amino 
(lytic) termini o f  a coat protein, making it possible to choose which end o f  a peptide 
should be left most exposed for interaction with the bait protein [166], although N - 
terminal fusion is still possible in filamentous phage via the g6p coat protein [170], 
Capsids o f  lytic phages such as T7 and lambda phages are assembled in the 
cytoplasm , whereas filamentous phage capsids are form ed in the periplasm [171]. 
The b iological constraints for folding the displayed protein are therefore different. 
Additionally, use o f  lytic phage involves tim e-consum ing purification steps between 
selection rounds to avoid panning amplified phage in the presence o f  cellular 
proteins from  the lysed bacterial host (including proteases), whereas non-lytic phage 
are secreted through the bacterial membrane and can be purified by  a simple PEG 
(poly[ethylene g lyco l]) precipitation step [172],
The methods described in this thesis utilise M l 3 bacteriophage; a filamentous, 
E sch e rich ia  co/z'-specific virus consisting o f  a circular, single-stranded D N A  
(ssD N A ) core surrounded by a protein coat [173]. In this study the displayed peptide
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or antibody fragment is fused to the g3p m inor coat protein (~  3 copies per phage) 
[174],
Phage display libraries can be created in two ways [175], by cloning the polypeptide:
1) into the phage genom e (phage vector) in frame with a coat protein, in w hich case 
the number o f  displayed polypeptides corresponds to the number o f  coat proteins, or
2) into a m odified phage genom e known as a phagemid, in which most viral genes 
have been deleted, but w hich still carries the gene encoding the coat protein. W hen a 
cell harbouring a phagemid is infected by helper phage (w hich supply the deleted 
phage genes), virions that display a mixture o f  recombinant coat proteins, encoded 
by the phagemid, and the corresponding w ild type proteins, encoded by the helper 
phage genom e, are produced [176]. Phagemid cloning enables the display o f  longer 
polypeptides than is possible with a phage vector [176]. In this thesis a library based 
on cloning into a phage genom e was used for peptide phage display (chapter 6), and 
one based on phagemid cloning for antibody phage display (chapters 4 and 5).
Other display surfaces can also be used to select for high affinity antibody or peptide 
interactions including: surface expression on bacterial, yeast or mammalian cells, or 
cell-free systems such as ribosom e display [177].
1.3.1 Antibody phage display
Unlike standard hybridoma technology, the generation o f  antigen-specific antibody 
fragments can be perform ed within a couple o f  weeks though antibody phage display 
[178]. Performed in vitro, phage display circumvents the need for im m unogenicity 
and is therefore particularly w ell suited to generating antibodies against self, low - 
im m unogenic (like IRF-1) or toxic proteins [178]. Additionally human antibody 
fragments can be generated, which w ould present a lower risk o f  immune response in 
subsequent therapeutic studies [179], Once an antibody has been selected, the phage 
can continue to act as a genetically stable source o f  the antibody, which can be stored 
over a long period. The antibody genes can be easily sequenced, mutated and then 
screened again for improved specificity [180],
A ntibody phage display relies on large (1 0 10 clones) naive or immune antibody 
libraries [178], Follow ing two to three rounds o f  selection, this population becom es
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enriched for antibody fragments specific for the target antigen. In order to generate 
the antibody library, antibody fragments are cloned into a phagemid upstream o f  a 
phage coat protein (usually g3p or g8p) and expression is controlled by the use o f  a 
promoter such as lacZ. Phagemids also carry an antibiotic resistance marker. The 
relatively small size o f  phagemid plasmids (~ 4.6 Kb) means that they have higher 
transformation efficiencies than phage vectors, enabling the construction o f  large 
libraries [181], Incorporation o f  an amber stop codon between the antibody fragment 
and phage coat protein results in their expression as a fusion protein in suppressor 
strains o f  E .c o li  (e.g. T G I) or as an isolated antibody fragment in non-suppressor 
strains (e.g. HB2151).
The phagemid alone is insufficient for the production o f  infective phage particles in 
bacteria as it does not contain all the genes needed for phage replication and 
assembly. These are provided by helper phage [182]. During the amplification step, 
bacterial cells already containing the phagemid vector are co-infected with the helper 
phage. The growth media is supplemented with glucose, which suppresses the lacZ 
promoter and therefore expression o f  the antibody-coat protein fusion. Once helper 
phage infection is com plete, the glucose is rem oved and production o f  antibody- 
displaying phage particles can com m ence [182],
1.3.1.1 Different types of antibody fragments
Multivalent naturally occurring human antibodies (IgG, IgM , IgA, IgE) are highly 
specific targeting reagents and provide our key defence against pathogenic organisms 
and toxins. IgG is most often developed for use as a molecular tool and therapeutic
[183], It is a Y-shaped, bivalent protein with two antigen-binding sites located within 
Fab domains and an Fc domain that mediates recruitment o f  cytotoxic effectors
[184]. The constituent domains o f  IgGs can be expressed as soluble antibody 
fragments, which retain the specific binding properties o f  a com plete IgG, either as 
monovalent (Fab, scFv, single variable V h and V l domains) or multivalent fragments 
generated through fusions o f  these moieties [185, 186]. Restricting antibody size 









Fab (fragment antigen-binding) are com posed o f  both the constant and variable 
regions o f  the antibody heavy and light chain (unlike scFv which are made up o f  only 
the variable regions) [187], Within the N-terminal variable (V ) domain o f  each chain 
are Complementarity Determining Regions (CD Rs, also called hypervariable loops) 
which form  the antigen binding site.
1.3.1.1.2 scFv
The two phage display libraries used in this thesis, the Tom linson and ETH -2-gold 
libraries [l 88, 189], both involve the display o f  single chain variable fragments 
(scFv) attached to the phage coat protein. scFv consist o f  the variable regions o f  the 
heavy (V h )  and light ( V l )  chains connected by a flexible polypeptide linker to 
prevent dissociation [190, 191],
1.3.1.1.3 Single domain (V) antibodies (nanobodies)
Naturally occurring antibodies, consisting o f  only a heavy chain, have been identified 
in camelids (camels and llamas) [192] and cartilaginous fish (w obbegong and nurse 
sharks) [193] and were shown to play an important role in the immune system o f  
these organisms. These heavy chain domains (known as VhH in Camelids and 
IgN A R  in sharks) display longer hypervariable loops than murine and human 
antibodies and are therefore better at penetrating cavities in target antigens such as 
enzyme active sites [194, 195],
M ouse single variable (V ) domains were shown to be functional [196] at an early 
stage o f  antibody engineering. It was subsequently established that antibodies based 
on human heavy chain and light chain variable domains ( V h  and V l )  selected by 
phage display also have good  antigen recognition and affinity [197, 198]. It has been 
proposed that, because o f  their smaller size, single domain antibodies could 
potentially target cryptic epitopes [199].
1.3.1.1.4 Multivalent antibody fragments
For many applications, it is desirable to engineer the m onovalent Fab, scFv 
fragments or V-dom ain m olecules into multivalent m olecules, which show increased 
functional affinity (termed avidity) and slower dissociation rates. Fab fragments have
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been chem ically cross-linked into bi- or trivalent multimers [200, 201]. Shortening 
the scFv linker induces self-assem bly into either bivalent [202, 203], trivalent [204, 
205], or tetravalent [206] multimers.
Multivalent antibody fragments are not only able to possess increased avidity (the 
number o f  identical binding sites) but can also be converted into bispecific antibodies 
with two different binding specificities fused into a single m olecule. Such antibodies 
can bind either two adjacent epitopes on a single antigen, thereby increasing both 
avidity and specificity, or two different antigens. Multivalent antibodies targeting 
more than one antigen have numerous potential uses and have already been utilised 
in recruitment o f  cytotoxic T- and natural killer (N K ) cells [207, 208] and targeting 
o f  toxins [209, 210], radionuclides [211] or cytotoxic drugs [212, 213] for cancer 
treatment.
1.3.1.2 Different types of library
There are several different types o f  antibody phage display library available. The key 
differences between available antibody phage display libraries are 1) the source, 2) 
the level o f  antibody diversity and 3) the type o f  antibody fragment displayed (fab, 
scFv etc.).
The genom ic information coding for antibody variable domain can com e from  B 
cells o f  various animals, but are typically murine [13], human [214], cammelid [215, 
216] or from  cartilaginous fish [217]. The donor can additionally be naive (non­
immunised) or immunised. Immune libraries provide an antibody repertoire enriched 
against the antigen that caused the original im m unogenic response in the donor. Such 
a library can be generated from immunised animals [164] or diseased humans [218]. 
For example, a human Fab phage display library produced from  lym phocytes o f  an 
individual still asymptomatic 10 years after infection with human im m unodeficiency 
virus type-1 (H IV -1) was used to generate single chain antibodies targeting HIV Rev 
and Tat regulatory proteins [218].
A ntibody fragment library construction involves: reverse transcription o f  the B -cell 
derived m R N A , PCR to am plify the V H  and V L  gene segments from  the cD N A  and 
restriction-based cloning to insert the V H  and V L  encoding D N A  into a phagemid
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vector to be expressed as a fusion with the g3p phage coat protein [164], scFv are 
thus expressed as single chains [ 164]. Additional synthetic diversity can be added to 
the antibody library through the random reassortment o f  VH  and V L  gene segments 
and by introducing artificial sequence diversity into the complementarity determining 
region (CD Rs) using degenerate oligonucleotide primers [189], To create a library o f  
Fab fragments the com plete heavy and light chains (conserved and variable regions) 
are amplified, and cloned into a phagemid vector under the control o f  two separate 
LacZ promoters or with an intervening ribosom al binding site [219]. One chain is 
expressed as a coat protein fusion and the other independently directed to periplasm 
by a signal sequence (pelB). During phage assembly the coat proteins are exported 
into the bacterial periplasm. Thus, an antibody chain fused to a coat protein will also 
be carried into the periplasm where it can be non-covalently attached to a pelB- 
antibody chain [174, 219].
The phagemid vectors are transformed into E .c o li cells to generate the antibody 
library. These phagemids can then replicate as normal plasmids. Then, upon 
infection with helper phage, which provide all the genes required for phage 
assembly, the phagemid is packaged into a phage particle and secreted into the 
culture medium [220], These antibody-displaying phage particles can easily be 
recovered through PEG precipitation [172],
The pre-constructed antibody phage display libraries used in the experiments 
described in this thesis are the Tom linson (I and J) [188] and ETFI-2-Gold libraries 
[189], both o f  which are human, non-immune and predominantly encode scFv.
1.3.1.3 Antibody selection strategies
The standard antibody selection protocol consists o f  five stages: 1) immobilisation o f  
the antigen, 2) a blocking stage to limit non-specific binding, 3) incubation o f  
antibody-displaying phage with the antigen, 4) washing to rem ove unbound phage 
and 5) elution o f  phage displaying specific high-affm ity antibodies [181]. Several 
antibody selection strategies are available and primarily differ in whether or not the 
antigen is predetermined and i f  it is selected in vivo  or in vitro. Phage display is an in 
vitro  technique which limits the possibility o f  selecting indirect binders. The antigen 
can be coated onto a plastic surface (as described in this thesis), displayed on cell
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surfaces [221-223] or as protein bands on nitrocellulose membranes follow ing 
electrophoresis [224, 225], Recently, phage-independent in vivo  screening methods 
based on the yeast-two-hybrid system have been developed to screen for antibody 
fragments that are functional within the reducing environment o f  the cell cytoplasm 
[226, 227],
The antibody epitope is not always chosen in advance. A ntibody phage display has 
been used to identify novel protein markers by  selecting antibodies that show 
differential binding between diseased and healthy tissues [228, 229]. The disease- 
specific antigens can later be identified through their antibody-binding specificity 
[126], Alternatively, as described in this thesis, the antigen can be pre-determined in 
order to study a specific protein or pathway. Additionally, when a target protein has 
already been partially characterised, specific protein functions can be targeted by 
using the relevant protein sub-domains or am ino-acid m otif as an antigen. For 
example, by  using a GST fusion o f  the kinase domain o f  Etk as an antigen, 
intracellular scFv were developed that could b lock  the endogeneous protein’ s ability 
to phosphorylate downstream substrates [230].
A  range o f  options are now  available to anyone wishing to develop a functional 
antibody fragment, including a choice of: library, antigen, selection technique and 
subsequent screening procedure. Additionally, in cases where a high affinity 
m onoclonal already exists, it can be engineered to give a functional single chain 
antibody, thus eliminating the need for library generation altogether [231],
1.3.1.4 Intracellular antibodies (intrabodies)
1.3.1.4.1 Stable intracellular expression o f antibodies 
Single chain antibodies are stabilised by inter- and intra-chain disulphide bonds, 
which are inefficiently formed or absent under the reducing conditions o f  the cell 
cytoplasm [232], This can lead to m isfolding, which (as with any other protein) is 
linked to reduced solubility, a shorter half life and tendency to aggregate triggering 
proteosomal degradation [233]. Yet numerous intracellularly expressed antibody 
fragments have been shown to remain active and specific to their target antigen 
(detailed in section 1.3.1.4.2). To explain the functionality o f  intrabodies in reducing
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environments, it has been proposed that intrinsically stable amino acid sequences 
could fold  properly in the absence o f  disulfide bond formation [233, 234],
1.3.1.4.2 Modes o f action
Intracellularly expressed antibody fragments have been successfully used to 
modulate the activity o f  their target proteins through a w ide range o f  mechanisms, 
including: altering intracellular localisation [231, 235-237], blocking enzyme activity 
[230], triggering target protein degradation [238], inducing a transactivating 
conformational change [239, 240] and disrupting normal protein-protein [227, 240- 
242] or DNA-protein [227] interactions.
B y relocating specific proteins away from  their natural site o f  action, intrabodies can 
disrupt specific signalling pathways. This can be achieved by fusing a specific sub- 
cellular localisation signal to the scFv. Previous work has shown that intracellular 
antibodies targeted to the endoplasmic reticulum (ER) can be used to capture specific 
proteins as they enter the ER, preventing their transport to the cell surface. For 
example ER retention m otifs added to intrabodies have previously been used to: trap 
the viral protein gp 160 in the ER thus blocking HIV-1 replication [236], to prevent 
localisation o f  cell surface receptors like the transferrin receptor (T fR ), the 
knockdow n o f  which leads to a reduction o f  cellular iron uptake and inhibition o f  
tumour cell proliferation [243] or b lock  transit o f  the oncogene ErbB-2 through the 
ER, thereby rendering the receptor inactive and reverting the ErbB-2-transformation 
phenotype [235]. scFv intrabodies that re-directed the ErbB-2 receptor to the ER 
have subsequently been shown to have in vivo  antitumor activity in erbB-2- 
overexpressing ovarian cancer animal models [244] and ovarian cancer patients 
[245],
scFv carrying nuclear localisation signals have also been shown to effectively 
modulate the activity o f  their target proteins. For example, a nuclear-targeting 
intrabody against the N F-kB subunit p65 caused the downregulation o f  N F-kB target 
genes and inhibition o f  glioblastoma cell angiogenesis, invasion, and intracranial 
tumour growth [237], Additionally, single chain intrabodies expressed without any 
additional localisation signal have been shown to sequester their target protein. A  
scFv derived from a m onoclonal antibody previously mapped to the DN A-binding
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domain o f  ATF-1 [246], a transcription factor overexpressed in melanoma cells, was 
shown to reduce melanoma tumour growth and metastasis [247]. The anti-ATF-1 
intrabody functioned by  retaining its target protein within the cytoplasm, thus 
inhibiting its transcription activation function [231], Finally, intrabodies against 
cytosolic caspase-7, a protein activated upon cell death stimuli to induce apoptosis, 
successfully retargeted the protein to the nuclei, thus inhibiting apoptosis [248],
Another mechanism through which the activity o f  a target protein can be disrupted is 
by  triggering its degradation. This can be an unplanned function o f  an antibody, 
observed follow ing its intracellular expression. This was true for an intrabody 
targeting the interleukin 2 receptor IL-2Ra, which was seen to induce rapid 
degradation o f  its target protein within the ER [249], Alternatively the ability to 
direct a target m olecule dow n a degradation pathway can be explicitly engineered 
into an intrabody by  adding a proteasome-targeting sequence [238],
Re-localisation and degradation o f  a target protein are effective means o f  disrupting 
all o f  its normal cellular activities. However, several studies have been carried out to 
develop intrabodies that target specific sub-domains and therefore specific activities 
or interactions o f  their target antigens. In such cases a single domain o f  the target 
protein is used as the target for antibody selection. A  single domain (light chain only) 
intrabody was used by Paz et al. (2005) to efficiently b lock  the autophosphorylation 
o f  the Etk and its tyrosine kinase function, by binding specifically to its kinase 
domain [230]. Intrabodies selected against an N-tenninal region o f  hC yclinT l that 
participates in Tat transactivation, an interaction essential for HIV-1 replication, 
were able to disrupt the hCyclinT 1 -Tat interaction without inhibiting basal 
transcription or inducing apoptosis and thereby inhibit viral replication [242],
Although disruption o f  normal antigen activity has proven a useful tool, activation o f  
some proteins by intrabodies has also been recorded. An anti-p53 scFv that only 
localised to the nucleus in p53-positive cells was able to restore transcriptional 
activity to a His273 mutant [239]. In another study p53 was targeted to a synthetic 
promoter containing tetracycline-operator sequences by an anti-p53 scFv fused to a 
tetracycline D N A  binding domain [250], Gene expression from  the synthetic 
promoter was lost in p 5 3  null cells and enhanced in tumour cells harbouring mutant
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p53 [250], illustrating a novel mechanism through which antibody fragments 
targeting disease-related proteins can be used as small m olecule therapeutics.
1.3.2 Peptide phage display
Peptide phage display technology is technically very similar to antibody phage 
display. The biopanning procedure is much the same, consisting o f  incubation o f  the 
target with the peptide library, washing away o f  unbound phage, elution o f  binding 
phage and amplification in a bacterial host for further selection. It differs in that 
peptides and not antibody fragments are displayed.
1.3.2.1 Different types of library
As with phage display o f  antibody fragments, the peptide is normally fused to the 
minor coat protein g3p o f  filamentous phage. Peptides are generally cloned into a 
phage, rather than phagemid, vector which means that the number o f  displayed 
peptides correlates with the number o f  coat proteins, hi the case o f  coat protein g3p 
that means 3-5 per virion. Cloning a peptide into the phage genom e rather than a 
phagemid relinquishes the need for helper phage, but limits the size o f  the insert. The 
g3p m inor coat protein has been shown to tolerate peptides o f  up to 36 residues in 
length [251], whereas the major coat protein g8p, o f  which there are -2 5 0 0  copies 
per virion, can display a peptide o f  only 6 amino acids in length before coat assembly 
is affected [252], In designing a phage peptide library a choice must be made 
between a longer peptide or one displayed at a higher frequency. Peptides displayed 
on the end o f  coat proteins gp3 and gp8 are tethered by their C-terminus, with their 
N-termini exposed. However, by  using the minor coat protein g6p, peptides can be 
displayed with an exposed C-termini, which may alter binding o f  some epitopes 
[170]. This format is used less frequently, as g6p fusions are incorporated into the 
phage capsid less efficiently than g3p fusions [170], The D coat protein o f  lytic 
bacteriophage A. can also been used as a peptide scaffold [172], Peptides can be fused 
to the D-protein N or C terminus as both ends are exposed on the surface o f  the 
phage head. However, bacterial lysis follow ing lytic phage replication makes the 
subsequent phage purification step more com plicated than for filamentous phage, 
which are secreted from  the bacterial cell membrane [172],
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Other considerations include the length o f  peptide displayed. Short peptides (~7-m er) 
are useful for identifying binding motifs concentrated in a short stretch o f  amino 
acids. Longer peptides (~12-m er) are useful for identifying m otifs that are more 
spread out, i.e. have more intervening amino acids. For example, the binding m otif 
L L X X H H X X A L  has only 6 essential residues, but could not be detected in a 7-mer 
library. Using a longer randomised peptide also increases the chances o f  identifying a 
peptide that interacts through multiple weak interactions, rather than a few  strong 
ones. A s longer peptides have the ability to fold  into short structural elements, like 
alpha-helices, they can be useful for identifying structured ligands [253], Constrained 
peptides, which shaped into a loop by a disulphide bond, can also be used for this 
purpose [254]. Constraining the conformational freedom  and thus decreasing the 
entropy o f  unbound peptides in a library can result in the isolation o f  higher-affinity 
ligands [255]. However, constraining a peptide could also trap it in a conform ation 
unable to bind a given target protein. In the end it is im possible to predict in advance 
which library is suitable for a given target.
The most com m only used peptide phage display libraries are made up o f  random 
peptides o f  a defined length. The peptide encoding D N A  inserts are derived from 
“ degenerate”  oligonucleotides usually com prising o f  the sequence 
N N K N N K N N K .. .etc. where N  is an equal mixture o f  A , G, C, and T, and K is an 
equal mixture o f  G and T, so that each o f  the 32 nucleotide triplets that encode all 20 
natural amino acids are represented [256]. However, a library may also be generated 
using peptides with limited variation, for example that all display some hom ology to 
a known ligand o f  the target protein [257].
The library used in the experiments described in chapter 6 o f  this thesis involves the 
display o f  random 12-mer peptides fused to coat protein g3p o f  M l 3 filamentous 
phage.
1.3.2.2 Peptide selection strategies
Like antibody phage display, peptide phage display can be used to identify novel 
disease markers for diagnosis or future therapeutic development. In such cases 
peptide libraries are pre-cleared for phage capable o f  binding to healthy cells/tissues 
and then selected against: the surface o f  cultured diseased cells [139, 258, 259],
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biopsy tissues [260], in vivo  in diseased animals [261] or humans [262], The last o f  
these is a particularly interesting strategy aimed at developing patient-specific 
therapies. Selection o f  tumour-specific phage in patients involves serial infusions o f  
phage libraries, recovery o f  tumour binding phage through biopsy and reinfusion o f  
tumour-binding phage.
Identification o f  the disease specific markers through binding assays and/or genom e- 
wide database searches using the peptide sequence (binding m otif) can contribute to 
a greater understanding o f  a disease phenotype [114, 259, 263], For example, a 
peptide associated with human atheroma tissues was found to be hom ologous to 
residues within IL-4 that were critical for binding to its receptor. The same study 
then went on to demonstrate that the IL-4 receptor was upregulated in atherosclerotic 
tissues [114]. Such disease-specific peptides can also be used for the targeted drug 
delivery [264].
Alternatively, by first identifying a particular target against which binding peptides 
are to be selected, phage peptide display can be used to identify peptide m otifs that 
have a high affinity for the target protein. Follow ing selection o f  a high-affmity 
peptide, its amino acid com position can be determined by sequencing the phage 
vector. This supplies a binding m otif which can then be used to: develop peptide 
aptamers that can modulate specific molecular interactions [265], identify novel 
interacting proteins which harbour the same m otif [264-272] or map residues crucial 
for a known interaction, such as an antibody epitope [266, 267], pro tease cleavage 
site [142, 268] or ligand-receptor docking [269]. It should also be noted that peptide 
motifs can be identified that m im ic the interactions o f  a known sub-domain, without 
bearing any sequence similarity [270, 271], For example, the TNF fam ily receptor 
B C M A  binds its ligand through a conserved six residue D X L  m otif ((F /Y /W )-D -X - 
L -(V /T )-(R /G )); out o f  10 novel peptides identified through phage display able to 
bind the ligand and disrupt this interaction only one contained the D X L  m otif [270].
A s previously described for antibody fragments, peptides can be selected for binding 
to specific domains o f  proteins to target localised functions. For example peptides 
selected as binding to the SH3 domain (expressed as a GST fusion) o f  the protein-
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tyrosine kinase Src were able to accelerate Src-mediated oocyte maturation and block 
co-precipitation o f  previously identified Src binding partners [251].
Peptides have also been selected against non-protein targets such as oligonucleotides 
[272], lipopolysaccharides [273] and inorganic materials [274, 275],
1.3.2.3 Bioactive peptides
Phage display peptides have been used extensively to develop reagents against a 
range o f  human disease types including: cancer [139, 276], H IV [277, 278], other 
viral infections [279], atherosclerosis (thickening o f  artery walls) [280], obesity 
[281], bacterial infection [282, 283], parasitic infection [284], autoimmune disorders 
[285], thrombosis and inflammation [269, 286] and neurodegenerative diseases 
[287], The technology has also been utilised to increase vaccine efficacy using 
peptides that m im ic epitopes on the disease-causing organism; such peptides are 
identified through binding to an antibody that targets the infectious agent [288, 289],
B iologically  active peptides can function through a variety o f  mechanisms, 
including: blocking the activity o f  enzymes (for example proteases [290] and 
isomerases [291]), disrupting ligand receptor docking [270], preventing nuclear- 
localisation o f  transcription factors [292], inhibiting polyglutamine protein 
aggregation associated with neurodegenerative diseases [287] and m im icking 
ligands, thereby acting as receptor antagonists [293-296].
The mechanisms listed above all involve the “ knock-out”  o f  a protein’ s function. 
H owever, peptides have also been identified that can activate a target protein upon 
binding. Such peptides can function by m im icking receptor ligands and acting as 
agonists [43, 257]. Phage display-derived peptides have also been used to activate 
non-receptor proteins, possibly through a conformational change or by m im icking a 
co-activator interaction [271].
In summation, both peptide and antibody phage display technologies are able to 
generate reagents that can map or modulate a protein’ s function.
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2 Aims
As the introduction to this thesis reveals, the post-translational mechanisms through 
which IRF-1 is regulated are poorly understood. The research conducted in this thesis 
is primarily aimed at the development o f  IRF-1-specific m olecular tools that can be 
used to study regulation o f  the endogenous protein. T w o approaches are taken to 
meet this goal. First, antibody phage display is used to develop single chain 
antibodies targeting IRF-1 (chapters 4 and 5). Second, peptide phage display is used 
to identify IRF-1-binding peptides (chapter 6). Another goal o f  the research detailed 
in this thesis is the identification o f  novel IRF-1-binding partners; this is also 




Cyclohexim ide (Supelco) was dissolved in H2O to 5 m g/m l and used at a 
concentration o f  30 gg/m l in cell culture medium. M G -132 (Calbiochem ) was 
dissolved in D M SO  to 10 m M  and used as indicated. DSP Dithiobis[succinimidyl 
propionate] (Thermo Scientific Picrcc) was used at 2 mM. Trypsin T-1426 Type XIII 
from Bovine Pancreas (Sigma) was prepared as a 10 m g/m l stock solution in 50 mM 
Tris-HCl pH 7.4, 1 m M  CaCl2 and stored at -20°C , this stock solution was then 
diluted 1/10 with PBS before use. The HRP substrate TM B (3,3 ',5 ,5  
tetramethylbenzidine) was supplied by Thermo Scientific Pierce, and used as 
indicated. Peptides (Chiron M im otopes) were synthesised with a SGSG spacer and 
N-terminal biotin tag. Oligonucleotide primers were provided by Sigma and used as 
described. HRP-conjugated protein A  (BD B iosciences) was used at a 1/1000 
dilution for detection o f  single chain antibodies as described.




A375 Human, skin, 1 0%  C 0 2, 37°C ,
malignant melanoma D M E M * media
HeLa Human, cervix, 5 %  C 0 2, 37°C,
epithelial adenocarcinoma D M E M * media
* DM EM : D u lbecco ’ s minimal essential media (G IB C O -B R L)
A 375 and HeLa cells were cultured in D M EM  (Invitrogen), supplemented with 10% 
(v /v) fetal bovine serum and 1% penicillin/streptomycin at 37 °C and 10% or 5%  
C O 2, respectively. For protein half life determination and accumulation assays, cells 




Follow ing plasmids were a kind gift from Dr Mirjam Eckert and were described in 
Dr Mirjam Eckert PhD thesis and publication [64]: pcD N A 3 IRF-1 wild type, 
pcD N A 3 IRF-1 P325A, pcDN A3 IRF-1 AC25, pcD N A3 IRF-1 AC70, TLR3-Luc, 
m TLR3-Luc, IFN-P-Luc, m IFN-p-Luc, C D K 2-Luc. The pTrcHis B, Gateway 
pD O N R  221, pDEST 14, pDEST 15 and pcD N A -D E ST53 vectors were supplied by 
Invitrogen. The TR A IL-luc, m TRAIL-luc, IL-7-luc and m IL-7 luc reporter gene 
constructs were described previously [90, 297].
3.4 Cloning
IRF-1 domains were cloned into the pTrcHis B vector (Invitrogen) and scFv 
antibodies were cloned into the Gateway system (Invitrogen). In this system genes 
are first cloned into the Gateway donor vector pD O N R  221, from  which they can be 
transferred into the appropriate destination vector (pDEST 14, pDEST 15 or pcD N A - 
DEST53) through hom ologous recombination.
3.4.1 PCR primers
3.4.1.1 Cloning of IRF-1 domains into the pTrcHis B vector
3.4.1.1.1 IRF-1 domain amino acids 1-140
Forward Primer 5 ’ -T T C T C G A G C C C A T C A C T C G G A T G C G C A T G -3 ’
Reverse Primer 5 ’ -T T G A A T T C C T A T G G A A T C C C C A C A T G A C T T C C -3 ’
3.4.1.1.2 IRF-1 domain amino acids 60-124
Forward Primer 5 ’ -T T C T C G A G C A C A C A G G C C G A T A C A A A G C A G G G -3  ’ 
Reverse Primer 5 ’ -TTG A A T T A C T A C T T T C T T T C T T T T C T C T G G T T C T T -3 ’
3.4.1.1.3 IRF-1 domain amino acids 117-184
Forward Primer 5 ’ -T T C T C G A G A A C C A G A G A A A A G A A A G A A A G  -3 ’
Reverse Primer 5 ’ -T T G A A T T C C T A C G A C A G T G C T G G A G T C A G G G C -3  ’
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3.4.1.1.4 IRF-1 domain amino acids 117-256
Forward primer 5 ’ -T T C T C G A G A A C C A G A G A A A A G A A A G A A A G  -3 ’
Reverse Primer 5 ’ -T T G A A T T C C T A G T A C C C C T T C C C A T C C A C G T T -3 ’
3.4.1.1.5 IRF-1 domain amino acids 256-325
Forward primer 5 ’ -T T C T C G A G A G G G G T A C C T A C T C A A T G A A C -3 ’
Reverse Primer 5 ’ -T T G A A T T C C T A C G G T G C A C A G G G A A T G G C -3 ’
3.4.1.2 scFv cloning into the Gateway system
3.4.1.3 pDEST14 vector (untagged E.coli expression)
Forward 5 ’ -
G G G G A C A A G T T T G T A C A A A A A A G C A G G C T T C G A A G G A G A T A G A A C C A T G  
A A A T  A C C T  A T T  G C C TA C G G C  A -3  ’
Reverse 5 ’ -
G G G G A C C A C T T T G T A C A A G A A A G C T G G G T C C T A T G C G G C C C C A T T C A G A T  
CCTC-3 ’
3.4.1.4 pDEST 15 vector (N-terminally GST tagged E.coli expression)
(In N-terminally tagged scFv gateway constructs the Shine-Dalgam o and Kozak 
sequences lie within the vector and is therefore not included in these primers)
Forward 5 ’ -G G G G  A C A A G T T T G T  A C  A A A  
A A A G C A G G C T T C A T G A A A T A C C T A T T G C C T A C G G C A -3 ’
Reverse 5 ’ -
G G G G A C C A C T T T G T A C A A G A A A G C T G G G T C C T A T G C G G C C C C A T T C A G A T  
CCTC-3 ’
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3.4.1.5 pcDNA-DEST53 vector (N-terminally GFP tagged 
mammalian cell expression)
Forward 5 ’ -G G G G A C A A G T T T G T A C A A A  
A A A G C A G G C T T C A T G A A A T A C C T A T T G C C T A C G G C A -3 ’
Reverse 5 ’ -
G G G G A C C A C T T T G T A C A A G A A A G C T G G G T C C T A T G C G G C C C C A T T C A G A T
C C T C -3 ’
3.4.1.6 PCR mix
The follow ing PCR m ix was made up in thin-walled sterile tubes (B D  Biosciences) 
and heated in a thermocycler.
Distilled water 34.1 pi
M gC l2 (0.1 M ) 1.0 pi
10 x  cloned pfu reaction buffer 5.0 pi
D N A  template (100 ng/pl) 1 pi
Forward primer (10 pM ) 0.2 pi
Reverse primer (10 pM ) 0.2 pi
Pfu turbo D N A  polymerase (2.5 U /pl) 1 pi
Total reaction volum e 50 pi
3.4.1.7 PCR Programme
15 min 95°C 
1 min 94°C 
35 cycles 1 min 72°C
1 min 50-70°C 
10 min 72°C
3.4.1.8 Purification of PCR product
Q IAGEN  PCR product purification kit used as described in the manufacturer’ s 
handbook
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3.4.1.9 Detection of DNA
Tris-acetate (TAE) buffer
40m M  Tris
5 x DNA loading buffer
15 %  (w /v) Ficol
0.25 %  (w /v) Bromophenol blue
0.25 %  (w /v) Xylene cyonol
20m M  Boric acid
Im M  ED TA  (pH 8.0)
Stored at room  temperature 
D N A  samples were mixed with 5 x D N A  gel loading buffer, and resolved on 1 %  
(w /v) agarose gel. Agarose gels were prepared by adding 1 g agarose into 100 ml 1 x 
TA E  buffer and heating in a m icrowave until the agarose pow der dissolved.
Ethidium bromide was added to the final concentration o f  0.5 pg/ml. Once the gel 
had set samples were loaded and run for 1 hour at 100 V  in 400 ml o f  1 x TAE 
buffer. D N A  was visualised using the Genesnap program Syngene under a U V 
transilluminator.
3.4.1.10 Cloning of IRF-1 domains into pTrcHis B
Digestion o f  pTrcHisB vector and IRF-1 domain PCR products was performed using 
the protocol described below . Buffers and enzymes were supplied by New England 
Biolabs, Inc.
Digestion reaction
30 pi o f  purified PCR product (concentration not determined) 
or 3 pi o f  vector (100 ng/pl)
1 pi o f  EcoRI (20 units/ pi)
1 pi o f  X h o l (20 units/ pi)
4pl 10 X  EcoRI buffer (100 m M  Tris-HCl, 50 m M  NaCl, 10 m M  M gC l2, 
0.025 %  Triton X -100, pH 7.5 at 25°C )
100 pg/ml Bovine Serum Album in (B SA )
Made up to 40 pi with nuclease free distilled H20
Each digestion mixture (containing PCR product or vector) was incubated separately 
at 37 °C  for 2 hours and inactivated by heating to 65°C  for 20 minutes. Digestion 
products were run on a 1% (w /v) agarose gel (see section 3.4,1.9) and purified using 
the QIAG EN  gel purification kit.
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Ligation o f  the cleaved pTrcHis vector and IRF-1 domain PCR products was 
performed according to the protocol below . Buffers and enzymes supplied by New 
England Biolabs.
Ligation reaction
3 pi gel purified insert (digested PCR product)
1 pi gel purified digested vector
0.33 pi T4 D N A  ligase (2,000 cohesive end units/pl)
1 pi 10 x T4 D N A  ligase buffer (10 m M  M gC l2, 1 m M  ATP, 10 m M  DTT, 
pH 7.5 at 25°C )
Made up to 10 pi with nuclease free distilled H20
Each ligation mixture was incubated separately at 4 °C  overnight and inactivated by 
heating at 65°C for 10 minutes. 5 pi o f  each ligation reaction was then transfonned 
(see section 3.4.2) into E .co li.
3.4.1.11 Gateway cloning of scFv
Anti-IRF-1 scFv were cloned into pDEST15, pDEST14 and pDEST53 for expression 
in bacterial and mammalian systems using Gateway technology (Invitrogen). The 
Gateway system involves hom ologous recombination o f  a PCR product into a 
holding pD O N R  vector (pD O N R  221) and then into a pDEST (14, 15 or 53) vector 
for expression. Reagents were supplied by Invitrogen.
Gateway cloning BP reaction (PCR product into pDONR)
BP™  Clonase reaction buffer 4 pi
attB PCR product 5 pi (concentration not determined)
D onor vector (pD O N R 221™ ) 300 ng 
BP Clonase enzyme mix 4 pi
Total reaction volum e made up to 20 pi with distilled water.
The reaction mix was incubated for 1 hour at 25 °C and terminated by the addition o f  
1 pi o f  2 pg/p l proteinase K  solution and incubation for 10 minutes at 37 °C. 5 pi o f  
the reaction m ix was then transformed into E .c o li  via heatshock (see section 3.4.2).
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Bacteria containing positive clones were grown selectively on LB/Kanamycin (50 
¡ig/m l) plates.
Gateway cloning LR  reaction (pDONR into pDEST)
LR ™  Clonase reaction buffer 5 pi 
Entry clone 100 ng 
Destination vector (pD E ST™ ) 300 ng 
LR  Clonase enzyme m ix 4 pi
Total reaction volum e made up to 20 pi with distilled water.
The reaction m ix was incubated for 1 hour at 25 °C  and terminated by the addition o f  
1 pi o f  2 pg/p l proteinase K solution and incubation for 10 minutes at 37 °C. 5 pi o f  
the reaction m ix was then transformed into E.coli cells via heatshock (see section 
3.4.2). Bacteria containing positive clones were grown selectively on LB/Am picillin  
(100 pg/m l) plates.
3.4.2 Heatshock transformation
Sterilised by autoclaving at 121°C fo r  Sterilised by autoclaving at 121°C
Luria Bertani (LB) media
1% (w /v) Tryptone 
0 .5%  (w /v ) Yeast Extract 
1% (w /v) NaCl
LB agar
1 %  (w /v) Tryptone
0.5 %  (w /v) Yeast extract
1 %  (w /v) Agar, granulated
20 minutes. fo r  20 minutes.




0.59% (w/v) potassium acetate
1.5% (w/v) CaCl2.2H20
15% (w/v) glycerol
pH adjusted to 5.8 with acetic acid
Buffer B
10 mM MOPS pH6.8 
0.12% (w/v) RbCl 
1.1% (w/v) CaCl2.2H20  
15% (w/v) glycerol 
pH adjusted to 5.8 with NaOH
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A  bacterial culture was grown in 50 ml LB media until the O.D. 600 nm reached 0.4. 
The cells were then centrifuged at 3,200 x g for 15 minutes at 4°C. The follow ing 
steps were all perfonned at 4°C. The bacterial pellet was re-suspended in ice-cold  
buffer A  (16 ml buffer A  per 50 ml o f  original bacterial culture). This m ix was 
incubated on ice for 10 minutes. The cells were pelleted again via centrifugation at
3,200 x g (15 minutes at 4°C ), resuspended in buffer B (2 ml buffer B per 50 ml o f  
original bacterial culture) and incubated once more on ice for 10 minutes. The cells 
were then aliquoted into pre-chilled tubes, snap frozen and stored at -80°C.
3.4.2.2 Heatshock protocol
DH 5a or BL21 DE3 (50 pi) competent bacteria cells were m ixed with 0.5 pg o f  
plasmid or 5 pi o f  ligation, BP or LR reaction product. Cells were then incubated on 
ice for 45 minutes and heatshocked through incubation at 42°C  for 2 minutes. This 
was follow ed by 5 minutes o f  incubation on ice. LB media (1 ml) was added to the 
transformed cells and the culture was incubated at 37°C  with shaking (225 rpm) for 
30 minutes. Transformed bacteria were then spread on LB/agar plates (50 pg/m l 
ampicillin). These plates were incubated at 37°C overnight to allow colony formation 
to occur. The colonies were then picked and grown separately overnight in 5 ml LB 
(50 pg/m l ampicillin) to enable D N A  plasmid amplification (see section 3.4.3).
3.4.3 DNA plasmid amplification




A ll sequencing was out-sourced to: D N A  Sequencing & Services, M edical Research 
Council Protein Phosphorylation Unit, Dundee.
3.4.4.1 Sequencing primers
IRF-1 domains pTrcHis forward 5 ’ o f  multiple cloning site:
S'- G A G G T A T A T A T T A A T G T A T C G -3  '
IRF-1 domains pTrcHis reverse 3 ’ o f  multiple cloning site:
S'- G A T T T A A T C T G T A T C A G G -3 ' 
scFv pliagemid (pIT2) LMB3:
5 '-  C A G  G A A  A C A  G C T A T G  A C -3 ' 
scFvphagemid (pIT2) pHENseq:
S'- C T A  TG C  G G C  C C C  A T T  C A -3 ' 
scFv pDEST53/l 5/14 T7 promoter forward:
5 ' -T  A  A T  A C G  A C T  C A C T  A T A G G G -3  '
Peptide phage display -96 g ill sequencing primer:
S'- CCC T C A  T A G  TT A  G C G  T A  A  CG -3  '
Peptide phage display -28 g ill sequencing primer 
S'- G T A  TG G  G A T  TTT G CT A A A  C A A  C - 3 '
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Transformed BL21 DE3 E .c o li cells were grown in 1L LB until the culture had an 
optical density at 600 nm (O.D. 600) o f  0.4. Protein expression was then induced by 
the addition o f  0.5 m M  IPTG until the O.D. reached 1 (approximately 3 hours later). 
Cells were centrifuged (3,200 x g, 10 mins, 4°C ), the supernatant discarded and the 
pellet snap frozen in liquid nitrogen. The pelleted cells were thawed in 2 ml bacterial 
lysis buffer and sonicated for 2 x 10 seconds (samples kept on ice between bursts o f  
sonication).
3.5 Protein purification from E.coli
Protease inhibitor m ix5'
Bacterial lysis buffer
50 mM HEPES pH 7.6 
150 mM NaCl 
1 mM EDTA*
1 x protease inhibitor mix8 (see below)
1 mg/ml lysozyme 
1 pg/ml leupeptin 
0.4 pg/ml aprotinin,
0.2 pg/ml pepstatin,
10 pg/ml soya bean trypsin inhibitor 
40 pg/ml Pefabloc 
0.12m M  Benzamidine
* ED TA excluded if proteins were to be purified on a Ni2+ column (see section 
3.5.1)
Triton X -100  was added to make up 1% o f  the lysate. The lysate was then incubated 
on ice for 20 min and centrifuged at 16,800 x g  for 10 minutes at 4°C. The resultant 
supernatant made up the detergent soluble fraction o f  lysate and the remaining pellet 
formed the insoluble fraction.
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E D TA  was excluded from die bacterial lysis buffer described above.
Approxim ately 2 ml o f  the detergent soluble fraction o f  lysate was mixed with an 
equal volum e o f  IM AC  5. The Lysate/IM AC5 mix was then fdtered with a 0.45 pm 
filter (M ilipore™ ).
3.5.1 His tagged protein purification
Loading Buffer IM A C 5 Wash with detergent IM AC 25
20 m M  Tris/HCl pH 7.5-8 20 m M  Tris/HCl pH 7.5-8
0.5 m M  NaCl 0.5 mM NaCl
5 m M  im idazole 25 m M  imidazole
0.5%  Triton X -100 
0 .5%  Tween 20
Wash without detergent IM AC 25 Elution Buffer IM AC150
20 m M  Tris/HCl pH 7.5-8 20 m M  Tris/HCl, pH 7.5-8
0.5 m M  NaCl 0.5 M  NaCl
25 m M  im idazole 150 mM imidazole
N i2_r-N T A  resin (Q IA G E N ) (250 pi) was washed thoroughly with IM AC5 and then 
kept in an equal amount o f  IM A C  5. N i2+-N T A /IM A C 5 and lysate/IM AC5 were 
com bined and rotated for 1 hour at 4°C. The m ix was poured into a column jacket 
(M oB iT ec) and washed with 5 colum n volumes (C .V .) o f  IM AC5, 20 C .V . o f  
IM AC 25 with detergent and 5 C .V . o f  IM AC25 without detergent. His-tagged 
protein was then eluted with 10 C .V . o f  IM AC  150 and collected in 1 ml fractions. 
The fractions were analysed by SDS-PAGE to determine which contained the 
purified protein.
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3.5.2 GST tagged protein purification
Elution buffer
100 m M  Tris/HCl pH 8 
20 m M  glutathione reduced 
NaCl 120 m M
TNEN buffer
20 m M  Tris/HCl pH 8.0 
100 m M  NaCl 
1 m M  EDTA 
0.5%  NP40
Glutathione Sepharose beads (150 pi, Amersham) were added to an equal amount o f  
TNEN buffer, plus 4%  (w /v) B SA  and approximately 2 ml o f  detergent soluble 
lysate. The m ix was incubated at 4 °C on a rotating wheel for 30 minutes and then 
washed 3 x with T N E N /100 m M  NaCl. After the final wash the beads were 
resuspended in 5 ml elution buffer and eluted overnight at 4 °C  on a rotating wheel.
3.6 Detection of protein: SDS-PAGE
Resolving gel - 1 2 %
40%  (v /v ) 30%  Acrylam ide mix 
0.375 M  tris pH 8.8 
0.1 %  (v /v ) SDS 
0.04%  (v /v ) TEM ED (Sigma)
0 .1%  (w /v ) Am m onium  peroxidisulphate
Stacking gel
16.7 (v /v) 30%  Acrylam ide m ix 
0.19 M  tris pH 8.8 
1% (w /v) SDS
0.1%  (v /v) TEM ED (Sigm a)
10 %  (w /v) Am m onium  
peroxidisulphate
Running buffer
129 m M  glycine 
25 m M  Tris pH 8.8 
0 .1%  (w /v) SDS
SDS-PAGE Sample buffer
5%  (w /v) SDS 
25%  (v /v ) G lycerol 
0.24 M  Tris pH6.8 
400 m M  DTT
0.1%  (w /v) Brom ophenol blue
The polyacrylam ide electrophoresis gels were prepared using the MiniProtean3™  
(B io-R ad) system as described by manufacturers. Each protein sample was mixed 1:1 
with SD S-PAGE sample buffer and heated for 2 minutes at 90°C. The samples were 
then loaded onto a gel and run at 100 V  until the brom ophenol blue dye front reached
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the bottom  o f  the gel. The separated proteins were then analysed by  im munoblot as 
described in section 3.8, or using Colloidal blue staining kit (Invitogen) according to 
the manufacturer’ s guidelines.
3.7 Protein quantification
Protein was quantified by the Bradford assay (reagent provided by Biorad, 
manufacturer’ s guidelines follow ed).
3.8 Immunoblot
Mammalian lysis buffer
50 m M  HEPES 
150 m M  NaCl 
0.1 m M  ED TA  
2 m M  D TT
1 x protease inhibitor m ix5' (see section 3.5)
10 m M  NaF 
0.1 m M  ED TA
Mammalian cells were lysed in the lysis buffer detailed above or 5 x reporter lysis 
buffer (Prom ega) (as part o f  IRF-1 transcriptional activity assays) and incubated on 
ice for 20 or 10 minutes respectively. Follow ing centrifugation at 16,800 x g for 2 
minutes the supernatant (detergent soluble fraction) or pellet (detergent insoluble 
fraction) were analysed by SDS-PAGE and transferred to a nitrocellulose membrane 
(P R O T R A N ™ ) electrophoretically at 100 V  for 1 hour. Purified GST-IRF-1 (0.3 
pg/lane) was analysed by  SDS-PAGE and transferred to nitrocellulose in the same 
way. The membranes were blocked in 5%  M P B S-0.1%  Tween (5%  M arvel milk 
powder in PBS containing 01%  Tween) for 1 hour at room  temperature and 
incubated with the appropriate primary antibody (see section 3.9) diluted in 5%  
M P B S-0 .1%  Tween overnight at 4°C, follow ed by the secondary antibody for 1 hour 
at room  temperature. The immunoblots were washed extensively between each step 
with PBS 0 .1%  Tween and antibody binding was detected with enhanced 









Caspase 3 Santa Cruz Biotechnology sc-7272 1/1000
CDK2 Santa Cruz B iotechnology sc-53220 1/1000
GFP Clonetech 632375 1/2000
GST Sigma G l 160 1/2000
G APD H Abeam ab8245 1/1000
His N o vagen 70796 1/2000
HP la M illipore M A B 3446 1/1000
IRF-1 BD Biosciences 612046 1/1000
IRF-1 Santa Cruz B iotechnology 
(C20)
sc-497 1/1000
IRF-2 Abeam ab55331 1/1000
ISG20 A bnova H00003669-M 01 1/1000
g3p (pIU)
M l 3 coat 
protein




PKR Santa Cruz Biotechnology sc-707 1/1000
ZNF350 Abeam ab67881 1/1000
Secondary antibodies were purchased from Dako Cytomation.
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3.10 EC L for enhanced chemiluminescence
ECL solution 1 ECL solution 2
0.02%  H20 2 
100 m M  Tris pH 8.5
2.50 m M  luminol
4 m M  p-coum aric acid
100 m M  Tris pH 8.5
ECL solutions 1 and 2 were com bined in a 1:1 ratio and used immediately to cover 
an im munoblot/dot blot (1-2 ml) or fill an ELISA well (100 pi) and thus induce 
enhanced chemiluminescence.
For peptide binding assays 96-well microtitre plates were incubated with 20 pg/ml 
streptavidin for overnight at 37°C. The streptavidin solution was then discarded and 
the plates washed with PBS containing 01%  Tween. Biotin-labelled peptides were 
diluted in PBS (quantities described in figure legends) and incubated with the prc- 
coated streptavidin plates for 1 hour at room  temperature. Non-reactive sites were 
blocked using PBS containing 3%  B SA  and the peptides incubated with scFv, GST 
or GST-IRF-1 (1 pg/m l) in PBS-0.1%  BSA for 1 hour at room  temperature. The 
plates were washed extensively with PBS-0.1%  Tween and scFv binding was 
detected using the appropriate primary antibodies (as indicated in the figure legends) 
and enhanced chemiluminescence.
The protein binding assays were performed by coating 96-w ell microtitre plates with 
the protein o f  interest (quantities detailed in the figure legends) in 0.1 M  NaHCCL. 
Non-reactive sites were blocked using PBS containing 3%  B SA  and the wells were 
incubated with empirically determined amounts (see section 3.7) o f  IRF-1 or scFv 
protein in P B S -0 .1% B S A  for 1 hour at room  temperature. Binding was detected 
using the appropriate primary antibodies (as indicated in the figure legends) and 
enhanced chemilum inescence (see section 3.9)
3.11 ELISA
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3.12 Antibody phage display: Selection and 
monoclonal screening
2 x T Y  media
1.6% (w /v) Tryptone 
1 0 % (w /v ) Yeast Extract 
5%  (w /v) NaCi
TYE plates
15% (w /v) Agar 
8%  (w /v) NaCl 
10% (w /v) Tryptone 
5%  (w /v) Yeast Extract
3.12.1 Anti-C-terminus scFv
Single chain antibodies (scFv) against the C-terminal 20 amino acids o f  IRF-l 
(LD SLLTPV RLPSIQ AIPC A P) were selected from the Tom linson I and J human 
scFv library (Geneservice). The two library stocks (I and J) provided were used 
separately during selection, i.e. against the same peptide in two separate 
immunotubes. The selection strategy was identical for both stocks. Stocks o f  the 
scFv library and helper phage were maintained according to guidelines provided by 
Geneservice.
3.12.1.1 Selection
Immunotubes (Nunc), with a volume o f  4 ml, were pre-coated with 20 pg/ml 
steptavidin (4 ml) for 2 hours at room  temperature and then washed 3 x with PBS.
A n excess o f  biotinylated peptide (50 pg/m l) diluted in PBS (4 m l) was then added to 
each steptavidin-coated immunotube and incubated at 4°C  overnight. The 
immunotubes were then washed 3 x with PBS and blocked with 2%  M PBS (2%  
Marvel m ilk powder in PBS) for 2 hours at room  temperature. The immunotubes 
were then again washed 3 x with PBS before being filled with 1013 cfu (colony 
forming units) o f  phage in 2%  MPBS. The im m obilised peptides were incubated with 
the phage for 1 hour on a rotating wheel and 1 hour standing; all at room 
temperature. The supernatant was then discarded and the tubes washed 10 (round 1) 
or 20 (rounds 2 and 3) x with PBS 0.1%  Tween. Bound phage were eluted with 50 pi 
o f  a 10 m g/m l trypsin stock solution (made up in 50 m M  Tris-HCl pH 7.4, 1 mM
CaCl2) in 450 pi o f  PBS.
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3.12.1.2 Amplification of selected phage
The eluted phage (250 pi) was added to a 1.75 ml culture o f  TG I bacteria (O .D . 600 
o f  0.4) and incubated at 30 °C in a water bath. The resultant phage-infected bacterial 
culture was pelleted by centrifugation at 11,600 g for 5 minutes and resuspended in 
50 pi o f  2 x T Y , before being plated on TYE plates (100 pg/ml ampicillin and 1% 
glucose) and grown overnight at 37 °C. The overnight bacterial growth was then 
loosened from the plate with a glass spreader into 2 ml o f  2 x T Y  containing 15% 
glycerol. 50 pi o f  the cell suspension was added to 50 ml o f  2 x T Y  containing 100 
pg/m l ampicillin and 1 %  glucose and grown at 37 °C , shaking (250 rpm), until the 
O.D . 600 was 0.4. At this point 5 x 1010 cfu o f  helper phage were incubated with 10 
ml o f  the bacterial culture in a water bath at 37 °C for 30 minutes. The culture was 
then centrifuged at 3,000 g for 10 minutes, resuspended in 50 ml 2 x T Y  (100 pg/ml 
ampicillin, 50 pg/m l kanamycin and 0.1%  glucose) and incubated overnight (30 °C 
and shaking at 250 rpm). The helper phage allowed mature phage particles to form 
inside the bacteria, which were then secreted into the media. The overnight culture 
was centrifuged at 3,300 g for 15 minutes before 10 ml o f  PEG/NaCl (20 %  
Polyethylene glycol 6000, 2.5 M NaCl) was added to 40 ml o f  the supernatant. The 
supematant/PEG/NaCl mix was kept on ice for 1 hour causing the phage particles 
secreted by the bacteria to precipitate. The precipitated phage was then collected by 
centrifugation at 3,300 g for 30 minutes. A ny remaining supernatant was rem oved by 
aspiration. The phage pellet was resuspended in 2 ml o f  PBS and centrifuged again, 
this time at 11,600 g for 10 minutes, to remove any remaining bacterial debris. 1 ml 
o f  the supernatant, made up o f  phage suspended in PBS, was then used in the next 
selection round. 3 selection rounds were carried out in total.
3.12.1.3 Phage titering
This step allowed the number o f  phage particles to be determined follow ing each 
selection round and separated individual phage clones prior to sequencing. LB media 
(10 m l) was inoculated with the TGI bacteria stock provided by Geneservice and 
grown at 37 °C  with 250 rpm shaking until the O.D. 600 reached 0.4. A  phage 
solution (unamplified phage eluates) was prepared for titration by being serially 
diluted ( lO ’ -lO 3) into 100 pi PBS. The TG I (900 pi) at an O D  600 o f  0.4 was added 
to each phage dilution and incubated at 37°C for 30 minutes. Each dilution (10 pi)
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was then spotted onto a TY E  plate containing 100 pg/ml ampicillin and 1 %  glucose 
and grown overnight at 37°C. Follow ing overnight incubation at 37 °C phage- 
infected bacteria form white colonies. The number o f  colonies on a plate was then 
multiplied by the dilution factor to give the number o f  colony forming units (cfu) in 
10 pi o f  the original phage solutions.
3.12.1.4 Production of monoclonal scFv:
Eluted 3,d round phage (10 pi) were used to infect 200 pi exponentially growing 
HB2151 bacteria (O .D . 600 o f  0.4) for 30 min at 37°C  in a water bath. The phage- 
infected bacteria (50 pi) was spread onto TY E  plates (100 pg/ml ampicillin and 1 %  
glucose) and grown overnight at 37°C. The follow ing day 100 pi o f  2 x T Y  (100 
pg/m l ampicillin and 1 %  glucose) was added to each well o f  a 96-well plate, then 
one colony o f  the overnight bacterial growth was transferred to each o f  these wells 
and again grown overnight (37 °C, shaking 250 rpm). 96 colonies were picked in 
total, com prising o f  48 colonies from selection with Tom linson library stock I and 48 
from selection with stock J. The overnight cultures (2 pi) were then transferred to a 
second 96-w ell plate, each well o f  which already held 200 pi 2 x T Y  (100 pg/ml 
ampicillin and 0.1 %  glucose). These cultures were allowed to grow for 3 hours (37 
°C, shaking 250 rpm) before 25 pi o f  2 x T Y  (100 pg/ml ampicillin and 9 m M  IPTG 
(isopropyl p-D-thiogalactoside) was added (final concentration 1 m M  IPTG). The 
IPTG induced expression o f  soluble scFv while the culture continued to be grown at 
30°C  overnight with shaking (250 rpm). The 96-w ell plate was then centrifuged at
3,200 x  g for 15 minutes to pellet the bacteria and leaving the soluble scFv in 
solution.
3.12.1.5 Dot Blot for screening soluble monoclonal scFv
A  nitrocellulose membrane, marked with a grid was incubated with 0.3 pg/pl GST- 
IRF-1 and blocked for 30 min in 5%  M PB S-1%  Tween. Each m onoclonal scFv (2 pi 
o f  the soluble scFv generated in section 3.11.1.4) was dotted onto the membrane and 
incubated for 1 hour at room  temperature in a humidified container. The membrane 
was then incubated with 1/1000 protein A -H RP in 5%  M PB S-1%  Tween for 1 hour 
at room  temperature. Between each step the membrane was washed extensively with
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PBS-0.1%  Tween and scFv binding was detected using enhanced 
chem ilum inescence (see section 3.9).
3.12.1.6 Preparation for sequencing
Pelleted bacteria from wells that produced IRF-1-specific scFv (that gave a positive 
signal in the dot blot) were re-suspended in 50 pi o f  LB and added to 50 ml o f  2 x 
T Y  containing 100 pg/m l ampicillin and 1 %  glucose and grown at 37 °C, shaking 
(250 rpm), until the O.D. 600 was 0.4. Am plification and phage precipitation was 
then carried out as previously described (section 3.11.1.2). Phage D N A  was extracted 
as described in section 3.13.
3.12.2 Anti-IRF-1 N-terminus scFv
scFv against the IRF-1 amino acids 60-124 were selected from the ETH -2-gold scFv 
library provided by Prof. Dario Neri [189], A  His-tagged domain made up o f  IRF-1 
amino acids 60-124 (60 pg/m l) diluted in PBS was immobilised on an Immunotube 
(Nunc). 2 rounds o f  selection were carried out as described in section 3.11.1.1. 
M onoclonal scFv were expressed from H B 2151 E. co li infected with 2nd round scFv- 
displaying phage. As with the anti-IRF-1 C-tenninus, scFv expression was induced 
in 225 pi cultures in a 96-well plate inoculated with individual bacterial colonies, 
with 1 m M  IPTG and shaking at 30°C overnight (see section 3.11.1.4). The 96-well 
plate was then centrifuged 3,200 x g for 15 minutes to pellet the bacteria and leaving 
the soluble scFv in solution. Phage stocks were titred as previously described (see 
section 3.11.1.3).
3.12.2.1 Colorimetric ELISA for screening of soluble monoclonal scFv
Purified His-tagged IRF-1 domain amino acids 60-124 (60 pg/m l) was incubated in a 
96-w ell microtitre plate overnight at 4°C. The wells were then washed 3 x with PBS- 
1% Tween and blocked with 5%  M PBS for 1 hour at room  temperature. 90 pi o f  PBS 
was added to each well, follow ed by 10 pi o f  soluble scFv-containing supernatant. 
The scFv were incubated with the im m obilised IRF-1 domain for 1 hour at room  
temperature, before each well was washed 3 x with PB S-1%  Tween. Bound scFv 
were then detected with 100 pi o f  1/1000 HRP-protein A  in 5%  M PBS, which was 
incubated in each w ell for 1 hour at room  temperature. The microtitre plate was again
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washed (3 x with PBS 1% Tween) before 100 pi o f  the HRP substrate TM B 
(3,3',5,5'-tetram ethylbenzidine supplied by Thermo scientific) was added, follow ed 
by 100 pi 0.16 M  sulphuric acid. The TM B gave a blue colour change, which turned 
yellow  follow ing the addition o f  sulphuric acid. The absorbance was then measured 
at 450 nm on a spectrophotometer.
3.12.2.2 Preparation for sequencing 
A s for anti-IRF-1 C-terminus scFv.
3.13 Peptide phage display
IPTG/Xgal stock
5%  (w /v) IPTG
4%  (w /v) Xgal (5-Brom o-4-chloro-3-indolyl-P-D -galactoside)
100%  (v /v ) dimethyl formamide 
(stored at -20 °C)
LB/IPTG/Xgal plates
99.9%  (v /v ) LB agar
(prepared as described under section 3.4.2 o f  methods)
0.1%  (v /v ) IPTG/Xgal stock
Top Agar
1% (w /v) Tryptone 
0 .5%  (w /v ) yeast extract 
0 .5%  NaCl 
0 .7%  agar
Sterilise d  by autoclaving at 1 2 1 °C  f o r  20 minutes.
Phage displayed peptides were selected for binding to His-tagged IR F -1 domains 
spanning amino acids 1-140, 1-124, 60-124, 117-184, 117-256, 256-325.
3.13.1.1 Selection
A  stock solution o f  50 pg/m l was prepared o f  each domain target in 0.1 M  N aH C 03, 
pH 8.6. Each diluted domain (150 pi) was then incubated in separate well o f  a 96-
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well microtitre plate overnight at 4°C  in a humidified container. This coating 
solution was then poured away and the wells were blocked (blocking buffer: 0.1 M 
NaHCC>3 (pH 8.6) and 5 m g/ml B SA ) for 1 hour at 4°C. The blocking solution was 
discarded and the wells washed 6 x with PBS 1% Tween. The phage library (2 x 1 0 " 
pfu) was added to each well in 100 pi o f  PBS 1% Tween, and then incubated for 1 
hour with gentle rocking at room  temperature. The phage solution was discarded, and 
the plate washed 10 x with PBS 1% Tween. Bound phage were then eluted with 100 
pi o f  0.2 M  Glycine-H Cl (pH 2.2) containing 1 m g/ml B SA  over 10 minutes (with 
rocking), the eluates were then transferred to sterile microcentrifuge tubes and 
neutralised with 15 pi o f  1 M  Tris-HCl, pH 9.1.
3.13.1.2 Amplification of selected phage
The phage selected by each domain were amplified simultaneously but separately 
according to the follow ing protocol. 20 pi o f  the ER2738 bacteria stock provided by 
NEB with the phage library was used to inoculate 20 ml o f  LB (15 pg/ml 
tetracycline) and grown at 37 °C with shaking (250 rpm) until an O.D. 600 o f  0.01 
was reached. A t this point, the phage eluate was added to the bacterial culture and 
amplified by continued incubation at 37 °C with shaking (250 lpm ). The culture was 
centrifuged for 10 minutes at 12,000 g at 4 °C. The supernatant was transferred to a 
fresh centrifuge tube and centrifuged again to remove bacteria. The resultant 
supernatant (16 ml) was then com bined with 2.67 ml o f  20%  PEG/2.5 M  NaCl, after 
which the phage was allowed to precipitate overnight at 4°C. The precipitated phage 
were collected through centrifugation at 12,000 g for 15 minutes at 4°C  and then 
resuspended in 1 ml o f  TBS (50 m M  Tris-HCl pH 7.5 and 150 m M  NaCl). The 
suspension was transferred to a microcentrifuge tube and centrifuged at 16,800 g for 
5 minutes at 4°C  to pellet and rem ove residual bacterial cells. The phage was then 
again precipitated (to reduce bacterial contamination) by adding 167 pi o f  20%  
PEG/2.5 M  NaCl and incubating for one ice for 1 hour, before centrifuging at 16,800 
g for 10 minutes at 4°C. The supernatant was discarded and the phage pellet 
resuspended in 200 pi o f  TBS. 100 pi o f  amplified phage (~ 10 12 pfu) was then used 




This step allowed the number o f  phage particles to be determined follow ing each 
selection round and separated individual phage clones prior to sequencing. LB media 
(10 m l) was inoculated with the ER2738 bacteria stock provided by NEB and grown 
at 37 °C  with 250 rpm shaking until the O.D. 600 reached 0.5. A  phage solution 
(unamplified phage eluates) was prepared for titration by being serially diluted (1 0 1- 
103) in LB, 10 pi o f  each phage dilution was added to 200 pi o f  the bacterial culture, 
briefly vortexed and incubated at room  temperature for 5 minutes. The infected cells 
were then added to tubes containing 3 ml o f  Top Agar, which had been pre-warmed 
to 45 °C. Follow ing another brief vortex, this Top Agar was then poured onto an 
LB /IPTG /Xgal plate and equally distributed. Follow ing overnight incubation at 37 
°C phage-infected bacteria formed blue plaques. The number o f  plaques on a plate 
was then multiplied by the dilution factor to give the number o f  plaque forming units 
(pfu) in 10 p i o f  the original phage solutions.
3.13.1.4 Preparation for sequencing
10 plaques per IRF-1 domain were picked for sequencing from the titre plates 
generated with unamplified eluted phage from the 3ld selection round. Each plaque 
was transferred to 20 ml o f  LB (15 pg/ml tetracycline) and precipitation o f  phage 
was carried out as previously described (see section 3.13.1.2).
3.14 Phage DNA extraction
Precipitated phage was pelleted (16,800 x g for 10 min at 4°C ) and re-suspended in 
100 pi o f  Iodide Buffer (10 m M  Tris-HCl pH 8.0, 1 m M  ED TA, 4 M  Nal). The 
suspension was incubated with ethanol (250 pi) for 10-20 minutes at room  
temperature. Precipitated phage D N A  was then collected by centrifugation (16,800 x 
g for 10 minutes at 4°C ) washed with 0.5 ml o f  70%  (v /v) ethanol, re-centrifuged and 
dried briefly under a vacuum. For subsequent sequencing and PCR reactions the 
D N A  was suspended in TE buffer and quantified using a spectrophotometer 
(Nanodrop N D -1000). Phage D N A  sequencing was out-sourced and the sequencing 
primers used are described in section 3.4.4.1.
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3.15 EMSA (electrophoretic mobility shift assay)
C l  probe sense  
5'-
A G C G G A T C C T C T A G A G T C T C A C T T T C A C T T T C A C T T T C A C T T C G A C C G A T G
CCC-3'
C l  p robe anti-sense 
5'-
G G G C A T C G G T C G A A G T G A A A G T G A A A G T G A A A G T G A G A C T C T A G A G G A T
CC G C T-3'
3.15.1 Labelling the probe
The follow ing reaction mixture was prepared and incubated for 2 hours at 37°C.
0.6 pg C l probe sense D N A 
0.6 pg C l probe antisense DNA 
10% (v /v ) T4 D N A  kinase buffer 
4%  (v /v ) T4 D N A  kinase 
0.004 m Ci y - 3 2  ATP
After this 52%  (v /v ) o f  TE buffer (Q IAG EN ) was added and the mixture heated to 
92°C  for 2 minutes, then allowed to coo l to room temperature. The “ hot”  probe was 
then purified through a Chroma Spin STE 10 column (Clontech) by briefly spinning 
in a tabletop centrifuge, before being collected into a 1.5 ml microcentrifuge tube for 
storage.
3.15.2 Assay protocol
6 X  E M SA  buffer
120 m M  HEPES pH 7.5 
300 m M  KC1 
30%  (v /v ) glycerol 
2.4 m M  D TT 
0.6 m g/m l B SA  
3%  (v /v ) Triton X -100
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GST-IRF-1 (quantities detailed in figure legends), 2 pi o f  6 X  EM SA buffer, 1.5 pi 
non-specific D N A  (1 pi o f  1 qg/ql p[d(I:C)] and 0.5 ql o f  1 qg/ql salmon sperm D N A) 
plus or minus 0.5 ql o f  an anti-IRF-1 antibody (1/1000 dilution, BD biosciences) or 
200 ng scFv were pre-incubated for 30 min on ice prior to the addition o f  the 32P- 
labelled C l probe (1 ql, from  section 3.15.1). Follow ing further incubation for 30 
min at room  temperature the reactions were analysed on a 5%  polyacrylamide gel 
and radiolabelled bands were detected using a phosphoimager.
3.16 Reporter assay
For luciferase reporter assays, cells were cultured in 24-wcll plates and transiently 
transfected with pCM V -R enilla /Luc (60 ng) together with 120 ng o f  either pi 25-luc 
IFN-P (w ild  type or mutant -IS R E ), TLR3-Luc (wild type or mutant -IS R E ), - 
683CD K 2-Luc, T R A IL -L uc (wild type or mutant -IS R E ), or IL-7-Luc (wild type or 
mutant -IS R E ) reporter gene constructs. Luciferase assays were performed 24 hours 
post-transfection using the Dual Luciferase® reporter assay system (Promega) 
according to the manufacturer's instructions. Luminescence was quantified using a 
Fluoroskan Ascent FI luminometer (Labsystems). Signals were normalised using the 
internal control (R e n illa  luciferase signal).
3.17 Sub-cellular localisation
As described in the manufacturer's handbook using the Thermo Scientific subcellular 
fractionation kit. Fractions (20 ql) were analysed through SDS-PAGE and 
immunoblotting as described in the figure legends.
3.18 IRF-1 turnover
For half life determination cells were transfected at 80%  confluence using Attractene 
(Qiagen) according to the manufacturer's handbook and as indicated in the figure 
legends; for endogenous IRF-1 half life determination, the cells were left 
untransfected. 24 hours post-transfection cells were treated with cyclohexim ide (30 
qg/m l) and harvested at time points 0, 15, 30, 45, 60, 90 and 120 min after treatment. 
For accumulation assays cells were also transfected at 80%  confluence using 
Attractene (Q iagen) as described in the manufacturer's handbook this time with
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either w ild type or mutant IRF-1 P325A. They were then treated with the 
proteosomal inhibitor M G 132 (50 pM ) and harvested at time points 0, 15, 30, 45, 60,
90 and 120 min after treatment. Detergent soluble cell lysate (mammalian cell lysis 
described under section 3.8) and the detergent insoluble pellet (solubilised via re­
suspension in 100 pi SDS-sample buffer and heating to 85°C for 10 minutes) were 
analysed by  SDS-PAGE/im m unoblotting as described in figure legends.
3.19 scFv  co-immunoprecipitation
Purified scFv (1 pg) in buffer A  (20 m M  Tris-HCl pH 7.5, 0.5 M NaCl) was 
incubated with N i2_r-N T A  agarose (15 pi) for 1 hour at 4°C then washed 2 x 5  min 
with buffer A  plus 5 m M  imidazole. The beads were subsequently incubated with 
detergent soluble HeLa cell lysate (500 pg), and mixed at 4°C for 2 hours. Unbound 
proteins were rem oved by washing 3 x with buffer A  plus 25 m M  imidazole, 0.5%
Triton X -100  and 0 .5%  Tween 20, follow ed by 3 x with buffer A  plus 25 m M  
imidazole. The beads were heated to 85°C for 10 minutes in SDS-sample buffer (100 
pi) to elute bound proteins. This eluate was analysed via SDS-PAGE and 
im munoblot as described in figure legends.
3.20 One-STrEP pull down
0 .2%  Triton X-100 lysis buffer without DTT
50 mM Hepes pH 8 
0.2%  (v/v) Triton X-100 
150 mM NaCl 
10 m M  NaF 
0.1 m M E D T A  
20 pg/ml leupeptin 
1 pg/ml aprotinin 
2pg/m l pepstatin
protease inhibitors
One-STrEP-tagged IRF-1 wild type, AC25 or AC70 (4 pg) were transfected into 
A 375 cells grown in 10 cm  plates. After 24 hours intracellular protein com plexes 
were cross-linked by  incubating the cells with 2 mM DSP (Dithiobis [succinimidyl 
propionate]) for 30 min at room  temperature, this reaction was then stopped through
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the addition o f  20 m M  Tris pH 7.5 for 15 min at room temperature. Cells were 
washed with co ld  PBS and harvested by scraping in the presence o f  1 ml 0 .2%  Triton 
X -100 lysis buffer. This lysis buffer contained no DTT as DSP is cleaved by 
reducing agents. The scraped cells were incubated on ice for 20 min follow ed by 
centrifugation at 16,800 x g for 15 min at 4°C. This lysate (0.5 mg) was added to a 
50%  suspension (40pl) o f  streptactin macroprep (IB A ) and rotated for 1 hour at room  
temperature. Beads were washed 1 x with wash buffer, (100 mM Tris pH 8, 150 mM 
NaCl, E D T A ), 4 x with PBS containing 0 .2%  Triton X -100 and then again 1 x with 
the same wash buffer as before. One-STrEP-tagged com plexes were eluted in 50 pi 
o f  SDS sample buffer by heating to 95°C for 5 min. After further centrifugation at 
1,600 x g for 5 min, 25 pi o f  the eluted samples were analysed by SDS- 
PAG E/im m unoblot using anti-ZNF350 and anti-IRF-1 antibodies.
3.21 Peptide pull-down
A375 cells were washed with cold  PBS then harvested by scraping in the presence o f  
l ml 0 .2%  Triton lysis buffer (described under One-STrEP pull down, section 3.20) 
supplemented with 2 m M  DTT. Avidin (40 pg/m l) was added to the lysates and they 
were incubated on ice for 30 min before being pre-cleared on Sepharose beads (l 00 
pi o f  beads/1 ml o f  lysate) for 1 hour at 4°C. Cleared mammalian lysate (0.5 m g) was 
then added to 100 pi (50%  suspension) o f  streptavidin-agarose (Sigma), which had 
previously been washed 3 x in wash buffer A  (100 m M  Tris pH 8, 150 mM NaCl, 1 
m M  E D T A ) and incubated for 1-2 hours with 50 pg/ml o f  biotinylated peptide. The 
lysate and streptavidin-agarose bound peptides were incubated for 1 hour at room  
temperature then washed 1 x with wash buffer B (PBS containing with 0 .2%  Triton 
X -100, 20 pg/m l leupeptin, 1 pg/ml aprotinin, 2pg/ml pepstatin), 4 x with wash buffer 
C (PBS containing 0 .2%  Triton X -100) and then again with wash buffer B. The 
samples were centrifuged at 1,600 x g for 5 min at 4°C  and excess liquid was 
removed. Bound proteins were eluted in 50 pi o f  SDS sample buffer by heating to 
95°C  for 5 min. 25 pi o f  eluate was then analysed through SDS-PAGE and 
im munoblot using anti-ZNF350 and anti-IRF-1 antibodies.
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4 In vitro selection and characterisation of 
anti-IRF-1 scFv
4.1 Introduction
This chapter describes the use o f  antibody phage display to select single chain 
antibodies (scFv) capable o f  binding to specific regions o f  IRF-1. A  peptide 
consisting o f  the C-terminal 20 amino acids o f  IRF-1 was used as an antigen in the 
phage biopanning procedure. Antibody selection by phage display and the 
importance o f  the C-terminus o f  IRF-1 in regulating its activities are outlined in this 
thesis.
4.1.1 Antibody phage display technology
Phage display technology relies on four principle features: genotypic diversity, 
selection pressure, amplification and genotype/phenotype coupling [298], First, a 
hugely diverse library o f  genes encoding full length proteins or peptides is cloned 
into phage DN A. This generates a large population o f  phage, each displaying a 
variable protein or peptide fused to an external coat protein. This initial phage 
population is brought into contact with a target antigen, non-binding phage are 
discarded and only those able to bind are selected. The now reduced population o f  
phage, displaying only high-affmity binders fused to their coat proteins, is amplified 
in a host bacterial culture. The amplified phage are again subjected to the same 
biopanning selection procedure until a sufficient enrichment o f  strong binders is 
achieved. The phage D N A  from this final population can be extracted and sequenced 
to allow identification o f  the antigen-binding proteins/peptides. Thus, phage display 
provides a selection platform through which specific, high-affmity interactions can 
be identified [169],
Antibody phage display involves the selection o f  antibody fragments displayed on 
the surface o f  phage [299]. The basic functional unit o f  an antibody, the 
imm unoglobulin domain (IgG), consists o f  four polypeptide chains: two heavy and 
two light chains connected by disulphide bonds. Both the heavy and light chains 
house variable domains, which each contain three variable loops, termed
76
Complementarity Determining Regions (CDRs), that are responsible for antigen 
binding. Recom bination o f  antibody variable (V ) genes, encoding the heavy (VH ) 
and light (V L ) variable domains, transfers the antibody-antigen binding capacity to a 
single chain polypeptide. Thus, large diverse sets o f  VH and V L  genes are amplified 
from lym phocytes [196, 300] and randomly paired to provide diverse libraries o f  
antibody single chain variable fragments, scFv [301], Sequence variability in the 
CDRs is increased by  PCR using partially degenerate primers [189],
The follow ing chapter will describe the selection and characterisation o f  single-chain 
antibodies selected from  the Tomlinson (I and J) [188] or ETH -2-gold [189] libraries 
using phage display. In both libraries the single-chain Fv antibody fragments are 
fused to the m inor coat protein g3p o f  filamentous phage and tagged with His and 
M yc.
4.1.2 C-terminal antigen
The ratio o f  the tumour suppressor IRF-1 and its hom ologous repressor IRF-2 
oscillates during the cell cycle, falling follow ing growth stimulation and reaching its 
highest point in growth-arrested cells [67, 302], Ectopic overexpression o f  IRF-1 
results in strong inhibition o f  cell growth, and abrogation o f  this activity is linked to 
tumour progression [302], This ability to inhibit cell growth is lost follow ing deletion 
o f  the C-terminal 70 amino acids and reduced by loss o f  the last 25 amino acids o f  
IRF-1 [64],
Mutant IRF-1 protein, lacking the C-terminal transactivation domain (splicing 
variants involving exons 7, 8 and 9), has been identified in cervical cancer patients 
[24] and shown to: com pete with wild type IRF-1 for DN A binding, have a longer 
half life and be expressed in a cell cycle independent manner [24]. Understanding the 
function o f  IRF-1 discrete sub-domains in the wild type protein could increase 
current understanding o f  the role these mutants play in tumour progression.
Further study o f  IR F -l ’ s C-terminus has revealed that it plays a role in modulating 
target gene expression [101] and regulating degradation [111]. The extreme C- 
terminal 70 amino acids o f  IRF-1 have been characterised as an enhancer domain 
[101], Unlike the more N-terminal transactivation domain (amino acids 184-256), the
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enhancer cannot independently increase transcriptional activity o f  a GAL4 DNA 
binding domain. However, in cooperation with the transactivation domain, this 
region can further enhance transcriptional activation [101]. The mechanism through 
which this domain increases transcription is not folly understood, but it has been 
shown to house one o f  tw o sites bound to by the transcriptional co-activator p300 
[12]. As yet no link has been found between IR F -l ’ s ability to bind p300 and its 
transcriptional activities.
IRF-1 can function both as a transcriptional activator and repressor. Earlier studies 
have described its ability to repress CDK2 [10, 62] and induce IFN-P expression 
[51], The establishment o f  a link between the extreme C-terminus o f  IRF-1 and 
enhanced induction o f  transcription [101] prompted investigation o f  this region’ s 
ability to influence I R F -l ’ s repressor functions. Deletion o f  the last 70 amino acids, 
loss o f  the enhancer domain, dramatically reduced IFN-P induction and CDK2 
repression [64], H owever, more detailed mapping revealed a C-terminal deletion o f  
the last 25 amino acids could increase IRF-1 induction o f  IFN-P and mitigate CDK2 
repression. Smaller deletion mutants and alanine substitutions revealed that amino 
acids 311-317 acted as an internal suppressor o f  IR F -l ’ s transcriptional activator 
function, i.e. mutation o f  these residues increases IFN-P induction. Furthermore, 
residues 306-310 were shown to be essential for CDK2 suppression [64], Although 
the transcriptional activities o f  IRF-1 were modulated, the C-terminal mutants o f  
IRF-1 used in this study retained the ability to bind DNA.
The extreme C-terminus was also shown to play a role in the stability o f  IRF-1. IRF- 
1 has an extremely short half life o f  20-40 minutes [110, 111]. Removal o f  the C- 
terminal 39 amino acids o f  IRF-1 generated a degradation resistant form o f  the 
protein and addition o f  these residues to GFP reduced its half life [110]. 
Polyubiquitination o f  foll-length IRF-1 has also been demonstrated [110]. Inhibition 
o f  the proteosom e leads to an increase in polyubiquitinated forms o f  IR F-1, 
supporting the connection between IR F -l ’ s ubiquitination and its degradation [110, 
111]. H owever, these two processes were uncoupled by a series o f  C-terminal 
deletions. Loss o f  the last 70 amino acids o f  IRF-1 prevented both polyubiquitination 
and degradation, whereas removal o f  the last 25 amino acids did not prevent
78
ubiquitination, but did inhibit degradation [111], indicating that a further regulatory 
step is required before the protein can be broken down. Expression o f  the C-tenninal 
70 amino acids as a truncated protein was shown to reduce ubiquitination o f  wild 
type IR F-1. One possible explanation for this observation is that the C-tcrminus may 
act as a docking region for ubiquitin-promoting co-factors (e.g. E3 ligases) and 
compete with full-length IRF-1 for these binding proteins.
To date, very little is known about IRF-1 interactions that influence degradation. 
Further evidence that these map to the extreme C-terminus o f  IRF-1 was provided by 
a study o f  chaperone interactions within this region [112], The Hsp90 inhibitor 
17AAG caused a decrease in intracellular IRF-1 levels after 12 hours. This decrease 
was lessened by  proteasomal inhibition with M G123, indicating that Hsp90 can 
protect IRF-1 from  proteosom al degradation. Additionally, the ability o f  an Hsp90 
inhibitor to decrease IRF-1 protein levels was shown to be dependent on Hsp70 
binding to IRF-1 between amino acids 306 and 318, specifically to an L X X L L  m otif 
[112], Prior to the decrease in IRF-1 protein levels (0-12 hours after treatment), 
17AGG inhibited IR F -l ’ s transcriptional activity thus implying that this may be 
enhanced by  Hsp90. Furthermore, Hsp90 was shown to increase the half life and 
protein levels o f  nuclear IRF-1.
An increase in the half life o f  IRF-1 has previously been linked to its upregulation 
during A TM -dependent D N A  damage response [29]. Tight control over IR F -l ’ s 
degradation pathway could  enable a speedy response to DNA damage, follow ed by a 
quick return to normal IRF-1 levels. Taken together the studies described here reveal 
the importance o f  the extreme C-tenninus o f  IRF-1 in regulating its protein turnover 
and the expression o f  downstream target genes. However, out o f  necessity these 
studies rely on exogenously expressed mutant proteins and it is not yet known i f  
these regions o f  IRF-1 are rate-limiting for the activity and turnover o f  the 
endogenous protein.
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Figure 4.1: Functional mapping of the C-terminus of IRF-1. Adapted from 
[303]
4.2 Results
This chapter details the validation o f  phage display as a technique through which 
IRF-1 targeting m onoclonal antibodies can be derived. The activity o f  these 
m onoclonal antibodies was examined in a series o f  in vitro assays. M onoclonals were 
selected on the basis o f  relative affinity and specificity follow ing cytoplasmic 
expression so that they could subsequently be developed as intracellular antibodies 
(the topic o f  chapter 2).
4.2.1 Polyclonal phage-scFv
To generate single chain antibodies (scFv) against the extreme C-terminus o f  IRF-1, 
a biotinylated peptide covering the last 20 amino acids o f  IRF-1 (amino acids 3 Ob- 
325) was used as the target antigen. Peptide-specific antibodies were selected from 
the Tom linson phage display library [188] in which diverse single chain antibody 
fragments (scFv) carrying His and M yc tags are expressed on the surface on phage
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particles as fusions to the minor coat protein g3p. Each scFv consists o f  antibody 
heavy and light chain variable domains connected by a flexible glycine serine linker.
The biotinylated peptide antigen (C2: LD SLLTPVRLPSIQAIPCAP) was captured 
onto streptavidin-coated immunotubes (Nunc), blocked with 2%  MPBS to reduce 
selection o f  plastic-binding antibodies and washed with PBS to remove excess 
peptide. T w o stocks o f  phage (I and J) are supplied with the Tomlinson antibody 
phage display library, which possess a diversity o f  1.47 x 108 pfu and 1.37 x 108 pfu 
respectively. Therefore, for each round o f  selection, two plastic immunotubes were 
coated with the target antigen and each incubated with a separate phage stock (either 
I or J). To each o f  the antigen-coated immunotubes 1013 pfu (plaque forming units) 
o f  phage were added. This equated to incubation with ~ 68000 (stock 1) or -73000  
(stock J) copies o f  each different phage-expressed antibody. Having each scFv- 
displaying phage represented at high frequency prior to selection increased the 
chances o f  detecting an antigen-binding clone. Phage were quantified (titred) based 
on colony growth o f  infected bacteria on ampicillin plates, as the scFv encoding 
phagemid vector contained an antibiotic resistance gene. The scFv displaying phage 
were incubated with the peptide antigen for 2 hours, 1 hour on a rotating turntable 
and 1 hour standing, both at room  temperature. Unbound phage was then discarded 
follow ing rigorous washing with phosphate buffered saline (PBS), and bound phage 
eluted with trypsin in PBS (see figure 4.2)
In order to produce new phage particles in the amplification step that follows 
selection, a bacterial host must be infected with both phagemid-carrying phage and 
helper phage. The resultant phage virions display the g3p coat proteins encoded in 
either the phagem id (which are fused to scFv) or the helper phage (which have no 
scFv attached). The insertion o f  a trypsin cleavage site in the helper phage g3p coat 
protein renders them incapable o f  infecting bacteria following trypsin-elution, 
whereas the trypsin cleavage site in the phagemid encoding scFv is inserted 
inbetween the coat protein-scFv fusion, so that phage carrying antibody fragments 
can be eluted and still infect a bacterial host in subsequent amplification steps [304], 
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Figure 4.2: protocol for selection of scFv-displaying phage targeting the C- 
terminal 20 amino acids of IRF-1. Continued on next page.
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fro m  th e  Tom linson lib ra ry  
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Figure 4.2: protocol for selection of scFv-displaying phage targeting the C~ 
terminal 20 amino acids of IRF-1 (figure continued from previous page). The 
selection procedure is based on that supplied with the Tomlinson phage 
display library, but adapted for use against biotinylated peptides rather than 
full length protein.
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Follow ing selection and amplification the polyclonal pool o f  1RF-1 binding phage 
was precipitated from the bacterial culture medium with PEG/NaCl and re-suspended 
in PBS. The polyclonal phage-scFv from each o f  the 3 selection rounds was 
resuspended in PBS and tested for its relative affinity to IRF-1 in an ELISA. The 
biotinylated peptide used as a target during phage display was immobilised on a 
plastic microtitre plate and separately incubated with the polyclonal scFv-displaying 
phage from  each o f  the 3 selection rounds. Following rigorous washing, the phage 
able to bind the peptide antigen were quantified using a HRP-conjugated antibody 
against the phage g3p coat protein, which emitted a measurable fluorescent signal 
follow ing the addition o f  enzymatic chemiluminescence (ECL) solution (see methods 
section 3.10). It can be seen in figure 4.3 that with each successive round the 
polyclonal pool o f  phage was successfully enriched for IRF-1 binding activity. The 
polyclonal pools  consist o f  a phage derived from both Tomlinson stocks I and J 
com bined for analysis.
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Round 1 Round 2 Round 3
Figure 4.3: (Left panel) Polyclonal phage from each selection round were 
amplified in TG1 bacteria precipitated from the bacterial culture medium and 
resuspended in PBS. Phage titre following amplification was -10  pfu 
(plaque forming units). A 1/10 dilution of phage from each round was 
incubated with 200 ng of immobilised GST-IRF-1. Binding was detected 
using an anti-M13 antibody, which targets the minor phage coat protein g3p, 
and enhanced chemiluminescence. RLlLrelative light units. (Right panel) 
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Figure 4.4: (A) Polyclonal phage from the third and final selection round 
were amplified in TG1 bacteria, precipitated out of the bacterial culture 
medium and resuspended PBS. Phage titre following amplification was ~1013 
pfu (plaque forming units). A 1/10 dilution of phage from each round was 
incubated with 200 ng of: C2 the C-terminal 20 amino acids of IRF-1 
(LDSLLTPVRLPSIQAIPCAP), an N-terminal IRF-1 peptide with no homology 
to C2 and control peptides 1 and 2 which show no homology to IRF-1. As 
each peptide was biotinylated, relative binding affinity was also evaluated for 
the streptavidin background. (B) Polyclonal 3rd round scFv-phage assessed 
for binding to increasing levels (0-2 pg) of immobilised target peptide in an 
ELISA format. Biotinylated peptides were as described for figure 7A. Binding 
was detected by anti-M13, which targets the minor phage coat protein g3p, 
and enhanced chemiluminescence. RLU: relative light units.
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Next the specificity with which the 3rd round polyclonal pool could bind the target 
antigen was determined. This polyclonal pool was seen to bind with greater stability 
to the C-terminal IRF-1 peptide (C2) than to the three control peptides (figure 4.4). 
This stable interaction suggests that the scFv-phage selected have a higher affinity 
for C2 than for the control peptides, but this experiment does not measure affinity 
(K d )  directly. Furthermore, negligible background binding to streptavidin was 
observed.
4.2.2 Monoclonal scFv screening
The phage displayed antibody fragments present in the 3rd round polyclonal pool 
could prove useful reagents in some in vitro  assays, but to extend their use to 
intracellular assays (as described in chapter 5), it was important to select antibodies 
that exhibit target specificity when expressed as soluble proteins without a phage 
scaffold. For this reason, the soluble monoclonal antibody fragments were screened 
for IRF-1 specificity.
A ll subsequent experiments described in this chapter and chapter 5 involve 
m onoclonal scFv. B y screening numerous monoclonal antibodies, rather than simply 
using the polyclonal antibody pool, interesting epitope specificities can be selected 
and antibodies against a wider range o f  antigenic determinants identified for further 
analysis.
Soluble antibody fragments are secreted by phage-infected bacteria following 
induction with IPTG (Isopropyl p-D-l-thiogalactopyranoside). To produce 
m onoclonal antibodies, the polyclonal phage-scFv were used to infect HB2151 
bacteria. Between the previously described antibody phage display selection rounds 
the TG I bacterial strain was used for phage amplification. However, TGI is a 
suppressor strain and w ould introduce a glutamate residue at the amber stop codon 
(TA G ) between the scFv and g ill gene (which encodes the phage coat protein g3p), 
causing a scFv-g3p fusion to be expressed, hr the non-suppressor strain HB2151, 
TA G  will be read as a stop codon. As the intention o f  the study is to transfer the 
minimal scFv required for binding out o f  the phagemid expression system, it was 
advantageous to select for scFv that did not require the gp3 coat protein scaffold.
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However, expression from  HB2151 has the disadvantage that any scFv carrying a 
premature amber stop codon  would now be tmncated and therefore at a selective 
disadvantage, even i f  they had exhibited a high relative affinity when expressed full- 
length during phage display. Additionally, some full-length scFv lose their antigen 
affinity when expressed without g3p, and only re-introduction o f  the coat protein can 
restore binding activity [305, 306], Should no high affinity binders have appeared 
follow ing expression o f  isolated antibody fragments from HB2151 bacteria, 
m onoclonal screening w ould have been repeated, this time following TGI 
expression.
Follow ing infection o f  HB2151 bacteria with the 3ld round polyclonal phage pool, 48 
individual colon ies were picked for each library (96 colonies in total). Production o f  
scFv for screening was performed on a small scale in 225 pi cultures. M onoclonal 
scFv were secreted from  HB2151 phage-infected bacteria into the culture medium 
follow ing induction. As the scFv were selected for binding against only the last 20 
amino acids o f  IRF-1, the first characterisation step was to verify binding to full- 
length IRF-1. The dot blot method allows simultaneous and fast testing o f  numerous 
antibodies against the same antigen. A  nitrocellulose membrane was coated with 
IRF-1, b locked  and then spotted with each antibody. Following incubation with the 
antibodies, the membrane was washed and antibody binding detected with HRP- 





Figure 4.5 Screening for monoclonal anti-IRF-1 scFv antibodies. (A) 
Diagram of scFv binding to full-length IRF-1 in a dot blot format. (B) Media 
from an uninfected bacterial culture (“control"), or one infected with 3rd round 
polyclonal scFv-displaying phage and thus secreting soluble polyclonal scFv 
(“polyclonal pool”), was spotted onto a nitrocellulose membrane coated with 
0.3 pg/ml GST-IRF-1. After extensive washing, bound scFv were detected 
using protein A-HRP and enhanced chemiluminescence. (C) As in B except 
soluble scFv were secreted from individual monoclonal phage-infected 
colonies.
The results suggests that the polyclonal pool o f  3rd round scFv contained clones able 
to bind the C-terminal 20 amino acids in the context o f  full length IRF-1 (figure 4.3 
and 4 .5B ) and allow  the identification o f  five monoclonal scFv capable o f  binding 
stably to the full-length protein. The relative affinities detected by the dot blot 
method are affected by several factors. scFv expressed from phage-infected bacteria 
may have low  solubility or fold  differently without the scaffold o f  a phage coat 
protein. Additionally, protein stability and secretion levels may have varied. 
However, the dot blot does create conditions appropriate for identifying stable, 
soluble antibodies that are likely to work in similar in vitro immunoblots, one o f  the 
uses for which novel anti-IRF-1 antibodies could be employed. One limitation o f  the 
dot blot is that the antigen was not first separated by chromatography. Therefore,
HRP-Protein A
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even though purified GST-IRF-1 was used as the target antigen, scFv may have 
bound low  level contaminants, a possibility which is tested for in subsequent 
characterisation steps, as is the possibility that the selected scFv targeted the GST 
tag.
4.2.3 Selected scFv  sequence
Sequencing o f  the five positive clones selected in the dot blot revealed that each 
consisted o f  only a light chain variable domain (VL). This was surprising, as the 
primary protein A  epitope has been mapped to the heavy chain [307], and the entire 
Tom linson phage display library was screened by its manufacturers so that it would 
only contain active protein A  binders [188]. The restriction sites Sfil/N col and X hol, 
between which the heavy chain should have been cloned, were intact, as was the 
intervening pIT2 phagem id sequence present in the unrestricted vector (Figure 4.6).
In agreement with the sequencing data, the library provider Geneservice reported that 
“ There are clones in the library with no insert or with only light chain”  and that they 
“ have seen specific binders from the library that only have a VH or V L ”  [308]. They 
go on to point out that “ Not all the clones in the library contain inserts, and with 
growth passage the number without inserts does increase, because clones that express 
no or low  levels o f  scFv-pIII fusion grow better and produce more phage.”  [308],
The selection o f  light chain-only antibody fragments from the Tomlinson I and J 
library has been reported elsewhere, and these short fragments were shown to remain 
active binders [309, 310].
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Figure 4.6: (A) Map of PIT2 vector adapted from Tomlinson (l+J) library 
manual. (B) Annotated sequence of scFv 3, one of the 5 anti-IRF-1-C 
terminus antibodies chosen following dot blot screening. Sequence is 
identical to the other anti-IRF-1 single chain antibodies apart from CDR2 and 
3. (C) Diagrammatic representation of antibody fragement expressed from 




The next stage in selection was to generate antibody fragments that could be 
expressed stably within cells. Cytoplasmic bacterial expression has been reported to 
increase protein yield [311]. Additionally intracellular antibodies (intrabodies) have 
previously been used to modulate the activities o f  their target antigen. Selecting 
antibody fragments that function follow ing cytoplasmic expression at this stage will 
increase the chance o f  successfully developing active intrabodies later. Such 
antibodies could be used to study the function o f  endogenous IRF-1 within the cell. 
The five m onoclonal light-chain antibody fragments that bound stably to IRF-1 
contain intradomain stabilising disulphide bonds, which may not form in vivo due to 
the reducing environment o f  the cytoplasm. It has previously been shown that scFv 
disulphide bonds do not form in the cytoplasm [232]. However, some scFv have been 
shown to tolerate the absence o f  this bond and maintain their binding activity in in 
vitro  assays [234, 312], One previously described method for selecting antibodies 
stable in reducing environments is to test antigen binding following E .co li [313, 314] 
or mammalian cell [315, 316] cytoplasmic expression. With this aim in mind the 
single domain antibodies were cloned into the Gateway vector system (Invitogen) for 
cytoplasm ic expression. Once cloned into this system, a DNA insert can easily be 
transferred between different destination vectors through homologous recombination, 
enabling expression with additional tags, or in completely different cell systems. This 
broadened the range o f  assays in which antibody activity could be characterised. As 
the sequencing revealed that none o f  the antibody fragments selected contained 
premature amber stop codons, they could be expressed in any E .c o li non-suppressor 
strain, and for this study were produced in the B L 21 strain.
Follow ing bacterial cytoplasm ic expression, the antibody fragments were purified via 
a His tag, which along with the scFv and M yc tag was cloned from the origin 
phagemid into the Gateway system, or through an additional GST tag. The GST tag 
was added through the Gateway system, as an available commercial anti-GST 
antibody gave very low  background binding on immunoblots compared to the 
accessible anti-His or anti-Myc antibodies. However, in all experiments assessing 
binding to G ST-IRF-1, anti-His was used for detection.
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Tagged scFv extracted from lysate following bacterial cytoplasmic expression have 
previously been shown to specifically bind to their target antigen without a re-folding 
or oxidising step to regenerate the intradomain disulphide bonds [296, 317],
Although the location o f  the tag (C or N terminal) has been known to interfere with 
antigen binding [318], such interference is difficult to predict prior to experimental 
validation, particularly in the case o f  the antibody light chain variable domains in 
which the primary binding regions (CD Rs) are located throughout the protein. The 
GST tag was N-terminal and the H is-M yc tags C-terminal.
Purified scFv were used as primary antibodies in a series o f  binding assays aimed at 
establishing their specificity for the target antigen, 1RF-1. By first purifying the scFv, 
their concentrations could be normalised to allow for better comparison o f  their 
relative affinities. The scFv were initially tested for binding to denatured protein. 
Purified H is-tagged IRF-1 and IRF-2 were run on an SDS-polyacrylamide gel, 
transferred to nitrocellulose, blocked and probed for binding to commercial anti-His, 
anti-IRF-1 and anti-IRF-2 antibodies, or the five monoclonal scFv (figure 4.7A).
Each o f  the scFv showed a similar level o f  binding to His-IRF-1, but did not detect 
any purified IRF-2. Next, scFv specificity for untagged intracellular IRF-1 was 
assessed. IRF-1 or IRF-2 were transfected into A375 cells, which were harvested and 
lysed after 24 hours. The lysate was separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and probed with commercial anti-IRF-1 and anti-IRF-2, or 
each o f  the purified scFv. A ll five cytoplasmically expressed scFv were able to detect 
denatured full-length IRF-1 in crude lysate, but not IRF-2 (figure 4.7B).
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Figure 4.7: (A) Purified His-IRF-1 (lane 1) and His-IRF-2 (lane 2) (0.3 
(jg/lane) were analysed on a 12% SDS-PAGE/immunoblot and probed with 
anti-His, anti-IRF-1, anti IRF-2 and the scFv antibodies (1 pg/ml). scFv 
binding was detected using anti-GST monoclonal antibody and enhanced 
chemiluminescence A colloidal stain shows the purity of His-IRF-1 and His- 
IRF-2. (B) Lysate from HeLa cells transfected with 1 pg of pcDNA3 IRF-1 or 
pcDNA3 IRF-2 were analysed by 12% SDS-PAGE/immunoblot and probed 
with the antibodies listed for A excluding the anti-His antibody. NS: non­
specific band detected by antibodies. The data are representative of at least 
2 independent experiments.
A  non-specific band was detected by all 5 scFv in lysate containing exogenously 
expressed IRF-1, but not in lysate from cells transfected with IRF-2 (figure 4.7B). It 
is therefore possible that this band may represent a modified form o f  exogenous IRF- 
1 that cannot be detected by the commercial anti-IRF-antibody, although further 
analysis o f  the “ N S”  protein band would be required to test this hypothesis.
The single chain antibodies were all originally selected for binding to the last 20 
amino acids o f  IRF-1. This region o f  IRF-1 has been implicated in the regulation o f  
degradation and transcription (see section 4.1.2), therefore antibodies that 
specifically target this epitope would be especially useful for studying IR F-1 
function. Figure 4.4 already established that the polyclonal pool o f  phage produced 
by 3 rounds o f  phage display could specifically bind the IRF-1 C-terminal peptide,
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however it was important to verify binding o f  the monoclonal scFv to the same 
antigen. Therefore, all five scFv were tested for binding to the C-terminal IRF-1 
peptide (labelled C 2) and other overlapping peptides spanning the complete length o f  
IRF-1 (figure 4.4). The peptides were also incubated separately with a commercial 
polyclonal antibody to the C-terminal 20 amino acids o f  IRF-1 (Santa Cruz 
B iotchnology) or with streptavidin-HRP (to check that equal amounts o f  biotin- 
labelled peptide had been captured per well). All five scFv showed stable binding to 
peptide C2, and in four out o f  five cases (scFv 1,3,4 and 5) binding to C l, a peptide 
that overlapped C2 by 15 amino acids (see figure 4.8B). This suggests that the scFv 
may have slightly different epitope specificities. For example, whereas scFv2 has a 
requirement for the IPCAP sequence at the C-terminus o f  the C2 peptide, these 
residues are dispensable for scFvl binding. Very low  binding was observed to all 
other IRF-1 peptides. The commercial antibody confirmed that peptides C l and C2 
represented the C-terminus o f  IRF-1; however, the relative affinity o f  the commercial 
antibody cannot be com pared to that o f  the monovalent scFv, as it is a polyclonal 
sera made up o f  bivalent IgG.
Detection o f  the peptide antigen and denatured full length protein are both useful 
ways to validate antibodies. However, the C-terminal 20 amino acids o f  IRF-1 may 
not be available for binding in the protein’ s native conformation. An ELISA has the 
advantage over an immunoblot that the protein is not first fully denatured. Therefore 
a titration o f  GST-IRF-1 immobilised on a microtitre plate was probed with either the 
scFv or anti-GST in the m obile phase (Figure 4.9A  top panel). This showed that all 5 
o f  the scFv antibodies were able to bind IRF-1, although there were differences in 
their ability to form stable com plexes. For example scFv3 and 4 bound better to IRF- 
1 in this assay than scFv2. Next the scFv were tested for their ability to specifically 
target the extreme C-terminus o f  IRF-1 by comparing binding to full length IRF-1 
and a C-terminal truncation (AC25) (figure 4.9A  top panel versus bottom panel). As 
expected, s cF v l, 2, 3 and 5 were no longer able to detect the protein, however it was 
revealed that scFv 4 can bind IRF-1 outside o f  the C-terminal 20 amino acids under 
the conditions o f  the assay. This lack o f  specificity was not previously detected in the 
peptide ELISA. It may be that this off-target binding is dependent on conformational 
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Figure 4.8: scFv binding to IRF-1 peptides. Continued on next page.
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Figure 4.8: scFv binding to IRF-1 peptides (figure continued from previous 
page). (A) Schematic of scFv binding to biotinylated peptides in a peptide 
binding assay. (B) Immobilised overlapping peptides covering the whole 
length of IRF-1 were incubated with each scFv (1pg/ml). Following extensive 
washing scFv binding was detected with an anti-His monoclonal antibody and 
enhanced chemiluminescence. A commercial anti-IRF-1 C-terminus antibody 
was used as a control, and peptide normalisation was demonstrated using 
HRP-streptavidin. The sequences of two overlapping peptides (C1 and C2) 
are shown in the inset. (C) Sequence of overlapping peptides covering the 
full length of IRF-1, kindly provided by Vikram Narayan.
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ELISA results can be affected by immobilised proteins partially unfolding to reveal 
more hydrophobic residues to the plastic surface o f  a microtitre plate [319]. To 
control for unfolding o f  either IRF-1 or the antibody upon immobilisation, the assay 
was perform ed in the alternative orientation, with the scFv immobilised on the plate 
and IRF-1 in the m obile phase (figure 4.9B). Under these conditions a more 
pronounced difference in stable binding was detected. In this case, scFv3 bound 
significantly better than the other scFv antibodies, with the exception o f  the non­
specific m onoclonal scFv4. Again this suggests that the epitope specificities o f  each 
scFv may differ and that some antibodies, for example scFv3, preferentially bind 
their epitope when IRF-1 is in a native conformation.The experiments described 
confirm  that antibody phage display can be used to develop soluble monoclonal 
antibody fragments that can retain antigen specificity following cytoplasmic 
expression and subsequent purification. It also shows that peptide antigens can be 
used to develop antibodies that can bind their target epitope within the context o f  a 
full-length protein.
4.2.5 N-terminal IRF-1 antibody
In a parallel effort to find IRF-1 antibodies that bound to the N-terminus o f  IRF-1, 
the E TH -2-gold  scFv library [189] was used to select antibody fragments that bound 
stably to an N-terminal domain o f  IRF-1 spanning amino acids 60-124 (figure
4.1 OB). This region o f  IRF-1 has been described as a homodimerisation domain, 
essential for an interaction between two molecules o f  IRF-1 in vivo [103]; however, 
this interaction has not been validated as direct or functionally significant. This 
region o f  IRF-1 was also shown to be highly disordered (have high entropy), see 
figure 4 .10A. Such flexible unstructured protein regions have been shown to be 
important for regulatory interactions [320]. Development o f  the anti-N terminal 
antibody (scFvN ) was as described for the five anti-C-terminal scFv, except in that 
only tw o rounds o f  biopanning were performed, and the antigen was a His-tagged 
recombinant protein domain. The ETH-2-Gold library, like the Tomlinson library, 
consists o f  filamentous M l 3 phage with diverse scFv antibodies (36 x 10 clones) 
displayed as fusions to the minor coat protein g3p. Again each scFv carries a His and 
M yc tag.
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Figure 4.9: Binding of the scFvto IRF-1 under non-denaturing conditions. (A) 
A titration (0-200 ng) of immobilised GST-IRF-1 wild type or GST-IRF-1AC25 
was incubated with the scFv antibodies (1pg/ml). scFv binding was detected 
with an anti-His antibody and enhanced chemiluminescence. An anti-GST 
antibody was used to confirm a titration of GST-IRF-1 (wild type or AC25) 
had been immobilised to the microtitre plate. The results are given as relative 
light units (RLU) for scFv binding plotted against IRF-1 amount and are 
representative of 2 separate experiments. (B) As in A except that the scFv 
were immobilised and GST-IRF-1 was in the mobile phase; binding was 
detected using anti-GST.
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Follow ing two selection rounds, one domain-binding clone was identified from the 
m onoclonal screen (outlined in red: figure 4.11 A). Monoclonals were this time 
screened in a colorim etric ELISA, in which scFv binding is still detected with FIRP- 
protcin A , but instead o f  using chemiluminescence, FIRP was quantified with its 
substrate TM B  (3,3',5,5'-tetramethylbenzidine) which yields a coloured product. The 
N-terminal targeting antibody fragment was sequenced and also shown to only 
consist o f  a light chain, suggesting that the phage amplification procedure used in 
this study favours only short inserts. An ELISA against overlapping peptides 
encom passing the entire length o f  IRF-1 mapped the epitope o f  scFvN to amino acids 
91 to 110 (encom passed by peptide 7), confirming its N-terminal specificity (figure
4.1 IB ). Limited binding was also seen to peptide 18, which is more C-terminal 
(amino acids 256-275) and unrelated in sequence, but this was much less stable than 
that displayed for the N-terminal antigen. The scFvN was also shown to bind 
specifically to full-length IRF-1 in an ELISA, either when the antibody or IRF-1 was 
im m obilised (figure 4.12).
IRF-1 amino adds 
60 124
1 325
Figure 4.10: (A) Graphical representation of entropy predicted along the 
length of IRF-1. Created by Prof. Kathryn Ball using The DISOPRED server 
for the prediction of protein disorder [321]. (B) Diagrammatic representation 
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Figure 4.11: (A) (Left panel) Monoclonal scFv’s secreted by phage-infected 
bacteria into culture media were incubated with GST-IRF-1. After extensive 
washing, bound scFv were detected using protein A-HRP and the coloured 
HRP substrate TMB. The clone selected for further analysis scFvN is outlined 
in red. Soluble scFv from 2nd round polyclonal phage and media from a 
culture in which scFv expression was not induced are used as controls in the 
bottom right wells; indicated with “+” and symbols respectively. (Right 
panel) Schematic of scFv binding to full-length IRF-1 in an ELISA format. (B) 
Immobilised overlapping peptides covering the entire length of IRF-1 were 
incubated with scFvN (1pg/ml). Following extensive washing, scFv binding 
was detected with an anti-His monoclonal antibody and enhanced 



















Figure 4.12: Binding of scFvN to IRF-1 under non-denaturing conditions. (A) 
A titration (0-200 ng) of immobilised GST-IRF-1 or GST was incubated with 
the scFvN antibody (Igg/rnl). Binding was detected with anti-Flis/enhanced 
chemiluminescence. The results are given as relative light units (RLU) for 
scFv binding plotted against IRF-1 amount and are representative of 2 
separate experiments. (B) As in A except that the scFv was immobilised and 
GST-IRF-1 or GST were in the mobile phase; binding was detected using 
anti-GST.
Owing to time limitations, no functional studies were earned out on the N-terminus 
o f  IRF-1; how ever scFvN remains a highly specific reagent available for future 
research into the activities o f  its target domain. In the experiments outlined in this 
thesis it has provided a useful control against which the anti-C terminal scFv could 
be compared.
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The ability to precipitate IRF-1 from cell lysate would enable purification o f  the 
protein for further in vitro  analysis and identification o f  co-precipitated binding 
partners. Therefore, to expand on the functionality o f  the scFv antibodies, their 
binding to IRF-1 in cell lysates was investigated. Each o f  the scFv (1 to 5 and N) 
were im m obilised on N i+ beads via their His tag. Lysate from HeLa cells transfected 
with either full length or AC25 IRF-1 was incubated with the scFv. Following several 
washing steps, scFv-bound protein was eluted by boiling the beads in SDS sample 
buffer and analysed on an SDS-PAGE gel (figure 4.13A). scFvN was able to co ­
precipitate both the full-length and truncated IRF-1. scFv 2, 3 and 5 specifically 
purified only the full-length protein which carried their C-terminal epitope. scFv 4 
was able to bind both full-length and truncated IRF-1, supporting earlier indications 
that it can bind outside o f  the C-terminal 20 amino acids o f  IRF-1.
The numerous structure-function studies outlined in the introduction arc based on 
purified or transfected protein. However, antibodies that bind the endogenous protein 
could eliminate the need for transfection. Therefore, untransfected HeLa cell lysate 
was incubated with each o f  the immobilised scFv and analysed as before (figure 
4.13B). Under these conditions, scFv 1 could also immunoprecipitate IRF-1, as could 
scFv 3, 4, 5 and N, but scFv2 binding was lost. This suggests that epitope availability 
may vary between transfected and endogenous protein, highlighting the need for 
reagents that can target the endogenous form. scFv4 again exhibited low specificity, 
as it also co-precipitated the housekeeping protein GAPDH, which none o f  the other 
scFv bound.
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Figure 4.13: (A) scFv antibodies immobilised on Ni+-NTA agarose beads 
were incubated with lysate (500 pg) from HeLa cells transfected with either 
WT or AC25 IRF-1 24 hours earlier. Bound proteins were analysed by SDS- 
PAGE/immunoblot and developed using anti-IRF-1 monoclonal antibody and 
enhanced chemiluminescence. (B) scFv antibodies immobilised on Ni+-NTA 
agarose beads were incubated with lysate (500 pg) from untransfected FleLa 
cells. Following extensive washing, bound proteins were analysed by SDS- 
PAGE/immunoblot developed with either anti-IRF-1 or anti-GAPDFI. 
Alternatively the gel was stained with colloidal blue (bottom panel). The 
results are representative of 2 independent experiments.
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4.2.7 EMSA
An electrophoretic m obility shift assay (EM SA) can be used to determine an 
antibody’ s ability to bind to its target protein in com plex with DNA. As most o f  IRF- 
1 activities are mediated through D N A  binding, a scFv that could attach to promoter- 
bound IRF-1 may be able to affect its intracellular function. As scFv3 could bind 
endogenous IRF-1 from  cell lysates, it appeared to be the best candidate for cell 
based studies using the C-terminal intracellular antibodies. Levels o f  scFv and the 
P32-labelled D N A  probe, which consisted o f  four IRF-1 binding elements (ISRE), 
were kept constant, and IRF-1 was increased. The EM SA established that scFv3 
could bind an IRF-1 :D N A  com plex producing a ‘ supershift’ (figure 4.14 lanes 12- 
14). Although scFvN had previously shown it was efficient at capture o f  endogenous 
IRF-1 from  detergent soluble lysates (figure 4.13), it displayed no significant binding 
to the IRF-1 :D N A  (figure 4.14 lanes 4-6). Consistent with its low relative affinity for 
IRF-1 when com pared to scFv3, the scFv2 antibody had only a weak band-shift 
activity in the E M SA  (figure 4.14 lane 9). Importantly the for later development o f  
IRF-1 specific intracellular antibodies, none o f  the three scFv tested bound DNA 
(figure 4.14 lanes 3, 7 and 11)
4.2.8 Epitope mapping
The data presented in the previous sections indicate that all five anti-C terminal IRF- 
1 single chain antibodies bind to denatured IRF-1 with a similar relative affinity, but 
show considerable variation in their ability to bind both recombinant and cellular 
IRF-1 under non-denaturing conditions. This implies that although all 5 C-terminal 
scFv target the last 20 amino acids o f  IRF-1, their precise epitope is reliant on 
different sequence specificities within this region. To map the amino acid residues 
essential for binding for scFv 1-5, a library o f  peptides based on the C-terminal 20 
amino acids o f  IRF-1 was generated in which the amino acids were sequentially 
mutated to an alanine for use in an ELISA. In agreement with their varied 
performance in earlier assays, the results revealed no two scFv bound to precisely the 
same epitope (figure 4.15). However, scFv3 and scFv5, which both specifically 
captured cell-expressed full-length IRF-1 (figure 4.13), required the proline residues 
at positions 322 and 325 (figure 4.15C).
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Figure 4.14: In this EMSA purified GST-IRF-1 (200 ng ) bound a 32P-labelled 
DNA probe (consisting of 4 x ISRE; Lane 1), to give a banding patterning 
consisting of two IRF-1 :DNA complexes, labelled S1 and S2. DNA-bound 
IRF-1 is supershifted by a commercial anti-lRF-1 antibody (Lane 2). scFvN, 2 
and 3 were used at 200 ng per reaction with a titration of IRF-1 (0, 50, 100 
and 200 ng; lanes 3-6, 7-10 and 11-14). The data are representative of at 
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S ubstitu ted  amino acid
LD SLLTPVRLPSIQ AIPCAP s c F v l 
LD S LLTP V R LP S IQ A iP C A P  scFv2
LD S LL IP V R LP S IQ A IE C A P  scFv3 
LDSLLTPVRLESIQ AIPCAP scFv4
Figure 4.15: Identification of scFv epitopes. (A) Immobilised biotinylated 
peptides, comprising of an alanine scan of the C-terminal 20 amino acids of 
IRF-1 (306 to 325) LDSLLTPVRLPSIQAIPCAP, were incubated with 1pg/ml 
of scFv 1 to 5. scFv binding was detected with anti-His. A peptide containing 
the epitope for scFvN is labelled as Co (for control, and is peptide 7 in figure 
4 .11B); the data are representative of 2 independent experiments. (B) As in 
A except using scFvN. (C) Diagrammatic representation of the amino acid 
motifs targeted by scFv 1 to 5.
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scFv3’s higher relative affinity for IRF-1 consistently observed in earlier 
experiments was supported by its requirement for three additional residues (Ser317, 
Leu310 and Thr311), compared to scFv5 requirement for only one other residue 
(Pro312). scFv4 s non-specific nature was explained by its extremely limited epitope 
consisting o f only two adjacent amino acids Pro316 and Ser317, a sequence found 
outside the C-terminus in the main body of IRF-1 and in GAPDH. As expected, 
scFvN did not bind to any of the C-terminal peptides but was specific for its epitope 
from the N-terminal domain of IRF-1 (Figure 4.15B).
Together, the characterisation of scFv antibodies selected against the C-terminal 20 
amino acids o f IRF-1 reveal differing specificities for binding to the full-length 
protein in non-denaturing conditions. In particular scFv3 was able to efficiently 
deplete endogenous IRF-1 from cell lysate and bind to an IRF-1 :DNA complex.
4.3 Discussion
This chapter outlines the in vitro characterisation of 5 scFv targeting the extreme C- 
terminus o f FRF-1. An N-terminus-targeting scFv (scFvN) is also described that can 
be used as a control in further anti-IRF-1 scFv analysis. Although scFvN is not used 
to study the N terminus o f IRF-1 in this thesis, it provides a useful reagent for such 
studies in the future. This chapter also describes adaptation of the Tomlinson phage 
display library for use against peptide targets, and shows that scFv developed against 
peptides still have the potential to bind stably to their epitope in the context of a full- 
length protein. The ability of the scFv3 to supershift DNA-bound IRF-1 indicates 
that it could be used in the future to study the ability of IRF-1 to dimerise on target 
promoters. Furthermore, as it can deplete endogenous IRF-1 from cell lysate it could 
be used to immunoprecipitate protein complexes containing IRF-1 (see chapter 6).
Having selected only single domain antibodies has both advantages and 
disadvantages. These antibodies may have a lower affinity compared to scFv 
comprising o f heavy and light chains. It has previously been shown that the cleft 
between these two domains can form an antigen binding pocket [322]. However 
numerous studies on functional single domain antibodies have shown that they can 
exhibit specific binding activity [323, 324] and that the light chain can prove to be a
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highly active paratope [198, 325]. Additionally, single domain fragment stability is 
independent o f the VH-VL interface and less reliant on the flexible glycine-serine 
linker that connects the heavy and light chain in a scFv.
Single domain antibodies consisting only of heavy domains are found naturally in 
some vertebrates [193, 215] and have are already extensively investigated for their 
technological and clinical applications [195, 217], However, the potential o f isolated 
light chains has only slowly gained recognition. Over the last 5 years free IgG light 
chains have been described as having a physiologically relevant role to play in mast 
cell activation during hypersensitivity responses [326-328] and have been detected at 
elevated levels in patients with autoimmune diseases [329], The potential for light 
chains to be used as low molecular weight, high affinity, antigen binders is supported 
by biochemical studies, which demonstrate that isolated antibody light chains are 
capable o f specifically binding target antigens [330-332], The reduction of antibodies 
to minimal binding regions could increase their usefulness. Smaller proteins may be 
able to target binding pockets inaccessible to their larger parent antibodies. It has 
already been shown that single domains can be further reduced by the deletion of  
non-essential complementarity determining regions (CDRs) [333], The affinity of 
such minimal binding domains will depend on their ability to fold correctly and 
maintain a stable structure, even when expressed cytoplasmically. The screen for 
scFv developed here, consisting of affinity testing in a range of platforms (based 
around immunoblot and ELISA assays) following cytoplasmic expression, has 
proven effective for detection of stable single domain antibodies with a high target 
specificity.
The selected monoclonal scFv characterised for binding to IRF-1 (1-5 and N) were 
derived from two different antibody phage display libraries, but the culture times 
between selection were the same. It is likely that the duration of the bacterial 
amplification step favoured selection of short clones, i.e. those that encoded only 
single domains. This may have added a selective pressure, not based on affinity, to 
the phage display system. In order to optimise this technique so that selection of 
clones is based solely on their affinity, shorter amplification times could be 
attempted in the future.
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The development o f a C-terminal antigen relied on a peptide antigen. However, there 
was no guarantee that the C-terminal 20 amino acids of IRF-1 would have a similar 
conformation in isolation to that displayed within the context of the full length 
protein. This may have reduced the number of clones that gave a positive signal in 
the dot blot screen. Another method for targeting the C-terminus would be to initially 
select scFv that can bind to the full length protein, and then from this reduced pool 
select for and discard those that bound a C-terminally truncated protein (IRF-1 
AC20). This would mean keeping and amplifying phage that showed low affinity for 
the truncated protein and were thus eluted with PBS. However, the disadvantage of 
this strategy would be that all phage selected for binding to full-length IRF-1 may 
target particularly “sticky’Vhydrophobic regions outside of the extreme C-terminus, 
so that the second screen for phage that cannot bind the truncated protein would 
reveal no positive clones. It appears in this study that the isolated C-tenninal peptide 
does contain epitopes exposed in native, full-length IRF-1, and that screening of a 
sufficiently large number of antibody fragments enables identification of a small 
number o f scFv able to target these epitopes.
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5 Development of an activating anti-IRF-1 
intrabody
5.1 Introduction
Following the publication o f the human genome, investigation of gene function and 
regulation must now be systematically approached. There is a clear need for 
molecular tools that can act on a gene’s functional products: proteins. Elucidation of 
the protein phenotype in intracellular complexes can be undertaken with the use of 
small molecules capable o f specifically binding a target protein within the cell. Such 
small molecules can take the form of non-protein chemical compounds [334 , 335], 
peptide or oligonucleotide aptamers [336] and proteins (such as intracellular 
antibodies, see below). This chapter details the characterisation of single chain 
intracellular antibodies (intrabodies) targeting the extreme C-terminus of IRF-l. It 
goes on to show that these intrabodies can modulate IRF-l’s transcription factor 
function and stability.
5.1.1 Intrabodies
Single chain intrabodies have previously been used to modulate the functions of their 
target antigens: by altering intracellular localisation [231, 235-237], blocking enzyme 
activity, [230] inducing a transactivating conformational change [239, 240], 
disrupting normal protein-protein [227, 240-242] or DNA-protein interactions [227]. 
Such antibodies are expressed in the mammalian cell cytoplasm and screened for 
intracellular efficacy.
As discussed in the last chapter, expression of intrabodies in the reducing 
environment o f the cytoplasm results in inefficient or absent disulphide bond 
formation [232]. Misfolded antibody fragments can have a reduced solubility, a 
shorter half life and tendency to aggregate triggering proteosomal degradation [233]. 
However, intrabodies fully functional under reducing conditions have been 
developed, and it has been proposed that antibodies fragments with an intrinsically 
stable amino acid sequence can fold properly in the absence of disulfide bond 
formation [233, 234, 337], There are currently no consistent rules for predicting
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intrabody folding and function [338], therefore identification of those able to 
modulate the activity o f a target protein relies on screening numerous candidates.
Antibodies that do not show strong in vitro binding can still exhibit a specific, 
reproducible and strong modulating affect on their target antigen following 
intracellular expression [239, 339], Preselection has allowed researchers to identify 
rare, stable scFvs from large scFv-phage libraries. Such strategies can involve 
selection o f antibody fragments that are functional either: 1) following cytoplasmic 
bacterial expression [314, 315] (and as described in chapter 4), 2) within the yeast- 
two hybrid system [337, 340] or 3) under in vitro denaturating and reducing 
conditions [341], Flowever, such antibodies must still be screened again to validate 
their functionality within the mammalian cell. A long half life and high steady state 
levels o f antibody accumulation have been described as critical for a functional 
intrabody [248], however this may not prove to be the case for target proteins with 
very short half lives, such as IRF-1. Furthermore low levels of antibody expression 
may decrease cellular toxicity caused by an exogenously expressed protein.
5.1.2 IRF-1 target genes
The functional studies described in this chapter examine the effect of intrabody 
binding on IR F -l’s degradation and its regulation of target promoters. To study 
modulation o f IR F -l’s activities as a transcription factor, reporter constructs based 
on the TLR3, IFN-J3, CDK2, TRAIL and IL-7 promoters are used, and the effects on 
endogenous ISG20, PKR and CDK2 protein levels are observed.
5.1.2.1 TLR3
The TLR3 (Toll-like receptor 3) recognises double stranded RNA following viral 
infection and stimulates downstream regulators of the immune response, such as NF- 
kB and type I interferons [342, 343]. IRF-2 has been shown to be constitutively 
bound to ISRE (interferon response elements) within the TLR3 promoter, whereas 
IRF-1 only binds in response to certain stimuli, such as ectopic IFN-J3 expression 
[344], IRF-1 has shown to efficiently upregulate a luciferase reporter construct based 
on the TLR3 promoter [344].
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5.1.2.2 IFN-(5
IFN-p (interfcron-p ) is a type I interferon that plays a role in anti-viral and anti­
tumour response and was the first target gene of IRF-1 identified [1,2], 
Electromotility shift assays confirmed that IRF-1 could bind directly to the IFN-p 
promoter and helped define the interferon regulatory factor binding site: ISRE [1], It 
was subsequently demonstrated that IRF-1 could increase transcription from IFN-fJ- 
reporter gene constructs [5], De novo synthesis of IRF-1 has been shown to be 
necessary but insufficient for viral-mediated induction of IFN-p in certain cell lines, 
indicating that a further post-translational step is required [67],
5.1.2.3 CDK2
CDK2 (cyclin dependent kinase 2) is a serine/threonine kinase and a catalytic subunit 
of the cyclin-dependent protein kinase complex. CDK2 activity during the cell cycle 
is restricted to the S phase during which DNA replication occurs and the preceding 
G 1 gap when the cell increases in size. This protein associates with cyclin E to 
regulate progression from G1 to S phase [345] and with cyclin A during DNA 
replication [346], Cyclin association activates the CDK2 kinase, and in turn CDK2 
phosphorylates target proteins involved in cell cycle progression. For example, 
CDK2/Cyclin E phosphorylates its own suppressor, p27, triggering p27 degradation 
by the proteasome [347]. Phosphorylation of another target, nucleophosmin, has been 
shown to be essential for centrosome duplication [348], Interestingly, nucleophosmin 
is also involved in post-translational regulation of IRF-1 [144], IRF-1 has been 
shown to inhibit CDK2 promoter activity in a dose-dependent manner [62], The 
region o f the CDK2 promoter required for IRF-1 repression was mapped, but did not 
display homology to the classic IRF binding site (ISRE). The authors did not 
therefore test for direct binding of IRF-1 to this site. However, the transcription 
factor Spl, an activator o f CDK2 expression, was shown to bind this region o f the 
promoter. Exogenous expression of IRF-1 was shown to reduce Spl-induced CDK2 
expression, leading the authors to conclude that IRF-1 repressed CDK2 by 
interfering with SP1-mediated induction [62],
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5.1.2.4 TRAIL
TRAIL (Tumor necrosis factor-Related Apoptosis-Inducing Ligand) is a cytokine 
that has been shown to induce apoptosis selectively in cancer cells, while normal 
cells remain insensitive to TRAIL-mediated apoptosis [349], TRAIL homotrimers 
interact directly with four different cell surface receptors: death receptors DR4 and 
DR5 [19, 350] and decoy receptors DcRl and DcR2 [19, 351, 352], Activation of 
DR4 and 5 by TRAIL induces apoptosis [353] whereas the decoy receptors lack 
functional death domains and can therefore cannot stimulate cell death [19, 351,
352]. The decoy receptors are primarily expressed in normal tissues and absent from 
tumour cells [351], Thus, it has been proposed that in these cells they compete with 
DR4 and DR5 for TRAIL binding, and in this way inhibit TRAIL-mediated 
apoptosis [349]. IRF-1 enhances TRAIL expression when exogenously expressed 
and has been shown to be recruited to the TRAIL promoter following exposure of 
cells to retinoic acid [90] or IFN-a [354], Additionally, siRNA knockdown of IRF-1 
reduces TRAIL expression and cell death in a human bladder cancer cell line [354], 
supporting TRAIL’S role as a mediator of IRF-1 induced apoptosis.
5.1.2.5 IL-7
IL-7 (Interleukin-7) is a cytokine that plays a non-redundant role in lymphocyte 
development, proliferation and homeostasis [355-357]. IL-7 and IL-7 receptor {IL- 
7R) null mice have been shown to have impaired B- and T-cell development [355, 
356]. hr support o f  these findings, injection into mice of an antibody able to block 
binding o f  IL-7 to its receptor was seen to cause a significant reduction in mature T- 
and B-cell numbers [358] and administration of human IL-7 to mice caused an 
increase in lymphocyte proliferation [359]. IL-7 also stimulates progenitor NK 
(natural killer) cell maturation [360] and protects NK cells from apoptosis [357]. Its 
proliferative effects have been linked to the down-regulation of the CDK2-repressor 
p27 [361], IRF-1 is recruited to the IL-7 promoter following IFN-y treatment [297], 
Additionally, exogenous expression of IRF-1 was able to induce expression from an 
IL-7-luciferase reporter construct, whereas siRNA knockdown of IRF-1 suppressed 
endogenous IL-7 expression [297]. Taken together, these results suggest IRF-1 could 
play a role in lymphocyte proliferation, in combination with its previously 
documented role in lymphocyte differentiation [43, 49].
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5.1.2.6 ISG20
ISG20 (Interferon Stimulated exonuclease Gene 20kDa) has been characterised as a 
3'-5' exonuclease with a preference for RNA over DNA [362], Its expression is 
induced by viral infection, and its overexpression has been show to trigger an anti­
viral response [363, 364], Overexpression of ISG20 conferred resistance to infection 
from three different RNA genomic viruses on HeLa cells [363], This anti-viral 
activity was lost following mutation of the exonuclease domain of ISG20 [363], 
indicating that the protein’s ability to degrade RNA was central to its anti-viral 
activity. Furthermore, ISG20 was seen to interfere with mRNA synthesis of 
Vesicular Stomatitis Virus (VSV) [363], IRF-l has been shown to mediate ISG20 
induction in response to interferons (types I and II) and double stranded RNA [365, 
366]. ISG20 is therefore a well validated IRF-l target gene that plays an important 
role in innate immunity.
5.1.2.7 PKR
PKR (Protein Kinase activated by double stranded RNA) is a serine/threonine kinase 
activated by binding of double stranded (ds) RNA to two N-terminal RNA binding 
domains [367], which causes dimerisation of the protein via its kinase domains 
[368], Once activated, PKR phosphorylates the translation initiation factor eIF2, thus 
inhibiting protein synthesis [369]. During translation initiation, eIF2 binds the met- 
tRNAj in a GTP-dependent manner and recruits it to the 40S ribosomal subunit; this 
complex (which includes other elFs) scans mRNA in a 5’ to 3’ direction until it 
reaches the AUG initiation codon [370]. At this point eIF2-bound GTP is 
hydrolysed, and GDP-eIF2 detaches from the 40S. The 40S can then associate with 
the 60S ribosomal subunit to form the 80S translation initiation complex which is 
able to form the first peptide bond [370]. The eIF2 guanine nucleotide exchange 
reaction is catalyzed by eIF2B and inhibited by phosphorylation of subunit a o f eIF2 
by PKR [371], The phosphorylation of eIF2 by PKR therefore also inhibits 
translation initiation. Although the PKR promoter does contain an ISRE, an 
interaction between the promoter and IRF-l has not been confirmed [372]. However, 
PKR protein levels have been shown to be reduced in IRF-l deficient embryonic 
fibroblasts and increased following exogenous expression of IRF-l [373].
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These proteins are a small representation of IRF-1 ’s role in mediating immune 
response and inhibition o f cell growth. Excluding PKR, the ability of IRF-1 to 
modulate expression of these proteins has been well characterised, and they 
demonstrate IRF-1 ’s ability to both activate and repress transcription.
5.2 Results
Three monoclonal scFv were brought forward for characterisation as intrabodies: 
scFv 2 and 3 against IRF-1’s C-terminal 20 amino acids and scFvN which targets the 
N-terminal putative homodimerisation sub-domain (amino acids 60-124). During the 
in vitro characterisation o f the scFv described in chapter 4, scFv3 fonned the most 
stable interaction with native IRF-1 and was also able to supershift IRF-1 in complex 
with DNA. scFv2 was chosen to act as a control for scFv3 as they are highly similar 
in sequence (figure 5.1C), with only five variant amino acids through the CDR2 and 
CDR3 regions, but have differing affinities and antibody specificities within peptide 
C2 (figure 4.15A). scFvN was used as a second control antibody, in preference to a 
non specific scFv, as it again has good sequence conservation with scFv3 (Figure 
5.1C) but binds outwith the IRF-1 C-terminal domain.
These scFv were amplified from their original phagemid vectors with primers that 
added a kozac consensus sequence for mammalian expression within the Gateway 
system (Invitrogen). A GFP tag was added to each scFv, as specific and high affinity 
antibodies targeting this tag were available. The scFv still carried the His-Myc tags 
that were attached to them during the initial phage display selection. Although no 
fluorescent microscopy studies are included in this thesis, the GFP-scFv provide 
reagents for such studies in the future.
5.2.1 The scFv3 intrabody enhances IRF-1-induced
transcription
High level expression of intracellular scFv has previously been associated with 
misfolding, aggregation and localisation to inclusion bodies [374]. If the GFP-scFv 
had been misfolded in the mammalian cell cytoplasm, they would presumably have 
been rendered inactive and incapable of binding, and thereby modulating, 
intracellular IRF-1. IRF-1 ’s best characterised function is that o f a transcription
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factor. Therefore, the ability of the intrabodies to modulate IRF-1 activity in a TLR3- 
luciferase reporter assay was investigated. The TLR3 promoter has been shown to 
contain IRF-1 response elements and to be upregulated in response to IRF-1 binding 
[344], Each o f the scFv intrabodies were transfected with a TLR3-luciferase reporter 
construct in either an endogenous IRF-1 background or with a constant level of 
transfected IRF-1 (Figure 5.1 A). In cells untransfected with IRF-1, low level 
stimulation o f the TLR3 promoter was seen with increasing scFv3 expression. It may 
be that scFv3 expression alone can in some way directly modulate the activity of this 
reporter construct or that this stimulation was mediated by endogenous IRF-1. 
Transfection o f IRF-1 alone stimulated the TLR3 promoter, in agreement with 
previous findings [344], and this stimulation was strongly enhanced by scFv3 co­
expression. Although expressed at comparable levels, scFv2 and scFvN did not 
produce such a pronounced increase in IRF-1 activity. Consistent with its weak C- 
terminal binding activity, scFv2 only mildly enhanced IRF-1-dependent stimulation 
of TLR3, and scFvN caused a slight decrease in TLR3 induction. Figure 5.1B 
confirms the expression of each GFP-scFv in this experiment.
It appears in figure 5.1 that scFv3 is able to stimulate IRF-1-mediated induction of  
TLR3. However, this induction must be shown to be dependent on IRF-1 binding to 
the TLR3 promoter. Furthermore, before any biological relevance can be attached to 
the modulation o f IRF-1 activity by C-terminus targeting-intrabodies, it would be 
helpful to know if  this effect is limited to TLR3 induction or if it applies to any other 
promoters regulated by IRF-1. Therefore scFv3 was co-transfected with IRF-1 in the 
presence o f TLR3, IFN-p and CDK2 promoter-luciferase constructs. IRF-1 has 
previously been shown to induce IFN-/3 and repress CDK2 at a transcriptional level 
[5, 62]. As IRF-1 directly binds interferon response elements in the TLR3 and IFN-/3 
promoters, mutated luciferase constructs in which the IRF-1 binding sites are absent 
were used as controls. No such control was used for CDK2, as IRF-1 is not thought 



















Figure 5.1: scFv3 intrabody activates IRF-1-dependent transcription. (A) A 
titration (0-250 ng) of GFP-tagged scFv2, scFv3 and scFvN were expressed 
in HeLa together with a TLR3(+ISRE)-luc reporter (120 ng), Rennila (60 ng) 
and IRF-1 (75 ng) as shown. DNA was normalised using an empty vector. 
Reporter gene activity was measured in relative light units (RLU) and is 
expressed as the ratio of Luc:Ren. The assays were carried out in duplicate; 
results are given as the mean ± half the range and are representative of at 
least 3 independent sets of experiments. (B) scFv protein levels were 
determined by SDS-PAGE/immunoblot and developed using an anti-GFP 
monoclonal antibody. (C) Sequence variation between scFv3, 2 and N. All 
variation was localised to CDRs 2 and 3.
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In the presence o f  endogenous IRF-1 (figure 5.2 lanes 1 and 9), TLR3 and IFN-p 
reporter gene expression was reduced by mutating the IRF-1 binding site (ISRE) in 
these promoters (lanes 5 and 13), indicating that endogenous IRF-1 was able to bind 
and activate these promoters. scFv3 was seen to enhance this induction in the 
presence o f the wild type but not the mutated promoters, supporting the hypothesis 
that scFv3 is acting in an endogenous-IRF-1 dependent manner in these cells. In the 
presence o f transfected IRF-1, both the TLR3 and IFN-P promoters were induced and 
again this induction was reliant on IRF-1 binding directly to the promoter (i.e. it was 
abolished upon ISRE mutation) and enhanced by scFv3 co-transfection. Intrabody 
expression had no observable affect on IRF-1-mediated repression of the CDK2 
reporter (lanes 17-20).
To confirm scFv3’s C-terminal specificity, its ability to modulate the transcriptional 
activity o f AC25 IRF-1 was investigated (figure 5.3). Stimulation of the TLR3 and 
IFN-P promoters in an endogenous IRF-1 background was again enhanced by scFv3 
expression (figure 5.3: lanes 1 vs. 2 and 9 vs. 10). As has been previously observed, 
transfected AC25 IRF-1 was able to induce expression from these two promoters 
[303], but this stimulation was unaffected by scFv3 co-expression. It might be 
expected that a slight increase would be seen following scFv3 expression because 
endogenous IRF-1 is still present in the cell. However, as AC25 IRF-1 is expressed at 
a much higher level than endogenous IRF-1, it is likely that it can out-compete it for 
promoter binding. In agreement with published data, AC25 IRF-1 is unable to repress 
the CDK2 promoter [303], and this result was unaffected by scFv3.
The data given in chapter 4 indicate that in vitro scFv3 specifically targets the C- 
terminal 20 amino acids o f IRF-1, binds stably to endogenous IRF-1 and can also 
bind IRF-1 in complex with DNA. Figures 5.1, 5.2 and 5.3 indicate that these 
characteristics are maintained following intracellular expression.
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Figure 5.2: HeLa cells were transfected with Rennila (60 ng) and either 
TLR3(+ISRE), mTLR3(-ISRE), IFN-(3(+ISRE), mlFN-(3(-ISRE) or CDK2- 
luciferase reporter constructs (120 ng), plus IRF-1 (100 ng) and scFv3 (100 
ng) as indicated. Reporter gene activity was measured in relative light units 
(RLU) and is expressed as the ratio of Luc:Ren. The assay was carried out in 
duplicate; results are given as mean ± half the range and are representative 
of at least 2 independent sets of experiments.
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Figure 5.3: FleLa cells were transfected with Rennlla (60 ng) and either 
TLR3(+ISRE), mTLR3(-ISRE), IFN-p(+ISRE), mlFN-(3(-ISRE) or CDK2- 
luciferase reporter constructs (120 ng), plus AC25 IRF-1 (100 ng) and scFv3 
(100 ng) as indicated. Reporter activity was determined as in figure 5.2. The 
assay was carried out in duplicate; results are given as mean ± half the range 
and are representative of at least 2 independent sets of experiments.
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The data presented in figures 5.2 and 5.3 (lanes 2 and 10) suggest that scFv3 can 
regulate the transcriptional activity of endogenous as well as exogenous IRF-1. To 
verify the effect o f scFv3 on promoter induction in the absence of exogenous IRF-1 
and to investigate the dose-dependency of this effect, a titration of scFv3 and scFvN 
was co-transfected with either the TLR3 (figure 5.4) or IFN-P (figure 5.5) reporter. 
Under these conditions, scFv3 increased luciferase production from both the TLR3 
and IFN-P promoters by 4-5 fold at the peak. In contrast, although expressed at 
similar levels to scFv3, scFvN had no significant effect on IRF-1 activity on either of 
the promoters used. scFv3’s ability to activate endogenous IRF-1 was also confirmed 
for reporters constructs based on the IRF-1-responsive promoter regions of TRAIL 
and IL-7 (figure 5.6). scFv3 was able to activate the wild type reporters (+ISRE) but 
not mutant constructs (-ISRE) that were previously been shown to be defective in 
IRF-1 binding [90, 297], As before, scFvN had no significant effect on reporter 
construct activation.
Next, the scFv’s ability to enhance transcription of endogenous IRF-1 targets was 
investigated. This was done by observing the protein levels of endogenous ISG20, 
PKR and CDK2 following transfection of HeLa cells with a titration of scFv3, 2 or N 
(figure 5.7). An increase in the levels of ISG20 and PKR, which correlated with 
increasing amounts o f scFv3, indicated that intrabody-activated IRF-1 can bind and 
induce transcription from endogenous target promoters. scFv2 and scFvN had no 
affect on ISG20 or PKR. Additionally, in agreement with data from the reporter 
assays (figure 5.2), CDK2 protein levels remained unaffected by any of the 
intrabodies (figure 5.7). Overall, the activity of scFv seen in these assays supports the 
conclusion that a sufficient quantity of the cytoplasmically-expressed scFv3 is 
correctly folding into a conformation capable of binding its intracellular target 
antigen. One interpretation o f the data presented here, showing that the scFv3 
intrabody can significantly increase IRF-1 ’s transcriptional activity, is that the C- 
terminus o f the endogenous proteins is rate-limiting for IRF-1-mediated gene 











Figure 5.4: HeLa cells were transfected with a titration of scFv3 or scFvN (0- 
250 ng) plus Renilla (60 ng) and TLR3(+ISRE)-luc (120 ng). Reporter activity 
was determined as in figure 5.2. The assay was carried out in duplicate; 
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Figure 5.5: HeLa cells were transfected with a titration of scFv3 or scFvN (0- 
250 ng) plus Renllla (60 ng) and IFN-p(+ISRE)-luc (120 ng), and reporter 
activity was determined as in figure 5.2. The assay was carried out in 
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Figure 5.6: FleLa cells were transfected with of scFv3 or scFvN (250 ng), 
together with Renilla (60 ng) and either TRAIL (+ISRE), mTRAIL (-ISRE), IL7 
(ISRE) or IL7 (-ISRE) luciferase reporter constructs. Reporter activity was 
determined as in figure 5.2. The assay was carried out in duplicate; results 
are given as mean ± half the range.
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Figure 5.7: HeLa cells were transfected with 0, 0.5 or 1 pg of scFv3, 2 or N. 
After 24 hours the cells were lysed and the detergent soluble lysate was 
analysed by SDS-PAGE/immunoblot and developed with antibodies against 
ISG20, PKR, CDK2, GFP (to detect GFP-scFv), IRF-1 or GAPDH. The 
results given are representative of 2 independent experiments.
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Alternatively, as the extreme C-terminus is involved in protein interactions which 
impact on IRF-1 localisation [112] and degradation [111], scFv3 may affect IRF-1 - 
mediated transcription through an indirect mechanism. This possibility is 
investigated in the next section.
5.2.2 The scFv3 intrabody co-localises with IRF-1 and 
decreases its half life
Possible changes in the localisation of IRF-1 in response to scFv3 were investigated 
using subcellular fractionation. Figure 5.8 shows that in untransfected cells, IRF-1 is 
almost exclusively detected in the soluble nuclear compartment (fraction 3) and that 
this is not affected by the presence of either scFv3 or scFvN. The data also provide 
evidence that the intrabodies co-localise with IRF-1.
The C-terminus o f IRF-1 has previously been shown to be required for efficient 
turnover [111], with truncation of the C-tenninal 25 residues leading to enhanced 
steady state levels due to the generation of a relatively degradation-resistant protein 
[111]. The half life o f soluble endogenous IRF-1 protein was therefore measured in 
cycloheximide-treated cells that had been transfected with scFv3 or scFvN, and this 
was compared to the half life in untransfected or GFP-expressing cells (Figure 5.9). 
Two independent experiments are shown which are representative of a total o f 5 such 
experiments. In each case scFv3 caused a decrease in the half life of detergent 
extractable IRF-1 to around 17 min, from a value of 41 minutes in the GFP alone- 
expressing cells and 77 minutes in cells expressing scFvN.
Interestingly, the rate o f degradation of scFv3 itself was similar to that o f IRF-1 
when the intrabody was present, suggesting that the scFv3:IRF-l complex may be 
co-degraded. It is possible that binding of scFv3 to IRF-1 changes detergent 
solubility rather than the half life, therefore the to.s for IRF-1 remaining in the 
detergent insoluble lysate was determined following extraction under denaturing 
conditions. As with the soluble fraction, the half life o f IRF-1 in the insoluble 
fraction was reduced in the presence of scFv3 compared to the control (Figure 5.10).
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Figure 5.8: HeLa cells were transfected with scFv3 or scFvN (1.2 ug) and 
fractionated after 24 hours. Fraction 1: cytosol, 2: membrane/organelle, 3: 
soluble nuclear proteins, 4: chromatin bound nuclear proteins, 5: cytoskeletal 
proteins (as described by Thermo Scientific). Fraction 6 was created by re- 
suspending the residual pellet in SDS sample buffer. The fractions were 
analysed by SDS-PAGE/immunoblot and probed with anti-IRF-1, anti-GFP, 
anti-HP1a (a nuclear localisation marker) and anti-caspase 3 (a cytosolic 
localisation marker). 20 pi of sample were loaded per well. The data are 
representative of 2 independent experiments.
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Figure 5.9: (A) T0.5 o f  IRF-1 in detergent soluble mammalian cell lysate. Figure 
continued on the next page.
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Figure 5.9: Continued from previous page. (A) To.5of IRF-1 in detergent 
soluble mammalian cell lysate. HeLa cells were transfected with empty vector 
(pDEST53, which expresses GFP alone), scFvN or scFv3 (0.6 pg). Post­
transfection (24 hours), the cells were treated with 30 pg/ml cycloheximide 
and harvested at 0, 15, 30, 45, 60, 90 and 120 minutes after treatment. 
Detergent soluble proteins were analysed by SDS-PAGE immunoblot 
developed using antl-GFP oranti-IRF-1 monoclonal antibody. The data 
shown here Is for an experiment performed in duplicate, thus experiments 1 
and 2, and is representative of 5 independent experiments. (B) Graphs 
showing the percentage of IRF-1 protein remaining since cycloheximide 
treatment, where protein level at time 0 is 100%. Relative protein levels are 
based on the density of the immunoblot bands shown in A and were 
determined using SynGene Imaging Systems. (C) Half life (in minutes) of 
endogenous IRF-1 in HeLa cells following transfections described in A. 
Calculated using the natural log of % protein remaining against time, thus to.s 
occurs at y = ln(50). Half lives shown are an average for experiments 1 and 2 
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Figure 5.10: To.sof IRF-1 in detergent soluble mammalian cell lysate. HeLa 
cells were transfected with with empty vector (pDEST53, which expresses 
GFP alone), scFvN or scFv3 (0.6 pg). Post-transfection (24 hours), the cells 
were treated with 30 pg/ml cycloheximide and harvested at 0, 15, 30, 45, 60, 
90 and 120 minutes after treatment. Detergent insoluble proteins were 
analysed by SDS-PAGE immunoblot developed using anti-GFP or anti-IRF-1 
monoclonal antibody. The data shown here is for an experiment performed in 
duplicate, thus experiments 1 and 2, and is representative of 5 independent 
experiments.
The results presented so far suggest that the observed increase in IRF-1 activity, 
caused by binding o f scFv3 to the C-terminus of IRF-1, is not due to a change in its 
localisation or a decrease in the rate of degradation. It also suggests that, in addition 
to its previously documented role as a requirement for efficient degradation o f IRF-1 
[111], the extreme C-terminus of IRF-1 may also be involved in preventing IRF-1 
from being degraded too rapidly.
5.2.3 A  single point mutation at the C-terminus of IRF-1 mimics 
the effect of scFv3 intrabody binding
The observation that the increase in IRF-1 transcriptional activity seen in the 
presence o f scFv3 was accompanied by a significant decrease in the protein s half 
life was unexpected, as deletion of the last 25 amino acids of IRF-1, which 
encompass scFv3’s epitope, has previously been associated with a decrease in the 
rate o f IRF-1 degradation [111]. Independent evidence was therefore sought that 
scFv3’s epitope, as well as being required for efficient degradation of IRF-1 [110, 
111], might also act as a ‘brake’ on IRF-1 turnover. During characterisation o f C-
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terminal truncation mutants, it was previously noted that a construct from which the 
four C-terminal residues had been deleted was expressed in cells at much lower 
levels than wild type DR.F-1 [64], Additionally, another researcher in the lab (Dr 
Emma Pion -  unpublished observation) noticed a mutant form of IRF-1, in which the 
extreme C-terminal residue of IRF-1 Pro325 was substituted with an Ala (IRF- 
1P325A), had a very short half life; similar to that displayed by intrabody-bound 
IRF-1. Figure 5.11A shows that this mutant is expressed at very low levels, but 
accumulates in the presence of the proteasome inhibitor MG 132, suggesting it is 
subject to rapid degradation. To investigate the difference in expression of wild type 
IRF-1 and the P325A mutant, their half-lives were determined in cycloheximide 
treated cells. The to.5 o f wild type IRF-1 in HeLa cells was approximately 30 min, but 
less than 15 minutes for the P325A mutant protein (figure 5.11B, left panels). To 
ensure this apparent decrease in half life was not caused by a re-localisation o f the 
mutant protein away from the detergent soluble fraction, the insoluble pellet was 
analysed following extraction under denaturing conditions. The half life o f the IRF- 
1P325A mutant protein was seen to be reduced compared to the wild type protein in 
the pellet extract (figure 5.1 IB, right panel), confirming that the mutation had 
increased degradation and not simply changed the protein’s solubility. In summation, 
mutation o f Pro325 is sufficient to trigger an increase in the rate of IRF-1 degradation, 
suggesting that factors which bind to the extreme C-terminal residues of IRF-1 could 
modulate its degradation.
Having identified a mutation within the scFv3 epitope that could mimic the effect o f  
intrabody binding on degradation, the next step was to investigate whether this 
mutant had a higher intrinsic transcriptional activity than the wild type protein.
Figure 5.12 shows TLR3-luciferase expression following transfection with wild type 
IRF-1 or the P325A mutant. Protein levels were normalised (figure 5.12B) as the 
P325A mutant expressed at lower levels than the wild type protein. It was seen that 
the P325A mutant consistently displayed higher activity than the wild type protein 
(Figure 5.12A). Thus the P325A mutant provides intrabody-independent evidence 
that the C-terminus o f IRF-1 can limit the rate at which the protein is degraded, and 
that changes in the rate o f degradation correlate with increases in the activity of IRF- 
1 as an activator of gene expression.
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Figure 5.11: Mutation of Pro325 mimics scFv3 binding to IRF-1. (A) A375 
cells were transfected with IRF-1 wild type and IRF-1 P325A (0.5 pg); 24 
hours later they were treated with MG132 (50 pM) and harvested at the times 
shown. IRF-1 was detected following analysis of the lysates by SDS- 
PAGE/immunoblot. The data are representative of 2 separate experiments, 
performed by Dr Emma Pion. (B) HeLa cells were transfected with wild type 
(wt) IRF-1 or P325A-mutant IRF-1 and treated 24 hours later with 
cycloheximide (30 pg/ml), before being harvested at the times shown. 
Detergent soluble (left panel) and insoluble (right panel) lysates were 
analysed by SDS-PAGE/immunoblot and developed using an anti-IRF-1 
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Figure 5.12: (A) HeLa cells grown in a 24-well plate were transiently 
transfected with TLR3(+)-luc (120 ng), Renilla (60 ng) and a titration of either 
of IRF-1 wild type (wt) (0-0.25 pg) or IRF-1 P325A (0-0.5 pg). Reporter gene 
activity was measured in relative light units (RLU) and is expressed as the 
ratio of Luc:Ren. The assays were carried out in duplicate; results are given 
as mean ± half the range and are representative of at least 2 independent 
sets of experiments. (B) IRF-1 protein levels were determined by SDS- 
PAGE/immunoblot developed using anti-IRF-1 antibody.
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5.3 Discussion
The data presented in this chapter indicate that the extreme C-tenninal residues of 
IRF-1 inhibit its ability to activate transcription, and that this negative regulation can 
be relieved using an intrabody that binds to this region of endogenous IRF-1 or by 
mutating the C-terminal residue of the protein (P325). In addition, the data highlight a 
possible role for the scFv3 epitope in coordinating a link between the rate of IRF-1 
degradation and its transcriptional activity. Previous studies have suggested that IRF- 
1 activity is regulated primarily at the level of transcription, as IRF-1 steady state 
levels increase in response to agents such as interferon treatment and DNA damage 
which induce its transcriptional activity [2], However, the data shown here suggests 
IRF-1 is also subject to post-translational regulation; that it is held in a latent or 
partially active state and that activity can be induced without an increase in its steady 
state levels.
As discussed in the introduction, single chain intrabodies have previously been used 
to modulate the function o f their target antigens in a cellular environment. 
Mechanisms employed by intrabodies to produce changes in target protein activity 
have included: altering their intracellular localisation [231, 235-237], neutralising 
enzyme activity [230], disrupting normal protein-protein interactions [227, 240-242] 
or DNA-protein interactions [227], Although most published intrabody studies 
involve the disruption of their target antigen’s activities, some have been used to 
alleviate intrinsic negative regulation as shown in this study. For example, a domain 
within the carboxy terminus of another tumour suppressor, p53, has been shown to 
negatively regulate its transcriptional activity [375], This inhibition could be relieved 
by C-terminal deletion of p53 or by binding of an anti-C-terminal monoclonal mouse 
IgG named PAb421 [375]. scFv intrabodies based on PAb421 and a second mouse 
IgG named 11D3 were shown to target the C-terminus of p53 and increase 
transcriptional activation o f a p53 mutant His273 [239]. This mutant displayed 10% of  
the transcriptional activity of wild type p53 in a reporter gene assay, which was 
increased to ~25% following co-transfection with either of the anti-C-terminal scFv 
intrabodies [239]. These antibodies were shown to function by increasing the 
sequence specific DNA binding ofp53 [239, 375].
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In the current study, the scFv3 intrabody was able to activate endogenous IRF-1 - 
induced transcription between four to six fold making it a powerful tool to study the 
normal intracellular functions of the IRF-1. However, there was no evidence that 
scFv3 could enhance IRF-1 s ability to bind DNA. Additionally, the scFv3 intrabody 
clearly did not act through re-localisation of IRF-1, as both were detected only in the 
nuclear fraction and any re-localisation would presumably have reduced IRF-1 
transcriptional activity. scFv3 binding may have switched the conformation and/or 
dynamics o f endogenous IRF-1 to a more active form. At present, structural 
information is only available for the N-terminal DNA binding domain of IRF-1, and 
the contribution of the C-terminus to the protein’s tertiary structure is unknown 
[100]. However, antibodies have previously been used to stabilise and help determine 
the structure o f  disordered proteins [376], and it may be possible to use scFv3 to 
determine the conformation o f activated IRF-1 in future studies. Alternatively, the 
intrabody may function by disrupting or enhancing the binding of IRF-1 co-factors. 
To date very few proteins have been shown to directly interact with IRF-1, and even 
fewer with the extreme C-terminus. However, the scFv3 epitope mapped in chapter 
4, contained within the last 20 amino acids of IRF-1 (amino acids 306 to 325 
LDSLLTPVRLPSIQAIPCAP), overlaps with a previously determined co-factor 
binding motif (LDSLLTPVRLPSIQAIPCAP). Hsp70 binding to IRF-l’s LXXLL 
motif has been shown to be essential for an Hsp90-induced increase in IRF-l’s half 
life [112], Additionally, deletion mutants of IRF-1 have previously indicated that 
amino acids 306-310, in which the LXLL motif is contained, are essential for IRF- 
l ’s ability to inhibit cell growth and mediated CDK-suppression [64]. However, the 
scFv3 intrabody did not affect CDK-suppression, which may mean it does not 
impinge upon LXLL co-factor binding.
Alanine scanning and deletion mutants have also been used to show that residues 
centred about amino acids 311-317 of IRF-1 house a negative-regulatory motif, the 
mutation o f which enhances transcription from the IFN-P promoter [64]. The data 
shown in this thesis indicate that this negative regulatory domain is rate-limiting in 
the endogenous protein, and as scFv3 binding is dependent on amino acids T and 
S317, it is possible that these residues are part of a novel co-factor binding element.
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In the absence o f small molecules capable o f modulating IRF-1 activity, past studies 
relied on the use o f  transiently expressed IRF-1 mutant proteins. It was therefore not 
possible to determine the effect o f the C-terminus on IRF-1 as a transcriptional 
activator under normal cellular conditions. By developing an intrabody that can bind 
to both endogenous and exogenous IRF-1, this study demonstrates that the last 20 
amino acids o f  IRF-1 contain a regulatory element that is normally rate-limiting for 
IRF-1-mediated gene expression.
Previously published data has shown that the last 25 amino acids o f IRF-1 are 
required for efficient degradation o f IRF-1 [111], The sharp decrease in half life 
caused by the scFv3 intrabody binding to this region seems to contradict this finding. 
However, fine mapping o f the C-terminus has revealed that a P325A IRF-1 mutant 
protein (unpublished work by Dr Emma Pion), which mimics the affect o f scFv3 
binding, also reduces the protein’ s half life. The fact that both the intrabody and 
point mutation operate through the same residue, P325, supports the idea that this 
change in half life is not an artefact and suggests that the two may be working 
through the same mechanism to increase the rate o f IRF-1 degradation.
The combination o f  the results shown here (figures 5.9 and 5.10) and those o f earlier 
studies that revealed AC25 mutants are degradation-resistant [111] indicate that the 
extreme C-terminus o f  IRF-1 contains elements that are required for efficient 
degradation and that act as a brake to prevent that degradation from being too rapid. 
The data indicates that this region may function in ‘ fine-tuning’ IRF-1 turnover 
dependent on cellular conditions. IRF-1 polyubiquitination has been shown to be 
essential but not sufficient for proteosomal degradation o f IRF-1, suggesting that a 
second step is needed [111]. Searching for proteins that interact with the extreme C- 
terminus o f  IRF-1 (the focus o f chapter 6) could provide further insight into the 
tightly regulated turnover o f IRF-1.
As both intrabody-bound IRF-1 and P325A IRF-1 have an increased transactivation 
activity and rate o f degradation, it is possible that these two co-localised functions 
may be linked. It is increasingly clear that both the proteolytic and non-proteolytic 
functions o f  the proteasome are required for correct regulation o f the transcriptional 
machinery, with evidence o f both the 19S and 26S proteasomes being associated
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with chromatin, components of the basal transcriptional machinery and/or various 
transcription factors [377-382], The precise mechanism(s) linking transcriptional 
activation with protein degradation remain unclear. However, evidence suggests 
roles for proteasome-mediated degradation in establishing limits for transcription, 
promoting the exchange of transcription factors on chromatin and stimulating 
multiple rounds of transcription initiation [6, 301, 383-386], As has been shown for 
other transcription factors, it is possible that binding of an activating co-factor to 
IRF-1 may also trigger degradation [248, 387],
Based on the results presented here, showing that significant enhancement of IRF-1 
transcriptional activity can be achieved by post-translational mechanisms, it is 
interesting to speculate that therapeutic approaches may be designed which induce 
downstream targets o f the IRF-1 tumour suppressor pathway in cancers which retain 
one or more IRF-1 allele. Conventional approaches, such as type I interferon therapy, 
that function, at least in part, by activating the IRF-1 pathway at the level of 
transcription [61, 388], are used sparingly as they are toxic and have severe side 
effects [389, 390], The use of intrabodies to activate IRF-1 post-translationally, in the 
absence o f increased IRF-1 transcription, could be a novel avenue for activating 
some o f the downstream signalling pathways stimulated by type I interferons.
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6 Selection of IRF-1-binding peptides and 
preliminary validation of ZNF350 as an 
IRF-1-interacting protein
6.1 Introduction
As discussed in chapter 5, scFv3 may be working by altering the IRF-1 ’ s structure 
and/or disrupting its co-factor interactions. The introduction to this thesis details the 
co-factors o f  IRF-1 that have previously been identified and shown to modulate its 
activity (section 1.2.5.4). However, the characterisation o f additional co-factors 
could help explain the mechanics behind IRF-Fs regulation and activation following 
cell stress and during the cell-cycle. In particular, its post-translational modification, 
which is not well understood (section 1.2.5 and [109, 111, 122]). This chapter 
describes the use o f  peptide phage display to identify IRF-l-binding peptides, the 
sequences o f  which were use to search human protein databases for putative IRF-1 
interaction partners. The preliminary validation o f one such binding partner, 
ZNF350, is also described.
6.1.1 Peptide phage display
Peptide phage display enables the identification o f peptide motifs able to bind a 
specific target protein. This technique is summarised in figure 6.3; briefly short 
peptides (usually 6-20 residues) are expressed on the surface o f filamentous phage 
virions and incubated with a target protein. Following rigorous washing, phage 
displaying peptides that bound the target protein are eluted and amplified in host 
bacteria. The amplified phage are secreted by the bacteria and can be purified to 
create a pool o f  phage that only display peptides with an affinity for the target 
protein. This pool can then be used in subsequent selection rounds against the target 
protein and thus becomes enriched for the highest affinity binders. Finally the phage 
DNA can be extracted and sequenced and the amino acid content o f the binding 
peptides revealed.
Peptide phage display involves the fusion o f a polypeptide to a phage coat protein. 
The peptide is thus displayed on the surface o f the phage virion and encoded for
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within the phage genome. Large libraries can be created that contain billions of 
phage, each displaying a different peptide. In this study the Ph.D. 12 (NEB) peptide 
phage display library was used. This library consists of linear 12-rner peptides fused 
to the minor phage coat protein g3p with an intervening flexible glycine-serine linker 
(Gly-Gly-Gly-Ser). The library contains 1.9 x 109 distinct clones. Unlike the 
previously described antibody phage display libraries (chapter 4), the phage particles 
in this library carry a complete phage genome and do not require additional genes 
provided by helper phage. Bacteria infected with these M 13 phage form plaques 
caused by diminished cell growth when plated. As these plaques can be difficult to 
see, the phage vector also carries a lacZa gene. This results in blue plaques when an 
a-complementing E.coli strain such as ER2738 and Xgal/IPTG plates are used.
Since its initial development as a means of mapping of antibody epitopes [169], 
peptide phage display had been successfully applied in the identification of: bio­
active molecules that can disrupt or activate target protein activities [43, 257, 292], 
disease or tissue specific bio-markers [139, 258, 259, 262], protein interactions with 
non-protein substances [273-275] and proteimprotein interactions [268, 279]. In 
some cases intelligent modification of the basic peptide phage display protocol has 
increased its usefulness. For example, the addition of a streptavidin binding motif N- 
terminal to the displayed peptide has allowed the identification of protease cleavage 
sites [268, 391, 392], In this case the phage are immobilised on a streptavidin 
surface, incubated with a protease and released into solution if their displayed 
peptide is cleaved. They can then be purified from solution and used again in 
successive selection rounds. Once the cleavage motif is identified, it can then be used 
to identify novel substrates of the protease. In this way a GenBank BLAST search of 
a motif derived from peptide phage display identified Matrilin-3, a cartilage 
component, as a substrate of ADAMTS-4, an aggrecanase responsible for the 
breakdown o f cartilage aggrecan in osteoarthritis [268]. The BLAST search resulted 
in over 9056 “hits” but, by focusing on those involved in pathways in which 
ADAMTS-4 was known to play a crucial role, this study was able to characterise a 
physiologically relevant interaction.
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In other studies recombinant domains of a protein have been used as the “bait” or 
target protein in peptide phage display [279, 393], This approach has the advantage 
that functions/interactions can be mapped within the full-length protein, but has the 
disadvantage that interactions that rely on the tertiary structure of the full length 
protein will be excluded. However, several studies have highlighted the importance 
o f contacts between short peptide motifs, particularly in transient regulatory 
interactions [394], and important interactions have been identified using isolated 
domains [279, 393], For example, the PreS domain of the hepatitis B virus (HBV) 
large envelope is known to be involved in viral attachment to the membrane of 
hepatocytes during infection [395]; to identify binding partners of this domain it was 
recombinantly expressed, purified and used as a target protein in peptide phage 
display [279], The resultant peptide consensus sequence was entered into a BLAST 
search, which gave a large number of “hits”. The authors narrowed down this list to 
those in which the target-binding sequence was exposed on the outer surface of the 
membrane, discarding all intracellular hits. The group went on to eliminate new or 
hypothetical proteins for which information was limited. This led to only three 
potential interaction partners being investigated and one, lipoprotein lipase, being 
verified and shown to be physiologically relevant. In another study using isolated 
domains, the eukaryotic protein:protein interaction domain GYF (glycine-tyrosine- 
phenylalanine domain) was subjected to peptide phage display [393], This provided a 
GYP-binding motif which was used to search the human and yeast proteome. 
Peptides were synthesised that contained the potential GYF-interaction sites from 
each protein hit. Proteins represented by peptides with the highest affinity for the 
GYF domain were carried forward for further analysis, and direct interactions 
between full-length proteins containing the GYF domain and GYF-binding sites 
validated through yeast-2-hybrid [393, 396].
The experiments described above show that peptide phage display can be used to 
detect physiologically relevant interactions; first by detecting a protein-binding 
peptide motif, then by searching for this motif in a protein database and finally by 
validating the interaction between two full-length proteins. Although such database 
searches can provide thousands of hits [268], filtering the proteins based on 
localisation and function can reduce those taken forward for future study to a level
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that can be managed with the resources available to a particular research group and 
increases the chance o f  characterising an interaction important in a specific signalling 
pathway or disease. In this study, domains ol IRF-1 are used as targets against which 
high affinity peptides are selected. The sequences of these peptides arc then 
determined and used to search protein databases for potential IRF-1 binding partners. 
Such proteins arc initially selected for homology to an IRF-1 binding peptide, but 
then subsequently for involvement in post-translational regulation, cancer 
progression and/or pathways in which IRF-1 is already known to participate.
6.1.2 Domains of IRF-1





  repression of Cdk2
homodimerisation
degradation
inhibition of IRF-1-induced transcription
Figure 6.1: Diagram indicating mapped functions of IRF-1 (see thesis 
introduction) and the 5 domains used as targets in peptide phage display 
(indicated by coloured bars).
Five domains o f IRF-1 were used as targets against which phage displayed peptides 
were selected. These domains spanned IRF-1 amino acids 1-140, 60-124, 1 17-184,
117-256 and 256-325 (see figure 6.1). Each was chosen based on previous functional 
mapping. Amino acids 1-140 encompass the DNA binding domain [5] and nuclear 
localisation signal (NLS) of IRF-1 [104], Domain 60-124 contains residues shown to 
be essential for an in vivo interaction between two IRF-1 proteins, although this 
interaction has not yet been validated as direct [103]. Amino acid 117 signals the
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start o f the nuclear localisation domain; this region was mapped in mouse IRF-1 
[104], but its sequence is almost identical to the human homologue (82.5/92.1 
identity/similarity) [397], Domain 117-184 includes the NLS and amino acids N- 
terminal to, but not including, the transactivation domain. The larger 117-256 
domain includes both the NLS and transactivation domain. The transactivation 
domain (amino acids 185-256) is required for induction of the IFN-fi promoter by 
murine [101, 104] and human [105] IRF-1. Additionally murine IRF-1 has been 
shown to be phosphorylated in a manner dependent on this region [109], Finally 
domain 256-325 contains the C-terminal enhancer domain of IRF-1 [101]. This 
enhancer region also carries residues required for association with the p300 co-factor 
[72] and Hsp70 [112]. Furthermore, this region has not only been shown to enhance 
IRF-1 induced transcription [105], but also to regulate IRF-1 turnover ([111] and 
chapter 5 o f this thesis), and CDK2 repression [64],
6.2 Results
6.2.1 Identification of IRF-1 binding peptides
Several studies reviewed in the introduction to this thesis (section l .2.4) have 
mapped specific functions o f IRF-1, such as transcriptional enhancement and DNA 
binding, to specific domains. Flowever, little is known about the regulation of these 
functions. To discover potential IRF-1 co-factors that modify its activity, and to 
begin to isolate aptamers that could later be used in chemical genetic screens, phage 
display was used to identify peptides capable of binding IRF-1. This technique is 
summarised in figure 6.3 and described in the introduction. Five His-tagged domains 
encompassing the full-length of IRF-1 were used as targets in peptide phage display. 
These domains were chosen based on previously mapped IRF-1 functions (figure 
6.1). The domains were cloned into the pTrcHis B vector, expressed in bacteria and 
purified on a nickel column (figure 6.2). A large and diverse library of peptide 
displaying phage was incubated with the immobilised domains. Specifically, a 
microtitre plate was coated with an excess (50 pg/ml) o f His-tagged domain. This 
immobilised domain was then incubated for 1 hour with 2 x 1 0  plaque forming 
units (i.e. infective phage particles) suspended in PBS-0.1% Tween. Phage that 
bound the domain with a low affinity were washed away, and high affinity phage
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were eluted with 0.2 M Glycine-HCl (pH 2.2), 1 mg/ml BSA. After elution, this 
acidic buffer was neutralized with 1 M Tris-HCl (pH 9.1).
This new pool o f phage, enriched for phage carrying peptides able to bind the IRF-1 
domains, was amplified in an E.coli bacterial culture. The newly replicated phage 
particles were secreted into the culture medium by the bacteria from which they 
could be purified through PEG precipitation. These phage particles were then used in 
a further two selection rounds (3 rounds in total). The final polyclonal pool o f phage 
was again used to infect bacteria, but this time individual plaques generated by 
infected bacteria were picked and phage DNA extracted. Sequencing of the phage 
genome revealed the amino acid composition of the displayed peptides. Although 10 
plaques were picked per domain, the resultant phage DNA was not always sequenced 
successfully. 50 plaques were picked in total, but the sequence of only 41 was 
obtained. In total 24 different sequences were obtained from the five domains (see 
figure 5.4). Some sequences occurred with a high frequency, for example 50% (5) o f  
the clones that were detected as binding the sub-domain spanning amino acids 117- 
256 had the same sequence “ALYKTSTATALL”. In this chapter, the analysis o f the 
24 different peptides selected is described. However, in parallel with this analysis, 
alternative sequencing services were tested (all sequencing was necessarily out­
sourced). In the end a more complete set of domain-binding peptide sequences was 
obtained and these are listed at the end of this chapter in figure 6.2.1 (new sequences 
shown in blue). However, owing to the time constraints of this PhD these sequences 
were not validated for their IRF-1 binding capacity, instead the possibility for future 
analysis is outlined in the discussion.
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Full length IRF-1 
PCR of domains
pTRCHisB j  Ugation of insert into plasmid






Lysate loaded onto Ni-NTA resin
J
His-tagged domain bound to Ni-NTA
Bacterial proteins washed away
I His-tagged domain eluted
Figure 6.1: Five domains of IRF-1 were cloned in the pTRFIis B vector for 
bacterial expression as His-tagged recombinant proteins. Following bacterial 
cell lysis the His-tagged domains were purified on a nickel column and used 
as targets in peptide phage selection.
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Figure 6.3: (A) Diagrammatic representation of the peptide phage display 
technique. In this study 3 selection rounds were performed. (B) A 12-mer 
peptide is encoded in the phage genome and expressed as a fusion to the 
minor phage coat protein g3p. Following selection phage DNA can be 
extracted and sequenced.
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1 SEW SYNSPPSLP 3 1-140 SEW SYNSPPSLP
2 HSKLNNRHHALL 1 1-140 HSKLNNRHHALL
3 ANPAWNADFSIF 1 1-140 ANPAWNADFSIF
4 NYSHLRVKLPTP 1 60-124 NYSHLRVKLPTP
5 ALYKTSTATALL 1 60-124 ALYKTSTATALL
6 HFHYPKKAGLPP 60-124 HFHYPKKAGLPP
7 SPFGMIAQQGLR 1 60-124 SPFGMIAQQGLR
8 NFMPSLPRLGMH 1 60-124 NFMPSLPRLGMH
9 SSYAPYVWQPIA 1 60-124 SSYAPYVWQPIA
10 NYXXDTTRPPSA 1 60-124 DTTRPPSA
11 TYHESQTSFTNT 1 60-124 TYHESQTSFTNT
12 WDDTLWPRPMRH 1 117-184 WDDTLWPRPMRH
13 AMAVKLNYPLGY 117-184 AMAVKLNYPLGY
14 HLKMMVAPRTSL 117-184 HLKMMVAPRTSL
15 VISNHAESSRRL 1 117-184 VISNHAESSRRL
16 LMSPNNNTLRIS 1 117-184 LMSPNNNTLRIS
17 HYSIRLPASASL 1 117-184 HYSIRLPASASL
18 AXXXEMTPHLNX 1 117-184 EMTPHLNX
19 QTSSPTPLSHTQ 1 117-184 QTSSPTPLSHTQ
20 ALYKTSTATALL 5 117-256 ALYKTSTATALL
21 ASITHFKSGKSH 4 117-256 ASITHFKSGKSH
22 SVSLPYANLATH 1 117-256 SVSLPYANLATH
23 XXDGCSAYESWW 4 256-325 DGCSAYESWW
24 XXXXMVAPRTSL 3 256-325 MVAPRTSL
Figure 6.4: Table showing the sequence of the 24 different peptides selected 
as binding to domains of IRF-1. Peptides are numbered arbitrarily and these 
numbers are used to identify each peptide in subsequent assays (column 1). 
Where sequencing was incomplete, unknown amino acids are represented 
by an “X". Ten peptides were sequenced per domain and the frequency with 
which any given sequence occurred out of these 10 is listed (column 3). The 
sequences of the biotinylated peptides generated from the phage displayed 
peptides are shown (column 5).
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Following phage peptide display, the selected sequences required validation as 
domain specific binders. The recurrent selection o f particular peptides against some 
domains (figure 6.4), such as DGCSAYESWW (peptide 23) against the C-terminal 
domain, suggests that enrichment of specific phage was successful, as does the 
selection o f the same peptide by two different but overlapping domains for example, 
ALYKTSTATALL was selected by overlapping domains encompassing amino acids 
60-124 (peptide 5) and 117-256 (peptide 20). Domain specificity was confirmed by 
testing peptide binding against immobilised and liquid phase domains (see figures 
6.5 and 6.6). The 24 phage display peptides were synthesised carrying a biotinylated 
tag (Mimotopes Pepset) and were either immobilised on a streptavidin-coated 96- 
well microtitre plate (figure 6.5) or incubated with immobilised IRF-1 domains 
(figure 6.6). As in the initial phage display selection, the domains carried His tags, 
however, as the peptides bound differentially to each domain, tag-specific binding 
was regarded as negligible.
Overall, it was shown that peptides bound specifically to the domains they were 
selected with and occasionally to overlapping domains. For example, some peptides 
selected as binding to domain 60-124 (peptide 8), 117-184 (peptide 14) and 117-256 
(peptide 22) also bound to the overlapping domain 1-140 (figure 6.5A and 6.6A). 
This provides further insight into the exact binding site of each o f these peptides; for 
instance, peptide 22 would appear to bind between IRF-1 amino acids 117 and 140 
(the region overlapped by domains 1-140 and 117-256). However, conformation as 
well as amino acid composition may be important for this interaction as this peptide 
does not bind domain 117-184, which also encompasses this region of IRF-1. 
Domain specificity can be seen most clearly for the two peptides selected against the 
extreme C-terminal domain. This domain does not overlap any of the others, and 
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Figure 6.5: IRF-1 domain binding to phage display-derived peptides. 
Immobilised peptides (200 ng) were incubated with each IRF-1 domain (1 
pg/ml). The graphs represent binding to the following domains, each named 
according to the IRF-1 amino acids they encompass: (A) 1-140, (B) 60-124, 
(C) 117-184, (D) 117-256 and (E) 265-325. The coloured columns indicate 
which of the 24 peptides were selected with the domain used in the assay. 
Following extensive washing, domain binding was detected with an anti-His 
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Figure 6.6: IRF-1 domain binding to phage display-derived peptides. 
Immobilised domains (200 ng) were incubated with each peptide (1 pg/ml). 
The graphs represent binding to the following domains, each named 
according to the IRF-1 amino acids they encompass: (A) 1-140, (B) 60-124, 
(C) 117-184, (D) 117-256 and (E) 265-325. The coloured columns indicate 
which of the 24 peptides were selected with the domain used in the assay. 
Following extensive washing, domain binding was detected with HRP- 
streptavidin and enhanced chemiluminescence.
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Yet, there were still several peptides that did not bind to any o f the domains, such as 
peptides 1, 16, 17 and 19 in figures 6.5 and 6.6, indicating that these peptides may 
need to be displayed as fusions to the minor phage coat protein or have their biotin 
tag removed before they show any binding activity.
As the aim o f this study was to identify peptides/proteins capable o f interacting with 
native IRF-1, it was essential to test for binding to the full-length IRF-1 protein. 
Therefore, binding assays were carried out using all 24 peptides selected by phage 
display, with either the peptides (figure 6.7A) or full-length IRJF-1 (figure 6.7B) 
immobilised. Full-length IRF-1 was expressed with a GST-tag to enable purification; 
therefore the peptides were also tested for binding to purified GST. Non-specific 
binding to GST was seen for peptides 17 and 20 in figure 6.7A and peptides 4, 9, 12, 
16, 17 and 19 in figure 6.7B. This supports earlier indications that peptides 16, 17 
and 19 lost their ERF-1-specific binding capacity outwith the phage display system. 
This interaction may have previously been stabilised by the g3p coat protein or 
negatively affected by biotinylation. The data also indicates that peptides 4, 9 and 12 
cannot bind their epitope within the context o f full-length IRF-1, as these peptides 
displayed only a low relative affinity for IRF-1 binding in both figures 6.7A and B. 
The capacity to bind full length IRF-1 outside the phage display system is important 
for peptides used as IRF-1-specific reagents capable o f detecting, purifying or even 
functionally modulating their target protein; even though such studies are not 
described in this thesis, the characterisation shown here highlights which peptides 
would be worthy o f further development. Surprisingly, peptide 1, which did not bind 
to any o f the IRF-1 domains (figures 6.5 and 6.6), was able to bind the full length 
protein with a relatively high affinity. The reason for this is not clear; however, it is 
possible that the availability of the peptide 1-epitope is different in the full-length 
protein and that this compensated for the peptide’s decreased ability to interact stably 
outside the phage display system.
Figure 6.8 indicates which peptides were able to bind an IRF-1 domain or the full 
length protein with a relative affinity 50% higher than that shown by the 24 peptides 
on average. Peptides 3, 8, 14, 18 and 24 were able to bind both their target domains 
in isolation and full length IRF-1 with comparatively high affinities. Peptides 18 and
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24 were o f particular interest as they were able to bind both a domain and the full 
length protein regardless o f which was immobilised, the peptide or the protein. The 
low affinity for GST and previously noted domain specificity all support the notion 
that phage display can be used to generate peptides which bind IRF-1 in a specific 
manner.
The amino acid sequence of phage-displayed peptides can be used to search protein 
databases for full-length proteins containing the same or similar sequence and which 
show the same affinity for a target protein [268, 279, 393], This can be done by first 
searching for a consensus motif [279] using multiple sequence alignment tools such 
as CLUSTALW (EMBL-EBI) to identify residues conserved in the target protein- 
binding peptides. Such alignment tools can also generate motifs in which an amino 
acid’s characteristic but not identity is conserved at a certain position, e.g. 
hydrophobicity. Additionally, flexible motifs can be created in which one or more 
amino acids are acceptable at a specific position. The quality o f any binding motif 
obtained would depend on the number o f sequences compared, which in this study is 
limited by inefficient sequencing. Initial CLUSTALW analysis revealed no strong 
consensus in the sequences selected against the domains o f  IRF-1; as a result, further 
motif searching has been postponed until a greater number o f peptide sequences can 
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Figure 6.7: Peptide binding to full length IRF-1. (A) Immobilised-peptides 
(200 ng) derived from peptide phage display were incubated with free GST or 
GST-IRF-1 (1pg/ml). Following extensive washing, GST and GST-IRF-1 
binding was detected with an anti-GST antibody and enhanced 
chemiluminescence. (B) As in A except that GST or GST-IRF-1 were 
immobilised (200 ng) and incubated with the biotinlyated phage display- 
derived peptides (1pg/ml). Peptide binding was detected with HRP- 
conjugated streptavidin and enhanced chemiluminescence.
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Figure 6.8: Summary of phage display peptide-binding to IRF-1 domains or 
the full-length protein. The symbol § indicates that the peptide was 
immobilised to the microtitre plate in the binding assay, that the protein was 
in the mobile phase and that Relative Binding Affinity (RBA; measured in all 
peptide binding assays in relative light units (RLU)) was 50% higher than the 
mean. To calculate the mean RBA with which peptides bound full length 
GST-IRF-1, the values were first corrected for GST binding. The symbol * 
has the same meaning as §, except that the protein was immobilised in the 
binding assay and the peptide was in the mobile phase.
Instead a search for a homologous sequence within a protein database was carried out 
using the peptide sequences presented in figure 6.4. The BLAST, Basic Local 
Alignment Search Tool [98], was used to search non-redundant protein sequences in 
the Homo sapiens genome. This provided 100 BLAST “hits” ranked according to 
homology (bit score) with the associated E-value displayed (which gives a measure 
o f the possibility the sequence occurred by chance). The E-values are unavoidably 
high for searches o f several large databases with short peptides.
The BLAST online search tool provided a short description of each o f the 100 hits 
and the GenBank accession number. Each description includes a short summary o f  
the known function and/or interactions of the “hit” protein. 24 peptides produced 
2400 BLAST hits. All 24 phage display-derived peptides were entered into the 
alignment tool to reduce the possibility o f excluding low affinity but biologically 
significant motifs.
Based on the GenBank description for each o f the hits, they were initially reduced to 
only those that were involved in post-translational regulation and/or processes in 
which IRF-1 has already been shown to play a role. Particular emphasis was given to 
hits involved in cancer biochemistry, in pathways already under investigation within 
the lab (e.g. TSC2), or detected in an earlier yeast-2-hybrid screen (data unpublished) 
e.g. ZNF350. This selection procedure was sufficiently stringent to limit the final 
number o f homologous proteins to 30. This was deemed a manageable number for 
subsequent analysis. Thus, 30 biotinylated 12-mer peptides (henceforth referred to as 
BLAST peptides) were synthesised that encompassed the protein sequence 
homologous to the phage display peptide (see figure 6.9). If more than one region 
within a protein was found to be homologous to a selected peptide, then 2 peptides 
were generated to cover each o f the homologous sequences; this was true for the 
KIAA0623 Kinase, SPEN homolog and Myc Binding protein 2 (PAM).
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The selection o f only 30 BLAST peptides meant that many proteins with the 
potential to interact with IRF-1 were excluded from this investigation. Their 
inclusion may have led to the discovery o f new functions for IRF-1 or unexpected 
forms o f post-translational regulation, but higher-throughput technologies than were 
available for this study would have been required.
The biotinylated peptides were screened first for binding to the IRF-1 domains, with 
either the BLAST peptide (figure 6.10) or IRF-1 domain (figure 6.11) immobilised 
on the microtitre plate. Overall, they retained the same domain specificity as their 
homologous phage display peptides. O f particular interest was BLAST peptide 30, 
which showed very stable binding to the extreme C-terminal domain (figures 6.10E 
and 6.1 IE), as had the phage display peptide upon which it was based (phage display 
peptide 24). The peptides were also screened against liquid phase (figure 6 .12A) or 
immobilised (figure 6.12B) full length GST-tagged ERF-1. In this binding assay 
several peptides displayed a relative affinity for full length IRF-1 50% higher than 
the average (figure 6.13). This includes peptides 2, 3, 4, 6, 14, 18, 24, 25, 27 and 28. 
These peptides, and the full-length proteins they represent, could now be evaluated 
for their ability to bind intracellular IRF-1. The time constraints o f this PhD have 
prevented more detailed study o f these BLAST hits at this time, but the preliminary 
binding analysis shown here could act as a basis for future studies.
The IRF-1 specificity shown by BLAST peptide 30 in these ELISAs led to its further 
study. Although it was not one of the peptides with a very high relative affinity for 
full-length IRF-1 (figure 6.13), it did interact more stably with IRF-1 than with the 
GST control (figure 6.12). Additionally, figures 6.10 and 6.11 clearly show that 
peptide 30 was the only BLAST peptide that bound with a high relative affinity to 
this region and that it did not bind well to any o f the other IRF-1 domains. As 
outlined in chapters seven and eight o f this thesis, the extreme C-terminus o f IRF-1 
plays an important role in regulating transcription o f IRF-1 target genes and 
degradation. This peptide contains amino acids 464-475 o f the ZNF350 protein (Zinc 
finger 350, also known as ZBRK1). A potential interaction between ZNF350 and 
IRF-1 is further investigated in the next section.
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Sequence No. Domain
1 ubiquitin-conjugating enzyme 
E2, J2 CAI23259.1 HSKLNNRHHALL 2 1-140 QANRHHGLLGGA
2 A kinase (PRKA) anchor 
protein 8 EAW84474.1 HSKLNNRHHALL 2 1-140 SVLNNRHIVKML
3 DEAD box AAH01238.1 HSKLNNRHHALL 2 1-140 GLNGRGHALLIL
4 receptorinteracting protein 
kinase 5 NP_056190.1 HSKLNNRHHALL 2 1-140 EVTMHHALLQEV
5 bcr-abl1 e19a2 chimeric 
protein CAM33013.1 ANPAWNADFSIF 3 1-140 TAEPNWNEEFEl
6 ABBA-1 NP_612392.1 SEWSYNSPPSLP 1 1-140 SWSYQTPPSVPS
7 SWI1-like EAW47681.1 SEWSYNSPPSLP 1 1-140 QPSYQTPPSLPN














11 MAPKKK19 CAI23047.1 SEWSYNSPPSLP 1 1-140 ASSPPSLPLSSA
12 Peptidylprolyl isomerase (cyclophilin)-like 5 AAI07889.1 SEWSYNSPPSLP 1 1-140 StWLSYHSIPSLP
13 SET domain, bifurcated 1 EAW53505.1 ALYKTSTATALL 5
60-124&
117-256 FSMKTSSASALE



















17 MAX gene-associated protein. AAI36660.1 WDDTLWPRPMRH 12 117-184 STDTLWRPMPKL
18 Fanconi anemia, complementation group 1
AAI44484.1 AMAVKLNYPLGY 13 117-184 VFAIDYELGR
19 Baculoviral IAP repeat- containing protein 6
NP_057336.3 HLKMMVAPRTSL 14 117-184 DQHLAMMVALQE
20 PRP8 protein BAA22563.1 ASITHFKSGKSH 21 117-256 GITHFRSGMSHE
21 Transcription factor B1, mitochondrial
NP_057104.2 ASITHFKSGKSH 21 117-256 RQLSISHFKSLC














25 Tuberous sclerosis 2 EAW85559.1 SVSLPYANLATH 22 117-256 VFAISLPYTNPS
26
27
Myc binding protein 2 










28 NUF2 NP_113611.2 SVSLPYANLATH 22 117-256 GFLPFSNLVTHL
29 Similarto F-box only protein 2 EAW56867.1 MVAPRTSL 24 256-325 QHHVAPRTSGRG
30 Zinc finger protein 350 Q9GZX5.2 MVAPRTSL 24 256-325 VPSVAPQTSLN!
Figure 6.9: Table showing the 30 BLAST peptides (column 7), the proteins in 
which the BLAST peptide’s sequence resides (column 2) and the phage 
display peptides to which they are homologous (column 4). Shared amino 
acids are shown in green. Peptides are numbered arbitrarily, and these 
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Figure 6.10: IRF-1 domain binding to BLAST peptides. Immobilised peptides 
(200 ng) were incubated with each IRF-1 domain (1 pg/ml). The graphs 
represent binding to the following domains, each named according to the 
IRF-1 amino acids they encompass: (A) 1-140, (B) 60-124, (C) 117-184, (D) 
117-256 and (E) 265-325. The coloured columns indicate which of the 24 
peptides were selected with the domain used in the assay. Following 
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Figure 6.11: IRF-1 domain binding to BLAST peptides. Immobilised domains 
(200 ng) were incubated with each peptide (1 pg/ml). The graphs represent 
binding to the following domains, each named according to the IRF-1 amino 
acids they encompass: (A) 1-140, (B) 60-124, (C) 117-184, (D) 117-256 and 
(E) 265-325. The coloured columns indicate which of the 24 peptides were 
selected with the domain used in the assay. Following extensive washing, 
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F i g u r e  6 . 1 2 :  Peptide binding to full length IRF-1 ( A )  Immobilised BLAST 
peptides (200 ng) were incubated with free GST or GST-IRF-1 (1 pg/ml). 
Following extensive washing, GST and GST-IRF-1 binding was detected with 
an anti-GST antibody and enhanced chemiluminescence. ( B )  As in A except 
that GST or GST-IRF-1 (200 ng) were immobilised and incubated with the 
biotinlyated BLAST peptides (1 pg/ml). Peptide binding was detected with 
HRP-conjugated streptavidin and enhanced chemiluminescence.
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1 §*
2 §* §* §*
3 § §*
4 § § §*
5












18 §* §* § § §*
19











Figure 6.13: Summary of BLAST peptide binding to IRF-1 domains or the 
full-length protein. The symbol § indicates that the peptide was immobilised 
to the microtitre plate in the binding assay, that the protein was in the mobile 
phase and that relative binding affinity (measured in all peptide binding 
assays in relative light units (RLU)) was 50% higher than the mean. To 
calculate the mean RLU at which peptides bound full length GST-IRF-1, the 
values were first corrected for GST binding. The symbol * has the same 
meaning as §, except that the protein was immobilised in the binding assay 
and the peptide was in the mobile phase.
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6.3 Prelim inary validation of ZNF350 as an IRF-1 - 
interacting protein
ZNF350 contains an N-terminal Kruppel-associatcd box (KRAB) repressor domain, 
a degradation signal, eight central C2H2 zinc fingers and a C-terminal repressor 
domain (CTRD) [398] (figure 6 .14). BLAST peptide 30 lies within the CTRD. The 
first seven zinc fingers are required for DNA binding, whereas deletion o f the eighth 
and the CTRD increases DNA-binding activity. The last nine amino acids o f ZNF350 
have been shown to be essential for oligomerisation, although the functional 
significance o f ZNF350’s ability to form tctramcrs is still unclear [399]. ZNF350 has 
been implicated in regulation of the DNA damage response [400, 401], It has been 
shown to represses DNA damage response genes [400] and to be quickly degraded 
upon DNA damage, thus releasing target genes from repression [401], The C- 
terminal repressor domain in which the IRF-1 binding element resides has been 
shown to function in a manner dependent on the breast and ovarian specific tumour 
suppressor BRCA-1 [398], whereas the N-terminal KRAB domain requires the co­
repressor KAP-1 to repress target genes [402],
ZNF350 was also detected in a yeast-two-hybrid screen for IRF-1-interacting 
proteins using a human breast tumour epithelial cell library (mRNA from these cells 
was reverse-transcribed and used to generate a cDNA library that encoded over 124 
million prey proteins: data unpublished). Additionally, our lab has recently shown 
that KAP-1 can be co-purified with an IRF-1 peptide (Narayan 2010, data 
unpublished). Each o f the more than 220 KRAB domain zinc-finger proteins (ZFPs) 
encoded by the human genome contains an N-tcrminal 75-amino-acid KRAB box 
that binds directly to KAP-1 [403]. KAP-1 then recruits various silencing molecules, 
such as the NuRD histone deacetylase complex [404], the methyltransferase SET 
domain protein SETDB1 [405] and members o f the heterochromatin protein 1 (HP1) 
family [406], In this study, one o f the peptides selected via phage display shows 
homology to a region o f the SET domain. However the BLAST peptide that 
contained sequence from the SET domain (BLAST peptide 13) showed low relative 
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Figure 6.14: Structure of Zinc finger 350 protein. The region corresponding 
to IRF-1-binding BLAST peptide 30 is indicated. ZNF350 contains an N- 
terminal Kruppel-associated box (KRAB) repressor domain, a degradation 
signal, eight central C2Fi2 zinc fingers and a C-terminal repressor domain 
(CTRD).
To establish an intracellular interaction between endogenous IRF-1 and ZNF350, 
IRF-1 was immunoprecipitated using the single domain antibodies described in 
chapter 4. scFv3 and N, the single domain antibodies that showed the highest 
apparent affinity for IRF-1, were both able to co-immunoprecipitate endogenous 
IRF-1 and ZNF350 (figure 6.15). This indicates that neither scFv3 nor scFvN disrupt 
the IRF-1 :ZNF350 interaction. A series o f peptide-interaction assays were then used 
in an effort to map the ZNF350 binding site. A series o f overlapping biotinylated 
peptides covering the full sequence o f IRF-1 were immobilised onto strcptavidin 
columns; next, untransfected lysate was added to each column and any bound protein 
was eluted after vigorous washing. Endogenous ZNF350 was found to bind 
specifically to a C-terminal IRF-1 peptide encompassing amino acids 300-320 
(figure 6.16). This finding supports earlier peptide phage display evidence that 
ZNF350 binds within the extreme C-terminal domain o f IRF-1 (figure 6.10E and 
6. HE).
The peptide pull-down was validated in a separate experiment in which endogenous 
ZNF350 was co-precipitatcd using the C-terminal IRF-1 peptides spanning amino 
acids 300-320 and 305-325, but not with a control N-terminal IRF-1 peptide, or with 
a peptide containing sequence from the protein p21 which was also used as a 
negative control (figure 6.17). These two IRF-1 peptides contain an LXXLL motif 
previously shown to be important for interactions with co-factors [112], However, an 
alanine scan o f this motif was unable to abrogate ZNF350 binding (figure 6.17), 











Figure 6.15: scFv antibodies immobilised on Ni2+-NTA agarose beads were 
incubated with FleLa cell lysate (500 pg). Following extensive washing, 
bound proteins were eluted by in SDS-sample buffer and analysed by SDS- 
PAGE/immunoblot developed with anti-IRF-1 or anti-ZNF350 antibodies. 
Alternatively the gel was stained with colloidal blue (bottom panel). The 
results are representative of 2 independent experiments.
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Figure 6.16: Overlapping IRF-1 peptides covering the entire length of the 
protein were used to generate affinity columns to which 0.5 mg of A375 cell 
lysate was added. Following rigorous washing, peptide-bound protein were 
eluted in SDS-PAGE sample buffer. The peptide pull-down was carried out in 
collaboration with Vikram Narayan. The eluates were then analysed through 
immunoblot with an anti-ZNF350 antibody.
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Lane 1 2 3 4 5 6 7 8 9
W ild type peptide: 301- M D A T W LD SL LTP V R L PSIQ A  - 320
Figure 6.17: (A) Biotinylated peptides were used to generate affinity columns 
to which 0.5 mg of A375 cell lysate was added. As the peptides were diluted 
in DMSO, lane 1 shows protein binding to DMSO alone. The IRF-1 peptides 
used were as follows: wild type amino acids 300-320 (lane 2), an N-termlnal 
IRF-1 control peptide covering amino acids 31-50 (lane 3), an alanine scan 
within amino acids 301-320 of the LXXLL motif (lanes 5-9) and a control 
peptide containing sequence from the protein p21 (lanes 10). Following 
rigorous washing, peptide-bound proteins were eluted in SDS-PAGE sample 
buffer. The eluates were then analysed through immunoblot with an anti- 
ZNF350 antibody. This peptide pull-down was carried in collaboration with 
Vikram Narayan and Lucy Malin. (B) The sequence of the wild type peptide 
spanning IRF-1 amino acids 301-320 with the LXXLL motif underlined.
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The importance o f  the C-terminus o f  IRF-1 for ZNF350 binding was further studied 
by attempting to co-precipitating endogenous ZNF350 with C-terminally truncated 
IRF-1 (figure 6 .18A  and B). One-STrEP-tagged wild type and AC25 IRF-1 were 
transiently transfected into mammalian cells and purified using a strep-tactin column 
(IB A  Gm bH ) (figure 6 .18A). Prior to lysis the transfected cells were treated with the 
chem ical crosslinker DSP (Dithiobis[succinim idyl propionate]), which forms a 
covalent link between interacting proteins to aid co-purification o f  weakly interacting 
co-factors, hr cells treated with DSP, endogenous ZNF350 was co-precipitated with 
transfected IRF-1 but not with the empty vector control. Unexpectedly, a smaller 
amount o f  ZNF350 also co-precipitated with AC25 IRF-1. This indicates that under 
the conditions o f  this experiment, ZNF350 can associate with transfected IRF-1 in a 
manner independent o f  the IRF-1 C-terminus. This may be through an intermediate 
protein or through a secondary binding site within IRF-1. To further examine the 
importance o f  the IRF-1 C-terminus in ZNF350 co-purification, the experiment was 
repeated with IRF-1 AC70 (figure 6.18B). In this instance no ZNF350 associated 
with the IRF-1 mutant.
These results indicate that the C-terminal 25 amino acids contain the primary 
ZN F350 interaction site, which is sufficient for co-precipitation o f  endogenous 
ZN F350 (figures 6.16 and 6.17). They also indicate that the C-terminal 70 amino 
acids house a second binding site that is required for a stable intracellular interaction 
between the two proteins (figure 6.18B), but is not sufficient for ZN F350 binding 
(figure 6.16). This m odel is represented in figure 6.19. As yet no direct interaction 
between full length IRF-1 and ZNF350 has been confirmed. A  logical next step 
w ould be to clone ZNF350 into a bacterial expression vector so that further in vitro 
validation o f  this interaction can be attempted; however, neither this nor any further 
validation o f  this interaction is described in this thesis and such analysis is instead be 
left for future studies.
Figure 6.20 summarises the strategy used in this investigation and several o f  the 











Figure 6.18: (A) One-STrEP-tagged wild type IRF-1, IRF-1 AC25 or empty 
vector were transiently transfected into A375 cells. Cells were then left 
untreated or exposed to 2 mM of the cross-linking agent DSP 
(Dithiobis[succinimidyl propionate]). One-STrEP-associated complexes were 
purified on Streptactin beads and analysed by SDS-PAGE and immunoblot 
with anti-IRF-1 (top panel) and anti-ZNF350 (bottom panel) antibodies. (B) 
One-STrEP-tagged AC70 IRF-1 was transiently transfected into A375 cells. 
Cells were then left untreated or exposed to 2 mM of the cross-linking agent 
DSP. One-STrEP-associated complexes were purified on Streptactin beads 
and analysed by SDS-PAGE and immunoblot with anti-IRF-1 (top panel) and 
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Figure 6.19: Modelling ofZNF350 interaction sites within IRF-1. 1: primary 
binding site housed in last 25 amino acids of IRF-1, sufficient for interaction 
with ZNF350 2: secondary binding site in the last 70 amino acids of IRF-1, 
this site is required for stable binding to ZNF350, but not sufficient for this 
interaction.
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on past structure-function mapping
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specific domains (ELISA)
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Analyse ability of peptides to bind domain 
in context of full-length IRF-1 (ELISA)
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Based on ELISA results, past yeasty- 
hybrid screen and results obtained in 
peptide pull-down by Narayan 2009 
(unpublished)ZNF350 chosen forfurther 
validation as an IRF-1 binding protein
ZNF350 co-immunoprecipitated with IRF-1
Further confirmation of direct 
ZNF350/IRF-1 interaction required
Figure 6.20: Flow diagram of the strategy used in this investigation. Possible 
additional avenues that could be taken to expand this study are indicated.
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6.4 Results from new round of sequencing
The analysis described in section 6.2.1 was hampered by an inefficient sequencing 
service (all sequencing was necessarily out-sourced), which meant that only a limited 
number o f  phage display peptides could be sequenced. Follow ing the trial o f  several 
alternative sequencing services, additional IRF-1-binding phage display peptides 
have now  been successfully sequenced (figure 6.21). The time constraints o f  this 
PhD prevented these sequences from being tested for binding to IRF-1 or being used 
to define a novel IRF-1 binding motif. H owever, they have been included in this 
thesis in the hope that they could be used in future analysis.
The additional peptides included those selected for binding to IRF-1 domains 
spanning amino acids 1-124 and 256-300. The first o f  these encom passes the D N A  
binding and putative homodimerisation domain, and the second the enhancer domain 
minus the C-terminal 25 amino acids which have been shown to act in CDK 2 
repression and contain the L X X L L  co-factor interaction m otif [64, 72, 112]. The 
domains were subjected to the same peptide phage display screen as the other IRF-1 
domains, but only four plaques were obtained follow ing three selection rounds 
against domain 256-300; thus, only four sequences were obtained. To gain further 
insight into peptides able to bind this domain, the second round-pool o f  phage could 
be sequenced, or the third round o f  selection could be repeated. An additional ten 
phage-displayed peptides were also sequenced for each o f  the previously described 
IRF-1 domains (those encompassing amino acids: 1-140, 60-124, 117-184, 117-256 
and 256-325).
The 12-mer phage display peptide 24 (figure 6.4), which was hom ologous to a region 
o f  ZN F350 (see figure 6.9), was sequenced in its entirety (figure 6.21): 
H SM V A PR TSLSP, and occurred with frequency (3 /10) equal to that determined in 
the previous round o f  sequencing (figure 6.4). The newly identified residues did not 
increase its hom ology to B LA ST peptide 30: V P S V A P Q T S L N I, w hich lies within 
Z N F 350 (figure 6.14).
These newly acquired sequences should aid future validation o f  IRF-1 binding m otifs 
and identification o f  novel binding partners.
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S E W S Y N S P P S L P 4 1 - 1 4 0
H S K L N N R H H A L L 2 1 - 1 4 0
A N P A W N A D F S I F 2 1 - 1 4 0
S S T R V K S A P A L L 2 1 - 1 4 0
H P K I I P H T L A A P 4 1 - 1 2 4
T F L S H S A G M L S L 1 1 - 1 2 4
S I I Q M N L H R P T S 2 1 - 1 2 4
A L N W S P K L P V P P 2 1 - 1 2 4
L P G K P Y M V E Q L R 1 1 - 1 2 4
N Y S H L R V K L P T P 1 6 0 - 1 2 4
A L Y K T S T A T A L L 2 6 0 - 1 2 4
H F H Y P K K A G L P P 2 6 0 - 1 2 4
S P F G M I A Q Q G L R 1 6 0 - 1 2 4
N F M P S L P R L G M H 1 6 0 - 1 2 4
S S Y A P Y V W Q P I A 1 6 0 - 1 2 4
S D T T R P P S A G L P 1 6 0 - 1 2 4
T Y H E S Q T S F T N T 1 6 0 - 1 2 4
W D D T L W P R P M R H 1 1 1 7 - 1 8 4
A M A V K L N Y P L G Y 2 1 1 7 - 1 8 4
H L K M M V A P R T S L 2 1 1 7 - 1 8 4
V I S N H A E S S R R L 1 1 1 7 - 1 8 4
L M S P N N N T L R I S 1 1 1 7 - 1 8 4
H Y S I R L P A S A S L 1 1 1 7 - 1 8 4
R L E M T P H L N A L L 1 1 1 7 - 1 8 4
Q T S S P T P L S H T Q 1 1 1 7 - 1 8 4
A L Y K T S T A T A L L 5 1 1 7 - 2 5 6
A S I T H F K S G K S H 4 1 1 7 - 2 5 6
S V S L P Y A N L A T H 1 1 1 7 - 2 5 6
H S M V A P R T S L S P 2 2 5 6 - 3 0 0
S A V P S S P A L L T A 1 2 5 6 - 3 0 0
D D P T S A T S W P A L 1 2 5 6 - 3 0 0
Figure 6.21: Sequence of 12-mer peptide selected as binding IRF-1 domains 
encompassing amino acids 1-140, 1-124, 60-124, 117-184, 117-256, 256- 
300 and 256-325. Newly identified sequence is shown in blue. Ten peptides 




The results detailed in this chapter show that IRF-1 binding peptides can be acquired 
through phage display and that the sequence o f  these peptides can be used to identify 
proteins that form  intracellular com plexes with IRF-1. Furthermore, these IRF-1 - 
binding peptides provide reagents that could be developed in the future and used for 
the purification, detection or potentially even functional modulation o f  IRF-1 
(bioactive peptides).
Peptide phage display can be used to quickly determine the amino acid sequence o f  
target protein binding motifs, but systematic approaches are required to sift through 
this information and use it to gain new insight into b iological pathways. In this study, 
peptides were tested for their ability to bind IRF-1 outside o f  the phage display 
system in an ELISA format. O f  particular interest were phage display peptides 3, 8, 
14, 18 and 24 which showed both domain specificity and high relative affinities for 
full length IRF-1 (figure 6.8). These peptides could be assessed in future studies for 
their ability to purify endogenous IRF-1 in peptide pull-down experiments or 
modulate IRF-1 expression follow ing intracellular expression. For instance, it would 
be interesting to know i f  phage-display peptide 24 or B LA ST peptide 30 could 
disrupt IRF-1 ’ s interaction with ZNF350 and i f  so what effect this had on the activity 
o f  both.
The use o f  isolated domains allows particular functions to be targeted and will aid 
future mapping o f  peptide binding sites. It also limits the possibility o f  peptides 
being selected against only one or two “ hot-spots”  (highly hydrophobic sites) within 
the protein [407, 408] which w ould reduce the number o f  functions studied.
H ow ever, the technique has limitations in that several o f  the selected peptides show 
no affinity for IRF-1 outside the phage display system. Additionally, the 
experimental process relies on constant screening o f  the selected peptides as epitope 
availability m ay be different in the isolated domain com pared to the full-length 
protein. Variation in epitope availability caused by im m obilisation o f  target protein 
during phage display and ELISAs also affects peptide binding. It can be seen in 
figure 6 that when full length IRF-1 is im m obilised (figure 6 .12B ), fewer peptides
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are able to bind than when the peptides themselves are im m obilised and IRF-1 is in 
the liquid phase (figure 6.12A).
In an effort to identify novel IRF-1 interacting proteins B LA ST peptides were 
selected for their hom ology to proteins involved in pathways interesting to this 
research group. This is a deeply biased final selection; however, restricting the 
number proteins studied on the basis o f  function and known associations has been 
used successfully in the past as a strategy for identifying physiologically relevant c o ­
factors [268, 279, 393, 396], It is possible that IRF-1 may interact with m ore than 
one site within another protein. The ELIS As described here involve interactions with 
peptides and do not take account o f  avidity. Binding partners that require several 
weak interactions may not be identified. The One-STrEP co-purifications involving 
C-terminally truncated IRF-1 suggest that ZN F350 may also bind outside amino 
acids 301-320 o f  IRF-1, even through these residues were all that was needed to co - 
purify the endogenous protein. That no other IRF-1 peptide could pull-down 
endogenous ZNF350 suggests that this secondary interaction is weaker, an idea 
supported by  the reduced amount o f  ZNF350 co-precipitated by  IR F -1 AC25. 
Alternatively, as association with the mutant protein was seen in the context o f  total 
cell lysate, it is possible that ZNF350 interacts with truncated IRF-1 through an 
unidentified intermediate. KAP-1 was previously identified as an IRF-1 interacting 
protein (Narayan unpublished) in a pull-down using an IRF-1 20-m er peptide; 
therefore, the possible contribution o f  this protein to IRF-1/ZN F350 com plex is 
worthy o f  further investigation. Another possible protein involved in this com plex 
could be B R A C 1, which also binds to the C TR  domain o fZ N F 3 5 0  targeted by IRF-1 
(the sequence o f  IRF-1-binding B LA ST peptide 30 lies within this region). Cloning, 
expression and purification o f  full-length ZNF350 w ill allow  a direct interaction with 
IRF-1 to be studied in vitro  and is therefore the next logical step in characterising this 
interaction.
A n interaction between ZNF350 and IRF-1 could have a number o f  consequences. 
Like IRF-1, ZNF350 has been shown to inhibit cell growth [409] and function as a 
transcription factor that can repress target gene expression [410], Previously 
published experimental evidence indicates that the ZN F350/K A P-1 repressor
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com plex functions through association with other proteins; for example, ZNF- 
mediated repression has been shown to be modulated by interactions between K A P- 
1, histone methyltransferases and histone deacetylases [404, 405]. It has also been 
suggested that this com plex has alternative functions as its association with the 
Epstein-Barr Virus replication protein BBLF2/3 stimulated D N A  replication and 
deletion o f  a ZN F350 binding site at the origin o f  replication impaired replication 
[411]. ZN F350 has also been shown to com plex with BRAC1 to repress transcription 
o f  G A D D 45 (Growth Arrest and D N A  Damage 45) [400], This study demonstrated 
that G A D D 45 repression required both the KAP-1 and BRCA1 binding domains in 
ZN F350 (also known as the K R A B  and C TR domains), although the presence o f  
KAP-1 within the repressor com plex was not confirmed.
Few proteins have been shown to interact with the C-terminus o f  IRF-1 despite its 
many known functions [112]. ZNF350 may shed light on the mechanisms through 
which the IRF-1 C-terminus switches between mediation o f  transcriptional induction, 
repression and trans-activation o f  other transcription factors [64, 72, 101].
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7 Final discussion
Previous studies have suggested that IRF-1 is primarily regulated through an increase 
in its expression in response to infection [2], cytokine stimulation [27] or D N A  
damage [29]; however it now  seems possible that post-translational regulation could 
also play an important role. One o f  the most significant finding o f  this study is that 
IRF-1 can be activated through its C-terminal residues in a manner linked to its 
increased degradation. This ties in with the finding by Wantabe et a l 1991 that, in 
cells transfected with IRF-1, transcription from an IRF-1-responsive reporter gene 
could be induced in the absence o f  de novo protein synthesis (i.e. in the presence o f  
cyclohexim ide ) through viral stimulation [67], It was also shown that the kinase 
inhibitor staurosporine could block viral induction o f  the same reporter gene, 
suggesting that phosphorylation may be acting as an activating post-translational 
m odification [67]. This idea was subsequently supported by a decrease in IRF-1 
activity observed follow ing mutation o f  potential phosphoaceptor sites in the 
transactivation domain: amino acids 219 to 231 [109], although it is possible this 12 
residue deletion had other affects on IRF-1 besides preventing its phosphorylation. 
H ow ever, no link has been made between the extreme C-terminal residues o f  IRF-1 
bound by scFv3 (amino acids 306-325) and phosphorylation; in fact the only IRF-1 - 
targeting kinase identified to date, casein kinase II, has been described as binding 
within the N-terminal 120 amino acids and phosphorylating residues between amino 
acids 138-150 and 219-231 [109], The results given in chapter 5 indicate that post- 
translational regulation, mediated by the extreme C-terminus o f  ERF-1, is rate- 
limiting for the activity o f  the endogenous protein. This finding highlights a new 
avenue through which anti-cancer downstream targets o f  IRF-1 could be activated 
through the action o f  biologies similar to/or based on scFv3.
The data in chapter 5 also reveal that both intrabody-bound IRF-1 and P325A mutant 
exhibit an increased transactivation activity and rate o f  degradation. The co ­
localisation o f  these two characteristics suggests that they may be linked.
Degradation is an obvious mechanism through which a signal could be “ switched 
o f f ’ , but degradation coupled with de novo protein synthesis is an energy-expensive 
means o f  regulation. However, such a process w ould enable efficient cyclin g  o f
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different transcription factor com plexes on the same promoter. A s detailed in the 
introduction to chapter 4 IRF-1 has a short half life o f  20-40 minutes, is 
polyubiquitinated and degraded by the 26S proteosom e [111]. Furthermore, 
fluctuations in IR F -l ’ s half life have been linked to its role in D N A  damage response 
[29]. It is therefore possible that tight control o f  IRF-1 turnover may be a mechanism 
through which its expression at specific points in the cell cycle  and in response to 
stress are controlled.
Several studies have previously linked proteosomal degradation with transcriptional 
regulation. Some transcription factor co-activators have been shown to possess 
ubiquitin ligase activity. For example, E6-AP (E6-associated protein) is an E3 ligase 
that directly interacts with and activates the transcription factor PR (human 
progesterone receptor) [387], Additionally, activation o f  the retinoic acid receptor by 
its ligand triggers both the receptor’ s transcription factor activity and its proteosom al 
degradation [248],
Proteosom al function has been m ore directly linked to the enhancement o f  som e 
transcriptional activities. For instance ERa (estrogen receptor)-m ediated transcription 
was seen to be lost follow ing inhibition o f  the proteosom e, whereas other 
transcription factors (S p l, p53 and E2F) were moderately stimulated [412], Several 
co-activators o f  ERa were shown to be subject to proteosom al degradation and, 
unlike ERa, show enhanced activity follow ing inhibition o f  the proteosom e.
Although the exact mechanism through which the proteosom e regulates E R a- 
mediated transcription is still not clear, it was suggested by the authors o f  this study 
that it may operate through co-factor turnover [412], For instance, proteosom al 
inhibition may lead to the accumulation o f  an as yet unidentified repressor.
The Drosophila co-activator TAFI (TBP associated factor 1), the central subunit 
within the general transcription factor TBP (T A T A  box binding protein), was shown 
to mediate ubiquitination o f  histone HI [413], Point mutations in TAFI that 
abolished H I-specific ubiquitination reduced cellular levels o f  ubiquitinated histone 
HI and also decreased the expression o f  genes targeted by the maternal transcription 
factor Dorsal [413]. Rem oval o f  histones w ould allow the D N A  to décondense and 
transcription factors to gain access. In further support o f  transcriptional regulation
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through degradation; RN A polymerase II has been shown to be ubiquitinated in 
response to D N A  damage [414], This may ensure transcription is halted so that the 
D N A  repair machinery can function. These results indicate that co-activator- 
mediated ubiquitination o f  proteins within the transactivation pathway may 
contribute to activation o f  eukaryotic transcription. H owever, it should be noted that 
these two studies did not validate a link between ubiquitination and proteosomal 
degradation, and that ubiquitination has also be shown to mediate subcellular 
relocalisation and lysosom al degradation [115].
The shortened half life o f  scFv3 bound IRF-1 may have been caused by aggregation 
or m isfolding, but this is not supported by the increased induction seen from IRF-1 - 
specific reporter genes. A s scFv3 affects on reporter gene activation were dependent 
on the IRF-1 binding site in these promoters, it is unlikely that scFv3 was stimulating 
the IFN-p or TLR3-luciferase genes in an IRF-1-independent manner. That CD K2 
repression was unaffected by scFv3 co-transfection suggests only a sub-set o f  IRF-1 
activities are regulated by the extreme C-terminal residues, although it is also 
possible that the scFv3 concentrations were not optimal for modulation o f  CDK2 
repression. This may mean that the scFv3 epitope can act as a switch, allow ing IRF-1 
to mediate alternative responses to different stimuli. This possibility could be 
investigated by profiling changes in the transcriptome caused by scFv3 activation o f  
IRF-1 in microarray assays. Such an experiment could be sim plified by labelling 
scFv3 with a cell penetrating peptide [410] and adding it directly to the culture 
medium. This would also further test scFv3 ’ s ability to activate a m ore global IRF-1 - 
mediated anti-tumour response. One key drawback o f  the study described in chapter 
5 is the limited number o f  downstream IRF-1 targets investigated, which was 
affected by  reagents available in the lab. As scFv3 has now  been validated as an 
activating anti-IRF-1 intrabody, future studies should be able to increase the number 
o f  scFv3 affects investigated. In particular, it w ould be interesting to know i f  scFv3 
can affect IRF-1 functions that are independent o f  D N A  binding, such as its trans­
activation o f  p53 through an association with p300 [72],
It is possible that the extreme C-terminus o f  IRF-1 acts as a co-factor docking site 
and thus modulates ERF-1 activity; i.e. that scFv3 binding m im icked a trans-activator
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or dislodged a trans-repressor. To investigate this possibility, and as part o f  a long 
term strategy aimed at identifying binding partners o f  IRF-1, peptide phage display 
was used to isolate IRF-1-binding peptides (chapter 6). One o f  these peptides was 
hom ologous to a region in the C-terminal repressor domain o f  ZNF350. The 
immunoprecipitation o f  ZNF350 with endogenous IRF-1 by scFv3 further validates 
the usefulness o f  the scFv antibodies developed in chapter 4 and indicates ZNF350 
m ay be a novel IRF-1 co-factor. It is possible that ZN F350 bound to scFv3 directly 
and non-specifically, although its ability to bind One-STrEP-tagged IRF-1 and the C- 
terminal IRF-1 peptide indicate that this is unlikely. Binding between full-length 
IRF-1 and full-length ZNF350 has not yet been shown to be direct, and hopefully this 
will be tackled in future studies. N o previous link between ZNF350 and IRF-1 has 
been reported, although both are known to regulate the D N A  damage response [71, 
401, 415], However, another member o f  my research group (Vikram Narayan: data 
unpublished) was able to purify Kap-1, a ZNF350 binding co-factor [402], from  cell 
lysate with an IRF-1 20-m er peptide. It is also possible that B R C A -1 , another 
ZN F350 co-factor [398], may be involved in a com plex involving IRF-1, a 
possibility that could be tested in a future scFv immunoprecipitation experiment. 
Additionally, the effect o f  IRF-1 co-transfection or knockout on a ZNF350 targeted 
reporter gene such as G A D D 45 could be investigated, as IRF-1 bound a peptide from 
the CTR D  domain o f  ZNF350 required for G A D D 45 repression.
The possible impact o f  this association has already been discussed as part o f  chapter 
3, but perhaps o f  greater interest for future research are the phage display peptides 
validated as having a high relative affinity for IR F-1. These peptides have been 
shown to bind IRF-1 in vitro  (ELISA), and could next be used to co-purify 
endogenous IRF-1. A ny peptide able to bind endogenous IRF-1 could then be tested 
for its ability to m odify the activity o f  endogenous IRF-1 follow ing intracellular 
expression. As these peptide would be smaller than scFv3 (20-m er com pared to 183- 
mer) they may be better able to penetrate active sites within the folded protein. They 
w ould also have the advantage that they were selected to domains spanning the 
length o f  IRF-1, and could potentially therefore target a more diverse range o f  IRF-1 
activities than the intrabodies. Although useful, a drawback o f  drugs like 
cyclohexim ide or staurosporine is that they globally affect protein synthesis and post-
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translational m odifications. For instance, the study by Wantabe et a l 1991 indicated 
that the proteins responsible for post-translational activation o f  IRF-1 do not 
themselves need to be de novo synthesised, whereas the cyclohexim ide treatment 
may have in fact blocked the synthesis o f  physiologically important IRF-1 regulators. 
Studies limited by such all-inclusive drugs emphasise the need for more precise 
agents that target not only specific proteins, but even specific domains and activities. 
This study has demonstrated that phage display can be used to develop such reagents.
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